var title_f25_13_25808="Resection interstitial pregnanc";
var content_f25_13_25808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52644&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interstitial pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 278px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEWAZsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACivG/+Fha7ovif4kf25NZ3uj+E4beZIba0MU04nTzFG8yEDYBtPHzdfl6VB4n+MesWGn6nHaeFmtdXsbixBhu7iOVHt7liFfKMMNkbcZOCwPIBoA9roryrUPjDFZeKRor+H755LeS2gv2jkV2t5ZlVsKqg7wm4bmBHfGadP8AFto9D1nV4/Cuqyadpt1JZG4WSNlklSbyzwCXVR94sVwOnJoA9Torx7Rfixquu+MPC9hpei2U2l6rFO000N9HMUMbqpZWBAwobcVK7jkYqv4R+J2u6prPguxttOOoWOsxXkk91OY4pl8m5aMkBSFARQCRglgRjnNAHtNFeJp8ZjpfgfSdVls5dWluY7y4lDzxwzrHBO6E+WinIAU/NgLgcnNdX8P/ABdd+JfHHiq3MhOk21npl1YxtGqsguIXdtxHJJwvUnHagD0GiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDipPhd4RlutbuJdOuZJdaQx6gX1C5YXC5yAQZMDGMDGNo4GBxVzVvAHhnVjqJ1DTBM2oRQQXB8+RSywnMWCGG0qe64Pqa8dvtI1zxH8T/FMOjWt21zZa9ZSpqhvgkWnxLFG0iiMtli4yMBSDnkitS5+HXieXwN4ka3a8i8SXeqTMiSam5WaxNwHES4cpHuUegPY4BNAHpU3w68MTahFfNYTLdpHFE0iXs6GZYgAnm4ceaQABl9xqwfA/h86LPpS2UkdlPdvfOsV1Mj+ezbmcOrBlOSehArwjWNI1Dwl4f0WTxLFeR+HV1qWe40e+1OCAyhoPkCMshQIsilvLL884FS+CPBOt+KvCnhuXVrTUJdN/sXUlKyXrxE3D3Ttb7hvVm+QggkFcY9qAPabX4ceFLSTSpbXSzDNpkz3FtMlzMsnmOwZ2d9+6XcVGd5bOOaW1+HXhe0GiC101oTossktiyXUytE0knmOCQ+XUtyVbI7YxxXiHiDwJ8Rb600Zv7KnbVLHTtPSG9gv4vNWaNh5wld5c5AzgxjDd2PSunl+H/iM+IX1tba8/tJPGq3cUg1H5RpJ2b8J5m0A/Nlcbz0xjFAHeXHwn8Fz2NrZvo7Lb28M1sgjvJ0JimcySIzK4LqWYnDEgE8Yrf0Hwto+gXl1daTZ/Z57qG3t5m8133RwIUiGGJA2qSMjk9814rF4J1a18G+IYPEenXdprSWN5NceKhquUndX82NggfeB8q8FV2hSBnJrvPgPHql34LPiPxDI7ap4gnOoOhJ2xREBYkUdAuwBv+BUAekUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFc9qnjbwrpMzRap4l0W0mU4Mc99EjA/7pbNY8/xb8AQnD+LtHP8AuXAf+WaAO5orz1fjR8O2cKPFen5JxzuA/PGK2tH+IXg/WbhYNM8T6NcXDHCwpeJvY+yk5P4UAdRRQDkZHSigAooooAKKKKACquqSzW9hNNbhWkiG/aVLblBywAHcjIHvjr0ql4n8S6L4W0/7d4h1O1062JwrzyBS5xnCjqxx2AJrxLxT+0RNJf3WleBfC97fX0WB9o1FTBGueVcx8NtI5+YocZPagD6Atp4rm3int3WSGVA6OpyGUjII/CnkhQSxAA5JPavl7TZfiV4g1C70rWfEI0i0tkKx2+iOsDZLc4JXfsQZDEsoTCjOTivRdJ+G9tqFrA9wn2tldHa71KaW9SZcAkqszNu3Y+9hAM8AjmgDvtR8Z+F9MlMWpeJNFs5AcbLi+ijOfoWFUR8S/AxbH/CY+Hc++owj/wBmpLXwDomnytNpWn6XazGMphdLthGScckKiscem4e+a0Lnw1YX17Kuo6XotzpvloIopLFWkVwW3EscgrjbgBQQc89KANTTdRstTtVudNvLe8t26S28qyIfxBIq1Xl3ib4J+FNRuGv9Dtn8P6qFwk2lyNbISOm5EIH4rg+9UbLw18QPDVnNLoviW9vYIz/x460q37ZB5ZJVKO6EdBlWGMYJ4oA9forzCw+K0en3UFn44019IMuVj1W3LT6dMynDDzcBo2BDZWRQVwcn19KtriG7t4ri1ljmt5VDxyxsGV1IyCCOCCO9AEtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUE4GT0oAKK5/QvF+i63pF5qVndMlpabmna4jaEogXcJCGAOxkwyt0IOfWtfTL+01TT7e+064jubO4QSRSxnKup6EUAWaKKKACiiigAooooAKK5zxp4x0rwjaQvqTyzXdySlnYWsZlubtx/BFGOWPI54AyMkVxVx4W8YfEI7/GOpSeG/D0iZTRdJmxcyA9rmfGOmQUTjkc5FAGl4z+Mng/wvcNZG/bVdX3+Wun6Yv2iYv/AHTj5Qc9ic+1YMfjj4peIZwnhr4f2+j2xGftXiC5K/TMS7XB9hmvRfCfg7w94Rs1tvDukWdioUKXjjHmOP8Abc/Mx9yTW/QB5L/ZPxn1IlL3xH4S0aN+smnWclw6D2EvB/E09fgtZ6jI03i/xT4n8QTSf62OW9MFu3sI48bR7A16vRQBx+k/DHwPpUCRWXhPRQE6PLaJK/4u4LH8637bQtItf+PXSrCHv+7t0X+QrRooAgaztWjMbW0JjP8ACYxj8qx7vwX4WvP+Pvw1ok+Tn97YRNz68rW/RQBw978LPCswJsLS50aXtJpF5LZlffbGwX8wagh8C65pVuV8P+PdeEnULq4i1CM+x3Ksn/j9d/RQB50uu/ELQrWRte8MafryISfO0C5KSbO2YJsEn/dc9eBVPQ/iy2t2rTWnhjULZlDsY9SuIbRgqHDt87dFPXHTvivUay7zRYZbxby0kks7wNud4jhZh0KyJ0cY4yfmHYigDzTXvjBe6fpNxf6d4bt9XSAqrpYap5+CSABujiZRyfWsnSvGXxU8WWNrLpuneHdBF8XWCG48y4ugqttaUrkKqKSASwJyQACSAdP45adqljZWOvRXs/8AYlooi1Owj3GJRyEuFUcgKzfOOfkOeq5r0jwqtvLpdteWiW8cEkCLDHA25IkA+6D3OSckYzgelAHG23w0stKsbrU72a98ReLp0CDVbwh5YpGOMwKflgRSxPyDKr3OBXQeHPAGgaJBGIrKOa4yJJZ5MlpZc5MjZJyxOOSScKozxXWUUAZVxpsUWsWeo2ton2hQ9vKyBVPlOd5J9fnVT+LdSa1aKKACiiigAooooAq39hBe2xiljQ4bzEYoDscdGAPeuMh8L6l4ble+8HJbRB2/0rR5XMdpcYz+9hCgiCVjjOAVPcZ+au9ooA8+sPihYJ5qeJtJ1Xw7JAVW4a8jV4oSzbVLPGW2oT0dgqn1rv45EljSSJ1eNwGVlOQwPQg1Q1XRdP1Vo2vrZJWTgN0LKeqN/eRuhU5B7ivN9d+FerW2rG++H3i/UfDkJjY/2aSZ7MSZUqEiY4jU/NkDpxtAAxQB6zRXIadpHi1tLgN94jSDUcfvQlvHcRZz1U7Izz9OPfrWNrekfE5d/wDYfijRZXGCovNO8tT7EqzEfkaAPSKZNLHBC8s8iRxICzu5wqgdSSegrzHT/DXxSumDax4902yQ/ej03SUkOPQPJ0+pU1qxfC/R7m7+1eJr3VfE8uQVTV7jzIEIHaBAsXvypoAp6p8ZfCUOoJpuhz3XiXVX5Sz0SE3TMO53jCYHc7uKtyar8QtUtt2k+HNG0YnkNrF80z494oFx/wCRK7Cx0nTrCYy2Nha20nliLdDEqHYOQvA6D0q7QB55JB8VggePUPBLyZ/1LWd0qkf7/mE/pVg+J/FejxxnxJ4Ra6jJCvc+H7n7WF9zE6pJj/dDV3dFAGV4f8RaR4igkl0TUba8WIhZVjf54m/uuh+ZDx0YA1oXVxBaW8k91NHBBGNzySMFVR6kngVka/4V0jXGaW7t2ivCNovLSVre5UegljIbHtnHtWLo/wAM9AsHka++2a6WIZf7bm+2+WfVTICRQBdXx5oN1FI+i3EuuFOMaTC10CfTeg2D8WFU9f1vxe2jtL4d8NxQ3ruEij1OcMee7LESAO5JcY9zgHsoIo4IkigjSOJBtVEXAUegAqFb+1fUZLATp9sSMSmEnDbCcBgO4zxkcZ4oA4W28F+JNYt0k8Z+MdQE5O42egN9ht0/2d4Hmv8AUsPpV4fC/wAJMii502W8YDG+8vZ52Pvl3PNdrRQBy1l4LstJ58O3eoaUQhURJcNNAfQmKQsv/fOD71z+v6drth4k0zVFlivtQa3WB/L3wxXITzGlgERchS6HehJOHhwTtNdf4vOsLoUz+HWiW+Rkb5495aMMC4QEgbyudueM4z61w1/f69qFhDew3ul6zBp2oW80i2kElrd2gWRRJ5sbO2W8oyBkwh9AelAGP4Gt9Q1x/Dv2WK6sdCazeJ3u0KTTWdrcL9mVlHCswYhsnlAxA+bjd8H2OoweJrDVJtRZ7TUZb97WzhlYQrZu/nRuUPBk3Nkv2Dqo4qnFqwTxfY6ZLqEd5o+oG5iitrdwIpIbjEyyMerEBgihezHtk1meNNIluda1ZvGGp6fHBLbvbaNpUEwT7LbHCvdTHjheG4yAVUAk7QAD22iqGg31nqWjWd5plw1zZyxgxTNnLjpk7uc8c55q/QAUUUUAFcf428XTaZcxaH4btF1TxVdrmC1yfKtkOR9ouWH3Igf+BMflXnkWbzWb3WGks/Cnl46SarKu6CLkgiMf8tZBg8D5R3P8Jv8Ahvw7Y+H4JlsxLLc3L+bc3dw/mT3D/wB527+wGABwABxQBj+C/BUWi3Uus6xcHVvFN2uLnUZh9wf88oB/yziBzhR1757dhRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBHdQQ3VtLb3MaSwSoY5I3GVdSMEEdwRXO+BdKtvCWh6b4VOqreXFrFK0CysBMbYSnb8vUhA8abunA9a6avP/AIqu2j3fhfxVCv8AyC9RS3u2JwBaXOIpM/RjE/8AwCgD0CiiigAooooAKKKKACiobWSSVWeSNUXd+7wTkr6kEDaevHP1rHvNYkuJp4tOMaWdur/a9SeQCOAgHITgh3Uj5s4UdzkEUAb1Z7a3pS+UTqVniWdrZD5y4aVc5jBz94YPy9eDXlviH4z+FtEv4Y7TUlS1inknu3lYnz0KvlIk+ZyxcqRwqcfe7V5VrPhrUvin4wutSs7fVNC0O9xGlol1ukvJvnkMj5Plr8qtwCcEIP4s0AfWN3d29nC015PFBEvJeVwqj8TXH+Hvij4P1y/n0+217T49QhmMBt5blAXYd4yDtkB65Un3wQQPHPgV8G9O1CG/1bxdZR6hGt/LFbx3UnnNthfauT0K5DZ9cKOmQfTrb4J+CReXF1d6NbSyzoyNGiCKJAXZ/lVAMfex9FAGAKAO9k1jTYtRgsJNQtEvp1LxQNKoeQDqVXOTj2q9XgvxJ+BHhT+ybvVdKtWh1GNAsYL4jJ5C/KuMncy8k9BWV4D8MT6n4V0u5sNd8TaReuDH5F5r06NLIjFWVV2hCCVyNpPGKAPo+mTzRW8LzTyJFEg3O7sFVR6knpXjFt8O/E2oavZS33ijxraaY8JSWOPXEWWCYFvmIWPa6EBQMHOeTWkvwP0ee+juNc8ReKfEEcZylvrN+LmIH1KFQD9DxQAzxd8d/DWl3P8AZ3heO48Wa04JjtdJHmpnH8UgBGP90NjuK5Xw146+KuomXUZ7LRLWCSVIGtr1sx2xkcLHgQ7pFIyN3mkZ7AV7Z4d8MaP4eV/7K0+zt5pAFkmhtYoXkA6A+WqjAHAGKv3dhb3bxNOmTG6ScHG4oSVzjqATkD1GaAPN9Ck+J+s6PDqKax4Si88vti/s64KhQxAYN5oPIGeR3rjrn4n/ABG8NeKdR0C48MW3iltPjgaWXThNEw8z7pLMpB+u3AwTk4OPedLsIdM062sbXcIIEEabjk4HqamWGJJpJkiRZpAA7hQGYDOAT3xk/maAPnyw8efE7XfEkll4f0/RdNeSfH2XVrs3Plgxu3DRKDj92x6nG9BgV1EzfFea7j06TXvCltftEZGFnaFwnp/rJAx6H+DHvXc6d4VWLxrqPia9uGmu5oxbW0Qx5cEIC9sZLlgxJz0bFdCLaAXBuBDEJyMGTYNxHpnrQB4dqXh74qzTW0LeNtUgmkO13XSrb7Ox46PEWeMcnlkP1qH/AIQPxXqP9mWviTxrrNtfNLI8E6CDzY9gYswKruRflQEByGDKT3Ue+Vwfi3S11TxZamG8/wBLEH2MI0hAiSQ732qOpZYstnqEReA7GgDkLD4ma54aaaDxFHB4q022Kq+raRH5MybskCW3Y7dxGG+RujL8vNeiaP4+8Lax9g/s7W7SZ74usCBiGLJjcrKRlWG4fK2DyKlvNG8N6Ro8pvYbOztAuJrmRhEzE8bmk4YsT3zkmvMPFXw703Wm0q58HaJOusaZPFcR6pPGtvBcpvDskucNJuHRghwcc0Ae3Tu0cEjxxtK6qSsakAuccAE4HPvXjs974t1G+sNYTTtEtNasnF5d6fE8qX8loMq9vtK4l4PDZ2FwMY616X4W8RWniS0uprNJontLhrS4hmADxTKqlkOCeRuFcN418XaTquieIEhWfTtZ0W6a1tLq8RoQLldpVonXO4HK/JwZBwRhs0AcDqum6ZL8WLHWtIvbqK31G4097XyEDK0TKCqokgVFXIOcEsOcKTnb2HiDStB1vxhqerl57NbNvsN5qmpT4t42X5iLZXP+tXJw4wqEkgMwqvGJrP4469rOtBfsGlabHHY+Tb4FxO0ce8Agk7wGwF64kHULmobXT7m68SXP9r26tDcSvcjS5LNLC9lYcyIJVUpdDAydsihh97jNAHsOgw2FvolhFo5jbTUgQWzRvvVo9o2kNk7sjBzk561eqvp0sE9jbyWYAt2QeWoXbtGOm3tjpjt0qxQAVR1DTIdQljN280kCDm234ic+rgfeH+yxK+2avUUAMVY4IQqhI4o1wAAAqqB+gFeaeNfiZcW+hatd+BtOj1hbC3eaTUpnK2Ksuf3aMOZpMjG1OOQCwNdddeFLLULxp9ZnvNUQ8La3Uubdf+2KgI31YE1T1e0TWdb0/RII5IdL0xory68pQsTsvMNv9AQJCMcBUHRqANzw82oPoOnPrXlDU2t0a6ESlUEpUFgAScAHI61oUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUjMFUsxAUDJJ4AFLRQBHBNFcRiS3lSWPJG5GDDIOCMj0II/CqfiHSLXX9C1DSNRVmtL2B7eXacMFYYyD2I6g9jXG/ELXP+EEnTxDDYxf2Y2yHUikeGYM+FkGOpjy7HPVSRkda6zwlq66/4X0rVkKEXttHPlAQuWUE4zzjPTNAFjQ72zv9Mhm0y5+1WqloVl3EktGxRgSechlIPuDV6vPPg1M5i8a2rcJaeKL+OMZ4CuVl49OZTXdwXtrcXE0EFxFJPCcSxq4LJ6bh1H40AWKKwNNvJr/xTqUNzaX1p/ZqosRaVfJuUkyfMULySNhX5uhBx3NWtc1yz0aMNdthjjjIGBz83PUDHOMkdcUAatcz45eRodOhs7oLetdI6WRUOLxRwyOMZCANuLD7u0HnocK/8QyTmWI3t7CJAWVYbmBeP7qfu959sAmkN3L4fIhkt47e8uZVSO+lfzHMRC/u2lmYPJKWyQFVgMgbTjkA2vGl/cJLbada3EUbXI2lFdllYsdqgsP9XHuIy/3v4VG4gjj/AB9rOn+CvAUulTwatIrZS3khZImubgyFvJhV9zct0ARlCkYJHNXG1BPB/hm98aeKLO/NzCJttug82QRl/lZ2OPmYKOu1VDbQqnIPm/gV/EvxD8dt4q1q3gins7m1FppcpObOy+0MJGUHpKGhXcx5K5HHyrQBg/CT4aPe6T4kvta0hrjxHc2+oWtlDczCRYgY4gnLHAJ85vmPOBkda+jfCPh630zz2RIfIhuXWxSLcogiEccWzacdPKK9xgA9zVHwReIPFPinRbW0hS20trSM3Of3txI0C5L9jhQgzx6Y4rs4o0iXbEiouScKMDJOSfxJJoA5/wAAaP8A2H4WtbNZjLGzSXC5XBTzXMhXrzguea6KsPQJHsrq50e6YtJEzz2z7SA8DNkDPTKE7SPQKf4q3KAEZQwwwBHoa5nUraO1lvrTULE3egaiDuWGAv5L7cOHVedrYBDAcNnOMg109cbrXxP8E6LPLBqfiXToZomKOgk3lWHUELnn2oA621gjtbaK3gBWKJAiAsWIAGByeT+NS15T/wALJ17xJo1zc/D/AMNfbC91JaWl1evJHE+1gPOI2D5CMkAsDxjrxU1n4A8R6ozSeM/ExuXkGJEsg8aqPSNdwjX3LIzEdx1oA7y88RaLZStFeaxp0Ei8sktyisPwJrnbj4q+CLditx4js4sdS+5R+ZGKdpfw08OaeGPk3VwxGN0twwx9FQqoPvjNbSeFdCEapJpNnOF6NcRCZv8Avp8k/nQBxtn8ZNC1TWbvT/D9tNrDW8gj3Wl3aAzZUHMaPMrOBnGQOoNaepfEa3sI7XzPDniVpp2ZTH9h2iLaOS8jMIwPTDGt6Lwl4bhIMPh/SEIIIK2UY5HQ/dq8NJ04EEWFoCOn7lf8KAOMn+JkcWnS3ieGtcuooyA5s/s9wEz3YpKdoA5JbAABrZ0rxhDfRxyyaTq0EEiB451hW5ikB7q8DSAj3rpgBkkAZPU1FaWsFnAsNpBFBCpJEcSBVBJJJwPUkn6mgDn18feEvtT2sniXSIbtG2tBPdpFID/uMQf0rktY186f8Qbe10RbTWdY1eOd7SOKceXapsgHm3BGSqYjbBAJY/KOScd9r3hvRPEMQj13SbDUVUYX7VAshX6EjI/Cjw/4d0bw7btBoWmWdhGwUP5EQUybRgFj1YgdySaAKmleG0iuBfa3ctq2qkq3nSriKFgP+WMWSIx78t6sa6CiigDkrtB4Y8Sy6nHFGuj6s6JelEIaG5+6k7Y42MAqMT0IQ9NxHMePmZPiFpl7Hd39hHpaJPex2EyJJdW8jhfOkXBMkMTKQ6kfKsm4EHGfUZ4o54ZIZ40kikUo6OoKspGCCD1Brx74jaTNa3Gh2ljqM9jqNhepLpuoqCzwWsn7popCT+8iWVoN4J5RkzyCaAINf0q51PxRH4dtliW1ntJtQhkmldo9UJljIlSdeUuEU8MASBjgpgDqdK1GfU9PSHxXHa32nyXC26zKnl3FlccBY7hVJCyAsAJYyoyVIADA1wtgrXd08EunwWlhfWUGqS2Wno0VxaXkMhguZrRwcBomWMsmMsG75Kt6B4S/sPxtZre3i2epahpV4IZLy3YCOeWMK6S/I2GBVkcK2dpPHIoA7DR9NttH06GxsVkW3izt8yVpWJJJJLMSxJJJySetXKKKACiiigCO5EzW8gtnRJypCNIpZVPYkAjI9siuR8R6l/wiGjwWGiW5v/EWpyutnDJkmec8vNMRyI1yCx4AGFGPlFdDrurwaNYtPOsk0rfLBbQgGW4kxkRxqSMscfQDJJABIzPDOgzQX9zrmtmObXbxfLJXlbWANuW3j9h1ZuN7cngKAAcx8L9KbTPFniaG81O/1PVIIrUX1zPOzRvcSB5X8tM4jUBkCqAMKF6816XXnPweke9u/HGqSsWe78Q3KKcceXDtgTH4R16NQAUUUUAFFFFABRRRQAUUUUAFFFFABWP4v1keHvDGp6t5fmtaW7yrHnG4gEgH29fbNbFfP37WPiC4g8FXWnRLJbiSWODe8gRZFbliB3+6VGccCX0BIB2/iLSY5vgjOfFj+fexaJLNdTTnnzmhLPz2G/oB6AdOK67wJp8mk+CPD+nToqTWmn28DqowAyxqD+oNc18Q3tfE/hHQ9Js51e28RXlrGjFSplt1P2iQgHBwYon6jv711XiPXINFtDI+x5drOIy4BCKMs5/2Rxk9BkZwOaAPP/8AiWabrniDTdKupWiur+TULyVp4pUN06Kjw4yMKoCEoxBy3DKQudBZvIigW5nildXjiaa6MbJAshwp/f7ZcE5wNzntk14p4K8X67PP428SaHcWb2E+uSTGKVY5URQmA7KSCilCBvyB8pBNey2l2+uaTaW+vat4Kj+22wHlW8fmkxFtpWPdJgrnK5AIz60AW7zxhp2lTGw0qawa8RhHd3LRgL5ir8wZFIfPQ8BscisfQPHGk6pquoyaveC7vQ0libDmOK1CnjfAzFj5hGRKUPHy/Lgg2NP+F+jW2qXkUeszXVrdBGitLqQTSQpGzB1jkyH2DcqgZO09c8AdQnhfStN0+HT7LSIp4gNpkBQzqWO3eS4+YAMxySTxwCaAMZLy4ur2KTQdJsY7QRu/nx2RbGMhlEnAyemNpPWsmxSwtdUa41Q6ZDrcDq6y6gVhit48g4ihyGdgvO8qvPQ8YrJ8XfFex8CwJZXz6jYZVkS1utGG84OCVaKWNPfI4968/wDN8RfE5bT7A+tab4OFzbRX93eXLx3M0czbcRBncBNrDJJOdwPIyCAa/wAQr6X4o3UWn6TLK/gK1lmie6U7H1a/S2mlAj/vIpjHYAsSRnjHvHhXTYLeJL62lWaG4tIFjfGWICkli3fdkE+/NZvgfwFp/haxtLONIpreyQx2ilWPljzpJAxyxUv84G4KDweSDgdTY2MFiJVtI0iikcyeXGiqoY9SAAOSeTnvQBmvpiWPiN9Ys4XaS9SO2vEj2gNtJ2StxklclTz90jrtFbdY+ueJtH0OSKLUr6OO4lIWO3jVpZpCf7sSAu34CuI1X4majqF0+meAvC2patqSv5cs97E1pa2h45kZgCTznYAGwKAO51zXbHSSkc8skl46NJFZWy+ZcThRztjHJHvwBxkiuF1rx54lubXyfDPhxWvZA4PmyPN9lI4HmeUjR788bPM65yQATV3wX4Bu7O+u9V8W6l/aOqXhDyxwO6wg9SvJBdOyxt8igDgnLH0CCKOCJIoI0jiQbVRFwFHoAKAPLPAPgLxCNOSTx7f6feXsiZcJE9zIrHuZJ2ZAfZI1UdsjFdto3gzw9o8qT2Wk2Yu0ORcvErSg+zEZH0GBXQUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZut6FpuuJCuq2iXAhcOmSQQQQcZBBxlVJHQ4GQcVpUUAcvp/gjTbDxa2vwXF95v78paNNm3iecoZXVcZBYxgkZxksQASa6G0s7azWRbO3hgWRzK4iQKGc9WOOpPrU9FABRRRQAUUUUAMaKNpEkZFMiZCsRyueuD2p9FFAHmHwHkYad4rspYjHNp/iG9tmyMbhv3hvxEg5r0+vMvhaDY/EH4m6TID5i6nDqIb+8lxCCMfQxkV6bQAUUUUAFFFFABRRRQAUUUUAFFFFABXzv8eLIeI/EUWlrHbRzXF5BpduIxvleWbZ5kj44GyHd1yVDL034r6IrwXVPEk9/8fPBdkyeRbPcXbfZ2hKSRbbZyoc/3mL+YR1w0WcEGgDrfFM9snxj8LLdTxWun6LpV3fsXbZGrSNHbp7ZwzgfUgda4j4zeM3tEubvVdPl1LQ7IOGsWheOOWVmUQJOOydWIc5JAAVc89dqN5PefFzxRZWRdbuDQ7RY5EkWM8yynyt5B2li6YOM8cYOCOP+LGhwyNY+GZoTf3Nwv2uS32SQxFgp8yXdklkjTeAAeHkXlmdiADy/4OfD7SNT0i38Wa/fSReeXhgt4vLsh5gZlIVpFMMuR/CSvcEEYr0Lx38MNL1eztXimsPDnlEQefd2T6e6x9WTfEfs77v7wX8+ldN4c0XV/hLoSpei31fwtcIscmnkIt1BMzYUBmIilG3CEEqSQgBOPmv3viPwdFcW/nReJvCJcAGdrKeytkbBOyQMpgJxnkgjHegDhZvhjq+i2Rn0XxX4m8lkJieKFNXgZj3AXDg/7QTOO/auT8R6HoEKRDxB8S/EGsXaSQ25sjPJHdOSSWCwyqDGDjYAx2qW3E/w17df+E73WNNe58F694fu4JHJWf7O0Tlh1IuLOSPn/gJrA1HSPiP4e09pIUu9XmjiP/LW31NOnK4mWGbBI6B3P1oA5LwdYfDnwlfvfatod/Bc31qdkcxW5MRfPmFGDluBtUOOc7zxuAHpmofF34eafYG0tn8+4upUtm0u2tfLmdmQKu5X2ADaFGScAbRnpU/wiik8R+EY9XvL2xhvLpmFxZ6ZYwwxWrKdpiZXRn3Agk7j1PAAxVL4m+GIZrvw/omjtbwaprN40ct39itvNhtUQtPIjeVkPjYoPYuKAI2+MM19owHg7wL4tvp2QLbSyWSm24OPmkWQggYPQ8+veqLw/F3xdb+Td2tpoNm0iNIHuhA0qA5ZB5PmSKD0OJFOM8iu6svCGuaPYxW2ieM9SZIwFRdWtobsADjGVWNyMerVd09vGdt5i6lF4f1FR9yS2ea0Y/VGEg/8eoAzvD/w+t7R3udVn825kADwWW62twB0UgHfL7mRmzk8DpXZ2dpb2UCwWdvFbwrkiOJAijPXgVzcviy7s51i1PwtrsQb/ltbRpdR/wDkNi/5oKst418OR3At7vV7WyuD0ivibZzzjhZApNAHQ0U2ORJY1eJ1dGGVZTkEexp1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHl87jRv2jLYyv5dv4h0FoYh/wA9Lm3l3EfhE5NeoV5v8YLWWLVPAWuWyZk0/X4IZW/uQ3GYXP5slekUAFFFFABRRRQAUUUUAFFFFABRRRQBFeS+RaTzESERoz4iQu5wM/Ko5J9AOtfPcMbWfxZ8BwTyu13Le3E91BdyLJcQFraRokJHG/DtJJjgGZAPlC19E14X8RdHufDeraVqtjCt1Ho15HqsszbpJxahwlwWc9ZHMzsewS3UdgKALsEMlj+0XqF7MitbagsNg3mdAfs4miIzx9+2lAPrXa+M9NaWSDVp1nP2a4gh8pSHUQG4iaR8Bd2SEGRkjC1F8V9AfUPCWr32l5j1u2hiu7WQc/vLaQzRqB7neufRzW3p9/H4q8LaZqek3DQwXq214jgnOzcjlDtI5IBUjPcg55FAFT4mWP8AaXgbVbPyZJvORE2xqSR86/Nx6dc9sZq1oEUet+DdHbWIIbw3FlDJKs6B1ZmjGSQ31PX1rXvbdbyzuLaRmVJo2jYocEAjBx7803To44rCCKCFoYo0EaRsMFVXgD8hQB5Rc/B/QhrOo/2HbfYFWWK6W3guJbaPLKVIVomDKcpuGdwB6LzT7qL4heFIYo/D6Xuv2sODLHq00NwWTPPlzK0cpbH99GJ9a7vxSq2Ys7u3Z4riXUbRHZXxvBkCbTz02s3FQa7qNzB468M6fbTlIrqK7edOCGVBGRx65PB+vrQBwGp/E7w7FrMemeKvDeuaPrlyFkje2t3aR05+dZI8SELgkgr0HQ1vxwy63rOgeLvCuq2XiPT7C1uLURGVVdzL5ZYiRRt3jy1G1lXqcmu71TSrDVY0TUbSG5EZ3RmRAWjbGNyN1Vv9oYIryLXfAGowfEmC58JeJbnR746fvOIkZbtwzfPcKMCX+FSzAtyDuyBQB39r4zAlki1jQNe0p4xlnltPPiP0khLrj64rQ0jxZ4f1mcwaXrWn3VyODBHcKZV+qZ3D8RXEW3iX4g6Ncra+JNH0a7iQ75NQt5JbeIxgHJ+64DZx94r9AOawrT4v+BfEer2Fl4p8N3mnXN0yC1k1ewjZZN5IRkOWYqSCN4G0HGSKAPb6iuraC7haG6hinhbqkiBlP1Brm7nwRpxkWTTbvVtJkU5/0C+kRPoYmJjP/fNLcWHiaNFk0TxDZ3SbeE1KyD7/APgcLJj/AL5NAFifwdoUkYWCwWxI6Pp8j2jA+uYipptv4dvLGJ00/wARarzyq3hS5VfxZd5/77psmq+IbGBGvPDy3rY+f+zLxGP4LMI/yyaSDxnpgtfO1KLUNJUEhv7Rs5IVXHq5GzHvuoAdaDxbbTsLt9D1GD+Fo1ltHH1B80H8xUdx4nvbGQLqHhfWghOPOtFjuk+uEff/AOOVt6Xqmn6tb+fpV9a3sHTzLaZZF/NSRVygDAm8YaBbSLHfapBYOwyq3+bUn8JAtbkMsc8SywSJJGwyroQQR7EUTwxXETRTxpLE3DI6hgfqDWFP4O0CSMpDpsVkSc77BmtHz67oip/WgDoKK5218OXVhEyWPiLV9v8ACt20dyB+LrvP/fVRWq+MbW6xcyaDqVrj7yrLaSflmUH9PwoA6eiuak8S3lnP5epeGtXjTOPPtVS6jPvhG3/+OVM/jDQIZVivNUgsZW+6l9m2Y/QSBTQBv0U2KRJY1kidXjYZVlOQR9adQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc78RNEk8R+B9b0q3O26uLZvs7ZxtmX5o2z2w6qfwpfh7rzeJvBGi6xJtFxdWyG4VQQEnA2ypg9Nrhlx7V0Nee/D/ZoHjTxZ4VdnzLcHXrPdwDDcH94qj/AGJVf/vsUAehUUUUAFFFFABRRRQAUUUUAFFFFABWR4h0u21QWkd5F5sIeSN1+c5WSJ42GF4/i6twBnvg1r0UAcL8LNTuDp974W1uUza34edbSd3H/HzARmCf33R4B/2lesfwNcQfDrVpPBGsTw22lzTSXHh64lbassTuWe2LHjzEduBn5lZcdCK4W9uNQk+J2t+KfDWqW82pWWoPp8kE8hEckCKEa1k6CP50LKQGOTuP3sD1Kw1/wj8QtKhtdVtbeSZLpI5dK1SECa3uQrOqtG3farkEcMAcE80Ad1WH4g8UeHvC0SnXdX07S1YF0S4mWNn5ySqk5POegryi5+DFxqr6gtprWq+Gbb7SVghsbqXy2jB5Ij37VBBIGPTp69P4c+CXgnQ1B/s5r+5IO+5vmEszsRgtvwCp/wB3FAHK+Pfjb4R1PR2tfD02oajcR3cB+12tpMI7MrIp85m2gkDn5QDu6dDmptR+Kekal4w0/WPDtnqWt2unW8qTx2Nq7TAuzLnaQAqgIGJYjCsnrivWtD8O6ToVv5OlWENum4vkZZiT3LHJJ/GruoWcd9Yz2sjSxxzKVZoXMb8+jDkUAYXg/wAVDxNbpc2lrC9k4OLm2vYriNWHVG2nIb2wasDS7bTNb1bxHeXDsz26pl+lvEgJYL9TyeOwrzr/AIVBeaJrUuu+GvF9xo90kZVilj9oEsQJIWVWf94evIAPpiofFeu/Ez7HpthYaXpeqT3jxTC7sFeOExq2SNzlwCw2tkgKvI+agD0nwbqU+qabJeXe5DLO0aK/B+QBWAH+8r9K5jVPhl4T1rVJn1C7urnXVvjqMd4LzF5a85WONx8yxLn5V6DjuM1mal8OtUnNpNd61cPctE0MsVkPLbZnKQxTMGMKKN2+QDzJD1I4UZGoeFbHQlg0GK4utVu2fdBp1nK9tJAhOdzXEYLnaB1b5jkGgDqtZ+FNvrVq1rqfi7xlPaMux4P7TCpIvdWCoNwPvmi2+D3hyzkWSxa5tnTlBEsUaqcdcIi/oRWN4f8AiNq9vruq6ZceGvEmqxWmEBtRbXRikBIKtKjqvIx8rDepznrxd1v4vR+HpgniPw9d6WWgMyrPe22/GflyokOAee+RjoaAKtz4K8ZWN8JtM8ZJp26XbDH5ksscvUhPKnaQAkD+Fs8Hms7V/F/xF8OhX1OfwvcMZxB5bIkEZ+shuSysRzjy2+la2h6hffEe4mu9Jv1g0qNmt5LyLO4AhSYokJBRtpBMjAMcjgD5a9E0Tw/peiRldOs4onPLS4y7n1Ldf6elAHja+OGeWKfX/hTeSC6B33ehxfbJEbOPmKojDjuGNax8XeFtE8SGwg8QeJtOha0S6ee5LzWkAL7AshnDNEcleu0fMBnPFexUjqroyOoZGGCCMgigDktNuvEFwI7jStW8P69prfxgNC3/AH8QyKf++RVq58RX9g4GoeGtUMecedYmO5Qf8BDCT/xymap4C8J6sEW90DTXMUglBjhEbBhg8lcE9uDwe9ef/FID4b6BbnwJq9xYa1d3UaWejyu13FekuFZFSQsYh8wJZSo6DqRQB6UfFuhxuiXeoR2Mj/dS+VrVj7ASBc1txSJLGskTq8bDKspyCPrTSnmwBLhEbcAHXGVJ79e1YeoeDdAvpVlfTkgnU5E1m7W0n/fcZU/rQB0FR3EMVxC8VxEksTjDI6hlP1BrCuNC1KKFV0nxFfW7L0W6jjukI9DuAc/995oWXxRZ2zGa30nVJV6eTI9oW+it5gz9WFAEk3hPRHjCQWCWWCWDWDtatn13RFTTbfQbyyhdLHxBqZycqt35dwF9sld5/FqLXxDMIt2q6HqunsBkjy1uR+BhLn8wKk0vxXoOqTmCy1W0e5BwbdpNkw+sbYYflQBFaDxTbzlbttF1CDHDxrLaOD7qTID+Ypz6/cW0gW/0LVIlJ2+dAiXCH3xGxfH1UVvUUAZP/CSaOsywz38NtM3CxXRMDt9FfBNawORkdKa6LIhWRVZT1DDINEcaRIEjRUQcBVGAKAHUUUUAFFFFABRRRQAUUUUAFFFFABXCfEyN9KudD8XW7rF/Y9z5d+xz81hMQs2cdQpEcnt5Zru6ranY22qabd2F9EJrS6heCaM9HRgVYfiCaALIORkdKK4n4T3l1/wj9xoWqMW1Lw/ctpcjsfmljQAwykdfniaM57nNdtQAUUUUAFFFFABRRRQAUUUUAFFFZPizVk0LwzqepyMq/Zrd5F3d3x8q/UtgfjQB498M/BV9rOpeMtfuXXT4NT1W4NskeHWUJPIpkZRgq3ygZVhuxk+tR/E74SarqV9p2taJqDWOq6eRM11CxaNvLIcExN827IBHzsDjkc5rt/hBpz+DdHh8FahefaLqyj8+GVlKmZXO+THqFkZh16YHYmvRKAPOPgX4xvfGHhe+k1oqus2WoT293Ev3Yzu3KF9U2sADz06mvR68C8R6Tqnwz+KOma54d+xWfhvWJI9LurZtwikk2sYd/LFWJygkxtX5cjBOfaNB1yDV0lj8uW11C3Ci6spwBLAzDIBxwR1wykqcHBOKANWiiigAoBB6c1k+JvtU/hfUjpOJLtrWQwAch22nC8EdemcjGaZZ27aP4eLbp5pUjEsvqSANwRM4QYHCrwPfuAa3loJGkCqJGUKXAGSBnAz7ZP5mkSCJJWkWNBK/3nCgM3AHJ/AfkKdG6yIrxsGRgCrKcgg9xTqAEVQowoAGSeB3PWob+1jvrOW2mMgjkG0mNyjD3DDkGp6gvru3sLOa7vZo4LaFS8kkjYVQO5NAHlmtfD3X9F1jUde8F+Iby3muY0RtPgsLU+cQfvOXKIT/ALXDY4yaqWvxK8UeEpbaz+JXh3cJjiO+0llkdhnAL24Ykd8lWb2Feg6R4kuNYvE+w6HqCacWIN3eJ9n3Dn5kjb5yDx1C9c1tQtZ6lAs8YiuIiWUMVz0OCOfcfpQBkQ+NfDkmlf2k2sWtvaBiha6Y27KwG4qUkwwbHOCM45rPn8aR3UZ/sWIz+dGv2V2UgyswJDCM4bZgHGcFu2FBeqes+AdBAub5vDttf3yXfn2ZwGeNn2A4LghUDZbGCo5IXPFTaFqGjaNo+patd3bT/ZLh7Oa8Ks5kkVgrJGoyxPmEpgZZmXvxQBd8Ra9YeBPCgvb5J5p3dY4rZG8ye8upDxGn95mY9uAB0AGBk+D/AAE1trH/AAkniS5+169M7TmNECRQMwxt6kuVGVBLYHJULmpfDeh3+ueIIvFni61FtcwKyaVpbEP/AGejcNI7DgzOAM44UfKCeSe7oAKKKKACiiigAqC7s7W8Tbd20M6+ksYYfrU9FAHPL4P0iC4afT47nTpW6/YrmSFP+/YOw/itPl03XIZw9hryvH3ivrRZB+DRlCPxzW9RQBiT32t2rx79GivYycM1ndKHHvskCjH/AAKnTeJLG1hSTUlurAMcE3MDBUPoXAKD/vqtmigCK2uIbqBJ7WWOaBxlJI2DKw9QRwalpFULnaAMnJx60tABRRRQAUUUUAFFFFABRRRQAUUUUAee+Jgvhj4maH4hXcLPXAuhXyj7olyXtpD77t8eT/z0WvQqw/HGgL4o8J6noxmMD3UJEUwGfKlBDRv/AMBcK34VV+HHiCTxJ4Ss7y8CpqcRa0v4hj93dRMUlXA6DcpI9iKAOmooooAKKKKACiiigAooooAK4b4r20N7Z6DZ6psXQ5tVhF+0oJjIGTEj4IO1pvKGemdueOD3NeYeN9VnuPFen+XOU8MLBdWOpvdWzPaSys8aqh5B3DbINy5AIKkjnAB6De6bHNbKlvttZogBBLGgzFjoAP7vYjuCRUdjfXb3Rt7/AE97YgYE/mo0Urc8Jg7ugJ+ZRj361pU2WNZUKOMqffFAGJ458NWnjDwnqeg6h8sF7CUEmMmJ+qOB6qwDfhXOfB3VtYuNHvdF8XSxSeJdEn+yXLrndPFjMU5z1Drk574PQ5A9ArhviL4U1HUZ7bxF4SuxZeLNNhdLdnUGK7iJ3NbzA9UYgYOflPIxQB3NQ3lzDZWstxcuI4Y13Mx5x+Hc+w615jonxr0ExGHxhBdeGNSjcwyR3kbPAzgZISZRtP0O0+1cD8X/AI06FbSWzaTqaaurxsUtbQ70Hbcz5Gw4yPuswycYzQB7T4a1GO70ux0rUrm3n1S6tpZp4YcoVj3lWJAJ24Zgv3uucHg10s8KT28kEu4xyIUbDFTgjB5HI+o5rwX4NfFe21XWYtK1DQ3sdauFjSSW4uYo3aMZ2CJGCAxLyAqZPJOCSTXvwIPTmgChFbJp0mbaJ2SeUeb8xwmQcEKBjrjOMdck8VZtbmC7i821ninjyV3xuGGR1GRU1UdR0jTtStri3vrOCaKdSsgZBlgffqDz16igCp4h8S6VoEedSvIY5Su5IS4Dt+BPAzxk4HvXN6h420e41Szt7G0k1PXnDG0sdyhto+9LycIARty2GBHQDJrn/FXh/RdOvNN8O6NYLbXN1LF5l2IfNKZ3KOSd2cB268Y4xksp8T9F15/FWmv4TsjCBYvD9sgUKbQYkQbf+/wOAMjbnBoA09e+JEmhaumn+INAaJ3VJIUSdZXmOQMxrj5yGIGAd3fHIrd1u4sfDukX/iTS9PQfZEL3kaWzJLJCoywVflwwA3DII6/3s18v+AvCkr+LdN1KGfVJNVF35Kvd25LeazKzy7jwGUmUE9TgdK+xNSmt7fTrqe9YLaxxO8rEcBACWP5ZoAdFdRTWUd3bkzQSIJEaMZ3KRkEevBzXjvwJ0mO+1LxZfXV1Je2emeI76HS4pF2pbljukcLgEsfMK5bOMHGMnLPF3izUfhp8F7a1LC31uw0+GCOWQq6rLhQsYGG3kDrkAcE5rr/gb4eu/Dfwz0m31Qs2qXQe+vGb7xlmYuQ3uAQp9xQB3tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeZ2qf8Il8apYFYjTPGEDTomeI763Ub8DoN8RBJ7lK9MriPilbKIfDWqjAl03XLNw3fbLIIHH5TfpQB29FAIPTmigAooooAKKKKACiiigDnPHutz6L4cu5NOaD+1ZIpBaLM2FDBCxcjqVQAsQOuMd65/wAG6ba638PJfCmqw+VdaaPsN4iNyJVwwmBzk7+Hz3JIPepvCsGj694h1jX7qaG9vZJptMt45DlYLeNyjRqp4yzwyOTjJ47CugvdHW01efXtKhY6jLGkVzCJNq3SLnbntvXJ2t/wEnByACHw1c39gtvpHiKSN7/a32e5VyRdIv1Aw4GMg5yOQT82OjrOljstf0tSGZ4HO5JEyjxurcEd1ZWHfoQQe4pul3c4maw1Ir9tjXcsigKLiMY/eKM8YJAYdj7EZANOiiigDg/F+hXsOpLqOjW3no0iyzQFsrI24KylDkEMrE5x8uGPU1F/wrbwHr0Et5F4csLW6llDvLBEsU0MycEZXgEHORyrHqGr0Gsu90+Zbz7dpciRXRwJo3z5dwo6Bsfdb0cAnsQwAFAHF3nw+caSLGZbLWtOKE3Gn3sWUkcAgNEST5LEenCtyK4jRrrxR8N7yE6XZ3+veC7v95bWpj/020UAboipwXeNYyoXdkg9DtOPcdLvprwOtzYXNnNGBuWXaVJOfuspIYcfqOnQS3dha3lvPBcQI8c3+sGMEnGAcjnIwMHqMDHSgDifDvxZ8LeILYy6dduxBCmMrhg2Tldp53ADdtxkg8AkMBYvviFYWulrfstv5AyHLXIwCPRlBTH1ZT6gHin+I/hh4R8SPHNrGjwXF7Gu0XZGJmA6b2H+sx/t7vXrzXNzfArwtcSzJcxRvZzEb4ks7eORgCDgyqgccjqpU+9AGdpvxe0HxB4uS3sI7Oe+RxbQW7zKkhkDcymU/IsQDEYUl2PAU8V6/ayWt6y3duyyMm+EOMjHzAMpHrle/pXJT/CfwFMhU+EtGXMRhzHbKhwcc5GPm4+91HrXBeM/B8vw/NnN4A1W6t7zVLyO2ttIn3SxTXDBgZPMB3RqqGRmzlcA4AO0gA9rZooo2h4mkjXzRCNu8gHIwOO4wD7da4HxP41h0+/I8UpHoegQ27XZkuplMl2UYARiMAnGSCQMlsgDI3CsSbwd8SdQkYXeteGrV5AqPdrbyXciAAYKxyAJn68+pPWug8DfCTw34Uv21Von1XX5G3yalfYeTcTn5FA2xjPTaMgcZoA47wf4Y1z4i+I7TxP45sJdP0Czk+0adpF0xaS4lx8s0ynhVXPyp19ePve50UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcL8UrG/1+LRfD2kzNby3V/FdXNyoBNtBAwlLgHqTIsaj3bPQGut1vVLPRNJutS1OYQWdshkkcgnA9ABySTwAOSSAKzPCNlciK41fVYzHqmpESPGc5t4hnyoPqoY7sdXZz3FAGzY2kFjZxWtqgjhiXaq5z+JPc9yT1NT1zeqeLrG08QRaFZpJqGsMBJLbwFcWsR/5azMSAi+g+8cjANdGrBlDKQQehFAC0UUUAFFFFABRRRQB4XpWl33hnWvEuq6XPcDRH1hxbxyPuS2cH95lSeFaWSUDb2LDqy17HoGr22uaVDfWTq0cg+ZQwYo3dTjjI/+v0Ncx4WdrH4geMNDuzF5N2YdWtI2bLPHJGIpuPQSRZP/AF09xndOgQWWoXWpaJFDaX90wa5AGI7rAAG8D+LAwGHI75HBALy6bAmqG/h3xzOmyUI2FlHYsvQsOgPXHGccU3WbSe5td9i8UWoQnfbyyJuVW7g+zDKnHrkcgUabqcV6zxMj295GAZbaXG9M9+OCP9oEir9AFTSri4utOgmvLRrK5df3tuzh/LboQGHDDPQ9xg8dKt1Q1ZJ0SO7tFDzW+SY8EmWM/eQe5wCPcAdCafYajb32/wCzsxCqjgspXcrjKsM9jyPqCO1AFyiiigBrosgAdQwByMjofWlRQiKozhRgZJJ/M9aghjuIy++YTBpSw3LtKIRwox1we5qnc6pPDeyp/Z1w9lCB5lyPU8/KnVgBjJHrgZwcAGpRVGLVrN5IkMoQzcwl+FlHYo3RsjnAOcdqvUARXlzBZWk91dypDbQI0ssjnCoqjJYnsABmuC8D38XjvxDN4vgM39i2YksNIWWPaJeR510uecNgRrnkBG/vEVhavDqXxY16SwtpprLwDYT+VfSLIh/taWNzuhQryIuMM27noBnOPW7eGK2t4oLeJIoIlCRxxqFVFAwAAOAAO1AElFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXM+MptQvoX0Dw9c/ZdUuowZbzGfsUDEgygd3OCqDI556KaAMTTQnjzxdNqTzrL4d8P3jW9rbbCBPfR433DHuqElEHI3Bm7LTvEesa34l1O68PeB50sktm8vUtedRItq/B8iFDxJNg/MfuoOvzEAXdSsG0Dw3pXhTwgjWkk4+yxTrgtaQgZkuDn7zDI69XdSe9dJoml2miaTa6dp8fl2tumxATknuWY9SxJJJPJJJPWgDmvCHwz8LeFrOSK002O7uZm33F7fgXFxcP/ed2H6DA9qu6n4G0C+kjnisv7PvI+Y7rTnNrKh/3kxn6NkH0rpqKAOJ8rx1oon8ibS/E9sCWiS5JsboD+6XRWjf67UpbbxpqqKF1bwP4js5e/k/Z7pPwaOUn9K7WigDkZPGkvko1t4V8T3EjLnyhaJGV9iZHVf1rD1Obxd4kEfmeB4rFYWJhlu/EJt5lJGMj7Mr8eo3V6VRQB5lo0fxO8PCWbV30fxPY4B+y2paC6jHHEbONsnf75UnHXtXY6H4p0rW/L/s6Z3LO8Lq0ZRoZk+9FIp+aNwATtYDIGRmtyuK8dfDvS/FTm9inutI15VCxapYSGOUYIKhwDiRQQOGzjsV60AT+J/Dl1feL9D1rTnSGe1hntpJioJRX2upweq7o9pUdRJnIwCL6eIHs7xrfxBaDTg0ipb3KyGWCbPQF9o2NnjDYzkYJ6DltC8cajoeqw+H/iRbxWN27eVZ61H8tlqJxkDJ/wBVKR/Ax5IO3qBXd63cR2mj3txPGsscULuY2GQ2BnH40AJq+kafrEUUep2cNysUiTR+YuSjqwZWU9QQQOlWoVkTIeTzB2YgA9T6cdMCuJu4de0vUNEsdN1w3mpXRkkvEvYd8JQL88qhcNGA5RVUNj5scnJrXv8AVtT0HT5LrWIILyFASZbJGUqf4QUJY4J43AnGRxjJAB0dcZ4psYdKuTqRX/RJj5U5y2UDsCdvXBL7WU9nz08wkdDY38OpS+fp1z5sEZCSL0Q7o1kVgcZJ2uvfGGPcVfgmjuII5oJFkikUMjochgehBoAytA1P7VElvcyxvdeWJI5FwBdRcYmUDoDkZH8J9ipOxWY+iWfmTywLJBNLJ5++ORhtkxjcq52gnvxhv4s0iai9jFt1oxxBSFF0vEUmeMn+4c9jxyME0AalFNLphTvXD8Lz1+lOoAz7jTeZnsZRbTSsGfK743P+0hI69yCCeOeK8f8Aj1oMFxpejQajAZBdXnkLbWEkib2YFmkILbAqornBByxTJAyD7hXA/GXTPtHhmLV4rhoLjRZheLhAwlQcPGQemQevUED3oA7DRNKsdC0i00vSrdLaxtYxFDEg4VR/M9yepPNXqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApAqqzEKAW5JA60tFAEX2aD7X9q8pPtOzyvMx8wXOdufTPP4D0qWiigAooooAKKKKACiiigAooooAhu7aC8tpLe8giuLeQbXilQOrD0IPBrhNS8H6joVm0fgybzdKfctxoN5MxidHwG8iViWgIG4heUz2XrXoNFAFe2tIbeWWZEU3EoUSzFQHk2jA3ED/63JqxRRQBzb6PJoeoTajoMW6C4cyXtgCB5rEj96hPRwBjbkKwwOCAat6Vcxi5BtTJJYXwNxDIeiP1dMHlSeWwe+8cYArZrhfE+nraa9pMytLa2p1aC5M68r5siSRtGP7oc+WD2Jc9zQB3VBGRg9KKKAMfU/DmnahFJG6SQhxg+RIUGezbR8u4dmxkdjWpHEUJPmyMC27DY4GMY6dO/1qSigArgvjRPKfClppVsdsut6naaZuxnakkoMhx/uK9d4SFBLEADkk9q4zwta3XiC+PiDWIkitVupJtLtMljGNvkidm6EugLKAMKsh6k5AB2lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUF9aQX9nNa3cYkt5kKOuSMg+45H1HNT0UAc2muRaAbew8SXQg3yeRa305xHc8EqHfAVZMAgg43EZXOcDds7u2vYvNs7iG4i3Fd8ThxkdRkd6bqVhaapYTWWpWsF3ZzLtkgnQOjj0IPBrnrDwLpWmRpFo8+q6dbp9yC21CURJ7LGzFQPYDFAHVVma5rum6HHE2p3SQtM4jhiALyzOeioi5Zz7AGsvVPB8GtWJstd1TVNRs2xuheRIQ2PUxIjfrWloXhzR9Ah8rRtNtrRcYJjQbm+rdT0HU0Ac/ZaVr3iK7+0+KpobXSFkZoNHtlIaRQ3yNcybvm45MQAX+9u6V2gAUAKAAOAB2paKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cornual resection and removal of interstitial pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25808=[""].join("\n");
var outline_f25_13_25808=null;
var title_f25_13_25809="Calculator: Fractional excretion of sodium";
var content_f25_13_25809=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"FractExcSodium_form\" name=\"FractExcSodium_form\" onkeydown=\"clrResults();\" onkeyup=\"FractExcSodium_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Fractional excretion of sodium",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          FENa = (UrineNa / SerumNa) / (UrineCr / SerumCr) * 100",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Urine Na",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Urine_Na_param\" onblur=\"FractExcSodium_fx(); minMaxCheck();\" onchange=\"FractExcSodium_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Urine_Na_unit\" onchange=\"FractExcSodium_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mEq/L\">",
"               mEq/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Na",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Na_param\" onblur=\"FractExcSodium_fx(); minMaxCheck();\" onchange=\"FractExcSodium_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Na_unit\" onchange=\"FractExcSodium_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mEq/L\">",
"               mEq/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Urine Cr",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Urine_Cr_param\" onblur=\"FractExcSodium_fx(); minMaxCheck();\" onchange=\"FractExcSodium_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Urine_Cr_unit\" onchange=\"FractExcSodium_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"0.001|0|mcg/dL\">",
"               mcg/dL",
"              </option>",
"              <option value=\"0.1|0|mcg/mL\">",
"               mcg/mL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"              <option value=\"0.0001|0|ng/mL\">",
"               ng/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Serum Cr",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Serum_Cr_param\" onblur=\"FractExcSodium_fx(); minMaxCheck();\" onchange=\"FractExcSodium_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Serum_Cr_unit\" onchange=\"FractExcSodium_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"0.001|0|mcg/dL\">",
"               mcg/dL",
"              </option>",
"              <option value=\"0.1|0|mcg/mL\">",
"               mcg/mL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"              <option value=\"0.0001|0|ng/mL\">",
"               ng/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Result:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              FE Na",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"FE_Na_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"FE_Na_unit\" onchange=\"FractExcSodium_fx();\" style=\"width:105px;\">",
"               <option selected=\"selected\" value=\"1|0|%\">",
"                %",
"               </option>",
"               <option value=\"100|0|fraction\">",
"                fraction",
"               </option>",
"               <option value=\"100|0|ratio\">",
"                ratio",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"center\" colspan=\"3\">",
"             <span class=\"medCalcFontOneBold\">",
"              Decimal Precision:",
"             </span>",
"             <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"FractExcSodium_fx();\">",
"              <option>",
"               0",
"              </option>",
"              <option>",
"               1",
"              </option>",
"              <option selected=\"selected\">",
"               2",
"              </option>",
"              <option>",
"               3",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      The fractional excretion of sodium (",
"      <b>",
"       FENa",
"      </b>",
"      ) can be calculated by entering the values from",
"simultaneously obtained urine and blood samples.",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Stein JH, ed.",
"        <i>",
"         Internal Medicine",
"        </i>",
"        . 4th edition. Mosby-Year Book. 1994.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25809=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function FractExcSodium_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.FractExcSodium_form){",
"",
"",
"doCalc = true;",
"if (Urine_Na_param.value.indexOf(',') >= 0){ Urine_Na_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Urine_Na_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Urine_Na_unit.options[Urine_Na_unit.selectedIndex].value.split('|');",
"Urine_Na = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Serum_Na_param.value.indexOf(',') >= 0){ Serum_Na_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Na_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Na_unit.options[Serum_Na_unit.selectedIndex].value.split('|');",
"Serum_Na = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Urine_Cr_param.value.indexOf(',') >= 0){ Urine_Cr_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Urine_Cr_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Urine_Cr_unit.options[Urine_Cr_unit.selectedIndex].value.split('|');",
"Urine_Cr = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Serum_Cr_param.value.indexOf(',') >= 0){ Serum_Cr_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Serum_Cr_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Serum_Cr_unit.options[Serum_Cr_unit.selectedIndex].value.split('|');",
"Serum_Cr = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"FE_Na =  (Urine_Na / Serum_Na) / (Urine_Cr / Serum_Cr) * 100;",
"",
"unit_parts = FE_Na_unit.options[FE_Na_unit.selectedIndex].value.split('|');",
"if (doCalc) FE_Na_param.value = fixDP((FE_Na - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.FractExcSodium_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.FractExcSodium_form){",
"",
"FE_Na_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f25_13_25809=null;
var title_f25_13_25810="Patient information: Uterine adenomyosis (The Basics)";
var content_f25_13_25810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87104\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/8/5251\">",
"         Patient information: Endometriosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/25/14738\">",
"         Patient information: Heavy periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/41/3731\">",
"         Patient information: Hysterectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/25/11666\">",
"         Patient information: Painful periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/52/21314\">",
"         Patient information: Uterine fibroids (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/16/6405\">",
"         Patient information: Abdominal hysterectomy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/63/26611\">",
"         Patient information: Endometriosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/35/23094\">",
"         Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/47/755\">",
"         Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/20/20804\">",
"         Patient information: Uterine fibroids (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Uterine adenomyosis (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H3539840\">",
"      <span class=\"h1\">",
"       What is uterine adenomyosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Uterine adenomyosis is a condition that causes heavy, painful periods in women. In women who have uterine adenomyosis, the uterus gets larger than normal (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      ). This happens because cells that normally line the inside of the uterus start to grow in the walls of the uterus. Uterine adenomyosis will be called just &ldquo;adenomyosis&rdquo; here.",
"     </p>",
"     <p>",
"      Adenomyosis often happens along with other problems that affect the uterus, especially endometriosis. Endometriosis is a condition in which tissue normally found only in the uterus starts to grow outside of the uterus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3539872\">",
"      <span class=\"h1\">",
"       What are the symptoms of adenomyosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heavy periods",
"       </li>",
"       <li>",
"        Painful periods",
"       </li>",
"       <li>",
"        Pain in the lower belly",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3539887\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have very heavy or painful periods, see your doctor or nurse. Often there are treatments that can help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3539902\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. None of the tests that are available can show for sure whether you have adenomyosis. Even so, there are some tests that can help your doctor or nurse figure out what might be causing your symptoms. For example, your doctor or nurse might send you for an MRI or an ultrasound. These tests create pictures of the inside of your body. They can show whether your uterus is enlarged.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3539917\">",
"      <span class=\"h1\">",
"       How is adenomyosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The only proven treatment for adenomyosis is surgery to remove the uterus, called a hysterectomy. But there are other treatment options that might reduce the heavy bleeding caused by adenomyosis, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        IUD &ndash; An IUD is a small device that fits inside the uterus and is normally used to prevent pregnancy. One type of IUD, which releases the hormone progestin, might help with the symptoms of adenomyosis. (IUDs must be placed in the uterus by a doctor or nurse.)",
"       </li>",
"       <li>",
"        Endometrial ablation &ndash; This is surgery to remove the lining of the uterus.",
"       </li>",
"       <li>",
"        Uterine artery embolization &ndash; This is a treatment that cuts off the blood supply to the uterus, causing it to shrink.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Treatments that can ease the pain of adenomyosis include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain medicines",
"       </li>",
"       <li>",
"        Birth control pills",
"       </li>",
"       <li>",
"        A medicine called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?0/48/774?source=see_link\">",
"         leuprolide",
"        </a>",
"        (brand names: Lupron, Eligard), which causes your ovaries to stop making the hormones estrogen and progesterone",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3539932\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, you should not have a hysterectomy, uterine ablation, or uterine artery embolization. Instead, work with your doctor to find other treatment options until after you have your children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3539947\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=see_link\">",
"       Patient information: Heavy periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=see_link\">",
"       Patient information: Painful periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=see_link\">",
"       Patient information: Uterine fibroids (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=see_link\">",
"       Patient information: Endometriosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/41/3731?source=see_link\">",
"       Patient information: Hysterectomy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"       Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/47/755?source=see_link\">",
"       Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       Patient information: Uterine fibroids (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"       Patient information: Endometriosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"       Patient information: Abdominal hysterectomy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/13/25810?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87104 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-0E8BE10A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25810=[""].join("\n");
var outline_f25_13_25810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3539840\">",
"      What is uterine adenomyosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3539872\">",
"      What are the symptoms of adenomyosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3539887\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3539902\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3539917\">",
"      How is adenomyosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3539932\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3539947\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87104\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=related_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=related_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=related_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/25/14738?source=related_link\">",
"      Patient information: Heavy periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/41/3731?source=related_link\">",
"      Patient information: Hysterectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=related_link\">",
"      Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/47/755?source=related_link\">",
"      Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=related_link\">",
"      Patient information: Painful periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/52/21314?source=related_link\">",
"      Patient information: Uterine fibroids (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_13_25811="Poractant alfa: Drug information";
var content_f25_13_25811=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Poractant alfa: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/60/22466?source=see_link\">",
"    see \"Poractant alfa: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Curosurf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Curosurf&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Lung Surfactant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F211419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/60/22466?source=see_link\">",
"      see \"Poractant alfa: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Premature infant with RDS:",
"     </b>",
"     Initial dose is 2.5 mL/kg of birth weight. Up to 2 subsequent doses of 1.25 mL/kg birth weight can be administered at 12-hour intervals if needed in infants who continue to require mechanical ventilation and supplemental oxygen. Maximum total dose: 5 mL/kg.",
"     <b>",
"      Note:",
"     </b>",
"     For intratracheal use",
"     <b>",
"      only",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, intratracheal [porcine derived, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Curosurf&reg;: 80 mg/mL (1.5 mL, 3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take from refrigerator and warm to room temperature. Inspect for discoloration. The color should be white to creamy white. Gently turn the vial upside down to get a uniform suspension. Do not shake. Slowly withdraw the entire contents into a 3 mL or 5 mL plastic syringe through a large gauge needle (at least 20 gauge). Attach the catheter to the syringe. Fill the catheter with poractant alfa. Discard the excess through the catheter so that only the total dose to be given remains in the syringe.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Before administering, assure proper placement and patency of the endotracheal tube. The endotracheal tube may be suctioned before administering the poractant alpha. The drug is administered intratracheally through a 5-French end-hole catheter cut to a standard length of 8 cm",
"     <b>",
"      or",
"     </b>",
"     through a secondary lumen of a dual-lumen endotracheal tube (without interrupting mechanical ventilation). Up to 2 repeated doses may be administered, using the same technique at 12-hour intervals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Administration using a 5-French end-hole catheter:",
"     </b>",
"     The infant should be stable before proceeding with dosing. The infant's ventilator settings should be changed to a rate of 40-60 breaths/minute, inspiratory time 0.5 seconds, and supplemental oxygen to maintain SaO",
"     <sub>",
"      2",
"     </sub>",
"     &gt;92%. Keep the head and body of the infant in alignment without inclination. Briefly disconnect the endotracheal tube from the ventilator, insert the 5-French catheter. This catheter is inserted into the infant's endotracheal tube with the tip positioned distally in the endotracheal tube. The catheter tip should not extend beyond the distal tip of the endotracheal tube. Each dose should be administered in two aliquots with each aliquot administered into one of the two main bronchi by positioning the infant with either the right or left side dependent.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Insert the first aliquot (1.25 mL/kg birth weight) and position the infant so that either the right or left side is dependent for the aliquot. Remove the catheter and manually ventilate the infant with 100% oxygen at a rate of 40-60 breaths/minute for 1 minute. When the infant is stable, reposition the infant such that the other side is dependent and administer the remaining aliquot using the same technique. Remove the catheter without flushing. Do not suction the airways for 1 hour after instillation unless signs of significant airway obstruction occur. Resume ventilator management and clinical care.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Administration using the secondary lumen of a dual-lumen endotracheal tube:",
"     </b>",
"     Slowly withdraw the entire vial content into a 3 mL or 5 mL plastic syringe through a large gauge needle (at least 20 gauge). Keep infant in neutral position and administer poractant through the proximal end of the secondary lumen of the endotracheal tube as a single dose over 1 minute (without interrupting mechanical ventilation); transient increases in F",
"     <sub>",
"      1",
"     </sub>",
"     O",
"     <sub>",
"      2",
"     </sub>",
"     , ventilatory rate, or peak inspiratory pressure (PIP) may be required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     pH: 6.2 (5.5-6.5; adjusted as required with sodium bicarbonate)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of respiratory distress syndrome (RDS) in premature infants",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Endotracheal tube blockage, oxygen desaturation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Pulmonary hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No known contraindications",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary hemorrhage: Pulmonary hemorrhage is a known complication of premature birth and very low birth-weight. It has been reported in both clinical trials and postmarketing reports in infants who have received poractant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transient adverse effects: Transient episodes of bradycardia, decreased oxygen saturation, hypotension, or endotracheal tube blockage may occur. Discontinue dosing procedure and initiate measures to alleviate the condition; may reinstitute after the patient is stable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For intratracheal administration only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Correct acidosis, hypotension, anemia, hypoglycemia, and hypothermia before use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Produces rapid improvements in lung oxygenation and compliance; may require frequent adjustments to oxygen delivery and ventilator settings.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Rapidly affects oxygenation and lung compliance; restrict use to a highly-supervised clinical setting with immediate availability of clinicians experienced in intubation and ventilatory management of premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Curosurf Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/mL (1.5 mL): $419.99",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F211397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Arterial blood gases, ventilator measurement assessment",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Curosurf (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CO, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HN, HU, IE, IL, IQ, IR, IT, JO, KP, KW, LB, LU, LY, MY, NL, NO, NZ, OM, PL, PT, QA, RU, SA, SE, SY, TH, TW, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F211389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli during ventilation and stabilizes the alveoli against collapse at resting transpulmonary pressures. A deficiency of pulmonary surfactant in preterm infants results in respiratory distress syndrome characterized by poor lung expansion, inadequate gas exchange, and atelectasis. Poractant alpha compensates for the surfactant deficiency and restores surface activity to the infant's lungs. It reduces mortality and pneumothoraces associated with RDS.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F211403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Information limited to animal models. No human pharmacokinetic information is available.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ainsworth SB, Beresford MW, Milligan DW, et al, &ldquo;Pumactant and Poractant Alfa for Treatment of Respiratory Distress Syndrome in Neonates Born at 25-29 Weeks' Gestation: A Randomised Trial,",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 355(9213):1387-92.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9510 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25811=[""].join("\n");
var outline_f25_13_25811=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211409\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211410\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211431\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211419\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211399\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211387\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211401\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211400\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211429\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211404\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211390\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299909\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222447\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323704\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211397\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038773\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211389\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211403\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9510\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9510|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/60/22466?source=related_link\">",
"      Poractant alfa: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_13_25812="Menotropins: Patient drug information";
var content_f25_13_25812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Menotropins: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12565?source=see_link\">",
"     see \"Menotropins: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F192622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Menopur&reg;;",
"     </li>",
"     <li>",
"      Repronex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F192623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Menopur&reg;;",
"     </li>",
"     <li>",
"      Repronex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702462",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to menotropins or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Cancer where hormones make it grow, ovarian cysts, pituitary tumor, adrenal gland disease, thyroid gland disease, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit working out while undergoing ovarian stimulation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of getting pregnant with more than one baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ovarian cyst.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Over stimulation of the ovaries.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin or a muscle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699527",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store powder at room temperature or in a refrigerator.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect powder from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use right away after mixing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12075 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-E01451B0F0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25812=[""].join("\n");
var outline_f25_13_25812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192622\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F192623\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029256\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029255\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029260\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029261\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029263\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029258\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029259\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029264\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029265\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12565?source=related_link\">",
"      Menotropins: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_13_25813="Clemastine: Pediatric drug information";
var content_f25_13_25813=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clemastine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/62/7142?source=see_link\">",
"    see \"Clemastine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/51/35636?source=see_link\">",
"    see \"Clemastine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F152461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tavist&reg; Allergy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/62/7142?source=see_link\">",
"      see \"Clemastine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &lt;6 years: 0.05 mg/kg/day as",
"     <b>",
"      clemastine base",
"     </b>",
"     or 0.335-0.67 mg/day clemastine fumarate (0.25-0.5 mg base/day) divided into 2 or 3 doses; maximum daily dosage: 1.34 mg (1 mg base)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 years: 0.67-1.34 mg clemastine fumarate (0.5-1 mg base) twice daily; do not exceed 4.02 mg/day (3 mg/day base)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 1.34 mg clemastine fumarate (1 mg base) twice daily to 2.68 mg (2 mg base) 3 times/day; do not exceed 8.04 mg/day (6 mg base)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F152447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as fumarate: 0.67 mg/5 mL (120 mL) [equivalent to clemastine base 0.5 mg/5 mL; prescription formulation]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as fumarate: 1.34 mg [equivalent to clemastine base 1 mg; OTC], 2.68 mg [equivalent to clemastine base 2 mg; prescription formulation]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tavist&reg; Allergy: 1.34 mg [scored; equivalent to clemastine base 1 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F152433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Perennial and seasonal allergic rhinitis and other allergic symptoms including urticaria (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13931347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F152497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, dizziness increased, dyscoordination, fatigue, headache, insomnia, irritability, nervousness, restlessness, sedation, sleepiness, somnolence slight to moderate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, epigastric distress, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficult urination, urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Thickening of bronchial secretions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clemastine or any component; narrow-angle glaucoma; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with stenosing peptic ulcer, GI or GU obstruction, asthma, prostatic hypertrophy, cardiovascular disease (including hypertension and ischemic heart disease), increased IOP, and thyroid dysfunction. May cause paradoxical excitation in young children.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13734140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause CNS depression, which may impair physical or mental abilities; effects may be potentiated when used with other sedative drugs or ethanol; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Concomitant use with monoamine oxidase (MAO) inhibitors may prolong and intensify the anticholinergic effects of antihistamines; avoid concomitant therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F152489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F152442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F152443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14387198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal clemastine use has generally not resulted in an increased risk of birth defects. Antihistamines are recommended for the treatment of rhinitis, urticaria, and pruritus with rash in pregnant women (although second generation antihistamines may be preferred). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1057438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Look for a reduction of rhinitis, urticaria, eczema, pruritus, or other allergic symptoms",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1057431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the GI tract, blood vessels, and respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1057445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 2 hours after administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 5-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 10-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1057446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Breast milk to plasma ratio: 0.25-0.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Majority of an oral dose eliminated in the urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/51/35636?source=see_link\">",
"      see \"Clemastine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13166 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25813=[""].join("\n");
var outline_f25_13_25813=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152461\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057439\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057433\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152447\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152433\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057443\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057442\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13931347\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152497\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057447\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057432\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13734140\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152489\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152442\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F152443\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14387198\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057438\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057431\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057445\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057446\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057437\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13166\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13166|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/62/7142?source=related_link\">",
"      Clemastine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/51/35636?source=related_link\">",
"      Clemastine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_13_25814="Permanent junctional tachy";
var content_f25_13_25814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Permanent form of junctional tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    12 lead ECG and lead II rhythm strip obtained from a patient with junctional tachycardia at a rate of 165 beats/min. The QRS complex is narrow and there are negative P waves with a long RP interval due to slow retrograde conduction via an accessory pathway. The tachycardia tends to terminate spontaneously and recur, as seen in the rhythm strip. Termination is due to retrograde block in the accessory pathway witrh absence of the retrograde P wave (arrow). An atrial premature beat (*) reinitates the tachycardia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25814=[""].join("\n");
var outline_f25_13_25814=null;
var title_f25_13_25815="Nuchal cords";
var content_f25_13_25815=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nuchal cords",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/13/25815/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25815/contributors\">",
"     Leonhard Schaffer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25815/contributors\">",
"     Roland Zimmermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/13/25815/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25815/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25815/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/13/25815/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25815/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/13/25815/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6183367\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A loop of umbilical cord around the fetal neck (nuchal cord) is a common finding at delivery. Nuchal cords have been associated with an increased risk for adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Whether prenatal ultrasound examination should attempt to identify the presence of nuchal cords and whether identification of affected pregnancies should alter antepartum and intrapartum care are controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183410\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term nuchal cord describes an umbilical cord that passes 360 degrees around the fetal neck. Nuchal cords can be classified as [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type A &mdash; A nuchal loop 360 degrees around the fetal neck where the placental end crosses over the umbilical end, entangling the neck in an unlocked pattern that can undo itself.",
"     </li>",
"     <li>",
"      Type B &mdash; A nuchal loop 360 degrees around the fetal neck where the placental end crosses under the umbilical end, entangling the neck in a locked pattern that cannot undo itself. This pattern can form a true knot when it passes down over the fetal body.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nuchal cords can occur as single or multiple entanglements around the fetal neck. They may be loose or mildly to severely constricting. Disruption of the smooth contour of the fetal neck compressing the skin in that area, referred to as the \"divot sign\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/5\">",
"     5",
"    </a>",
"    ], has been used to define tight nuchal cords [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183459\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The formation of nuchal cords may be a random event",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    related to excessive fetal movement or a long umbilical cord [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183484\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuchal cords are a common finding, whose prevalence varies by gestational age. At term, the prevalence ranges from 15 to 34 percent in the largest retrospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. In one study of 13,895 singleton deliveries &gt;20 weeks of gestation, the overall prevalence of nuchal cords at birth rose in a linear pattern from 5.8 percent of deliveries at 20 weeks of gestation to 29 percent of deliveries at 42 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/11\">",
"     11",
"    </a>",
"    ]. The increasing frequency was statistically significant and occurred with both single and multiple nuchal cords.",
"   </p>",
"   <p>",
"    Single nuchal cords are more common than multiple nuchal cords; the prevalence of single and multiple nuchal cords is 11 to 28 percent and 2 to 7 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/9,10,13-15\">",
"     9,10,13-15",
"    </a>",
"    ]. In one study, the prevalence of single, double, triple, and quadruple nuchal cords at delivery was reported to be 10.6, 2.5, 0.5 and 0.1 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183631\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of nuchal cords is unclear; they may form at any time and then disentangle and possibly reform or they may persist. The following two studies attempted to evaluate this issue.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 200 consecutive pregnancies, the probability that a nuchal cord would persist in a specific individual increased with gestational age so that only 1 of 12 (8.3 percent) of nuchal cords detected at 20 to 23 weeks of gestation was again present at 30 to 32 weeks, while 4 of 15 (26.6 percent) of nuchal cords detected at 30 to 32 weeks of gestation were again present at 36 to 38 weeks and 45 of 53 (84.9 percent) nuchal cords detected at 36 to 38 weeks of gestation were again present at birth [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/16\">",
"       16",
"      </a>",
"      ]. However, it is possible that some nuchal cords disentangled and reformed between serial examinations.",
"     </li>",
"     <li>",
"      Another prospective longitudinal study including 84 pregnancies found that the formation and disentanglement of nuchal cords were random events [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/17\">",
"       17",
"      </a>",
"      ]. While the prevalence of nuchal cords rose from 12 percent at 24 to 26 weeks of gestation to 37 percent at delivery, there was little evidence that a nuchal cord would persist with advancing gestation. At all four time points of study evaluation, the proportion of fetuses that had a nuchal cord at the previous observation was not different from the proportion of fetuses with a new nuchal cord. A nuchal cord was present on only one of four study points in 55 percent of the 50 fetuses with a nuchal cord. When a nuchal cord was present on two or more occasions, more than half of the events did not occur sequentially. True persistence from one time point to the next occurred in 24 percent of fetuses and 60 percent of the fetuses had a nuchal cord on one or more occasions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies did not discriminate between single and multiple nuchal cords, a factor which may affect the likelihood of persistence. In addition, the relatively long intervals between ultrasound examinations prevent distinguishing persistence versus resolution with reformation of the nuchal cord.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183676\">",
"    <span class=\"h1\">",
"     ULTRASOUND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuchal cords may be identified during an obstetrical ultrasound. To identify a nuchal cord, both longitudinal and transverse views of the fetal neck should be obtained. A nuchal cord is diagnosed when the umbilical cord is visualized encircling at least three-quarters of the fetal neck. Visualization of the cord encircling at least half of the neck may be classified as suspicious for the presence of a nuchal cord (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67672 \" href=\"UTD.htm?7/2/7204\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54917 \" href=\"UTD.htm?21/63/22515\">",
"     image 2",
"    </a>",
"    ). Color Doppler imaging or Doppler flow velocimetry enhances sensitivity.",
"   </p>",
"   <p>",
"    Findings that may be misdiagnosed as nuchal cords include occult prolapse where the cord is adjacent to, but does not encircle, the fetal neck, cystic posterior neck masses, fetal skin folds, and amniotic fluid pockets [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the American Institute of Ultrasound in Medicine (AIUM) does not consider attempts to visualize the presence of a nuchal cord a part of the standard prenatal ultrasound examination [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/19\">",
"     19",
"    </a>",
"    ] and prenatally diagnosed nuchal cords are not routinely reported in ultrasound reports since they can be considered a normal finding. (See",
"    <a class=\"local\" href=\"#H6184752\">",
"     'PRENATAL SCREENING AND PREGNANCY MANAGEMENT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183738\">",
"    <span class=\"h2\">",
"     Sensitivity of ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sensitivity of ultrasound for detecting nuchal cords at term has generally been reported to be about 70 percent for gray-scale imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], and 83 to 97 percent with color Doppler [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/20-23\">",
"     20-23",
"    </a>",
"    ], with some exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that performed ultrasound examinations on 180 women admitted for delivery at term with cervical dilation of at least 3 cm and rupture of the amniotic membranes, the chance of new nuchal cord formation or disentanglement between ultrasound examination and birth was minimized [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/20\">",
"       20",
"      </a>",
"      ]. A nuchal cord was present at birth in 64 cases. The sensitivity of color Doppler imaging was significantly higher than for gray-scale imaging (96.8 versus 70.3 percent); specificities were similar for both methods (89.7 and 87.9 percent, respectively). Agreement between two independent observers was high (kappa &gt;0.6). These results were confirmed by a similar smaller study that reported color Doppler sensitivity and specificity of 96 and 100 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study that compared gray-scale, color Doppler, and three-dimensional ultrasound techniques for detecting nuchal cords found no significant difference in overall diagnostic accuracy [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/21\">",
"       21",
"      </a>",
"      ]. In this study, ultrasound examinations were performed in 120 singleton cephalic pregnancies during the week before term delivery and 35 fetuses had a nuchal cord at birth. The overall performance of the these techniques was as follows: gray-scale (sensitivity 68.6 percent, specificity 80 percent, accuracy 76.7 percent), color Doppler (sensitivity 82.9 percent, specificity 77.7 percent, accuracy 79.2 percent) and three-dimensional ultrasound (sensitivity 71.4 percent, specificity 82.4 percent, accuracy 79.2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12602594\">",
"    <span class=\"h3\">",
"     Multiple versus single nuchal cords",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuchal cords are easier to detect when there are multiple loops. In one study, Doppler ultrasound correctly identified 94 percent of multiple nuchal cords and 72 percent of single nuchal cords noted at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/22\">",
"     22",
"    </a>",
"    ]. In another study, the sensitivity of detecting a nuchal cord before delivery was higher when there were multiple nuchal cords (60 percent versus 37 percent when there was a single loop), but these differences were not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/24\">",
"     24",
"    </a>",
"    ]. The authors had difficulty distinguishing whether the nuchal cord was single or multiple.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12602606\">",
"    <span class=\"h3\">",
"     Type a versus type b nuchal cords",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on the sensitivity of ultrasound for diagnosis of type A versus type B nuchal cords.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12602628\">",
"    <span class=\"h3\">",
"     Loose a versus tight nuchal cords",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound cannot consistently and reliably distinguish between tight and loose nuchal cords [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]; however, indentation of the fetal neck suggests that the cord is tight. Tightness may change during labor as the fetus descends through the birth canal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183967\">",
"    <span class=\"h1\">",
"     POTENTIAL EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether nuchal cords are associated with a statistically significant increase in any adverse event. Available data are of low quality and suggest that there is no increased risk or no more than a minimal increase in adverse perinatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nuchal cords have been associated with fetal demise, impaired fetal growth, meconium stained amniotic fluid, and an increased rate of intrapartum fetal heart rate abnormalities leading to an increased rate of operative delivery, low five-minute and umbilical artery acidemia. They have also been associated with a long-term risk of neurodevelopmental abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6183980\">",
"    <span class=\"h2\">",
"     Antepartum",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12602569\">",
"    <span class=\"h3\">",
"     Fetal demise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from large retrospective studies have not demonstrated an increased risk of stillbirth in fetuses with nuchal cords compared to those without [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/11,26,27\">",
"     11,26,27",
"    </a>",
"    ]. However, case reports of stillbirths with one or more nuchal cords, indentation marks in the tissue around the fetal neck, otherwise normal prenatal and postnatal evaluations, and no other explanation for the demise suggest that nuchal cords can be a cause of fetal death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of a nuchal cord alone is insufficient evidence of demise due to strangulation, but causality is supported by the presence of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Petechial hemorrhages of the head and neck, which are characteristic findings in strangulation [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vascular congestion and thrombosis of umbilical cord vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cord edema or hemorrhage into the Wharton's jelly [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vascular ectasia, vascular thrombosis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombotic vasculopathy (avascular villi, villous stromal karyorrhexis) involving the umbilical cord vessels",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chorionic plate and stem villous vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Absence of other conditions associated with fetal demise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One potential mechanism for fetal asphyxia is restriction of carotid artery blood flow from tight entanglement around the neck; however, severe venous congestion may be sufficient to cause asphyxia and demise. Another potential mechanism is compression of the umbilical cord vessels themselves when the cord becomes tightly compressed against itself or the fetal neck. Both mechanisms may be involved. With increasing cerebral hypoxia, loss of fetal tone may lead to loosening of the nuchal cord if multiple loops are not present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12602460\">",
"    <span class=\"h3\">",
"     Impaired intrauterine growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of nuchal cords on fetal growth is unclear.",
"   </p>",
"   <p>",
"    Studies that have not discriminated between single and multiple nuchal cords have not reported a clinically significant impact of nuchal cords on birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/8,32\">",
"     8,32",
"    </a>",
"    ]. In a study of 57,853 deliveries, fetuses with a nuchal cord had a small but statistically significant reduction in birth weight compared to those without nuchal cords (mean birthweight was 55 grams lower in the group with nuchal cords) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/32\">",
"     32",
"    </a>",
"    ]. In contrast, another study of 166,318 deliveries reported mean birth weight of infants with nuchal cords was significantly higher than in infants without nuchal cords (mean birthweight was 58 grams higher in the group with nuchal cords) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others have reported that multiple nuchal cords reduce birth weight by 93 to 180 grams and observed a significant negative correlation between the number of nuchal cord entanglements and birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/9,13,33\">",
"     9,13,33",
"    </a>",
"    ]. However, these findings were not present in other series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12602468\">",
"    <span class=\"h3\">",
"     Abnormalities in tests for fetal assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little information on the effect of nuchal cords on standard tests used in fetal assessment.",
"   </p>",
"   <p>",
"    A prospective study that compared umbilical Doppler indices in 115 third trimester fetuses with sonographically-detected nuchal cords to indices in 115 age-matched controls found that the nuchal cord group had a slight, but significant, decrease in umbilical artery Doppler indices (ie, decreased impedance to flow); cerebral vascular resistance was not affected by the presence of nuchal cords, even in the subgroup of 12 fetuses with multiple nuchal cords [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/36\">",
"     36",
"    </a>",
"    ]. The decrease, rather than an expected increase, in umbilical artery vascular resistance was attributed to chance. Other small prospective studies have found no differences in umbilical and cerebral artery Doppler indices between groups of fetuses with and without nuchal cords [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/22,37\">",
"     22,37",
"    </a>",
"    ]. However, a case report described absent end-diastolic flow and absent fetal movement on routine ultrasound examination of a 30-week fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/6\">",
"     6",
"    </a>",
"    ]. Cardiotocography showed repetitive severe variable decelerations. Emergency cesarean delivery was performed with delivery of a 1200 gram, acidotic (pH 7.10) infant with a tight double nuchal cord. Laboratory evaluation and placental histopathology were otherwise normal so the metabolic acidosis was attributed to the nuchal cords.",
"   </p>",
"   <p>",
"    Prospective studies of term and postterm pregnancies have not found prelabor amniotic fluid levels to be reduced in the presence of nuchal cords [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/24,38,39\">",
"     24,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to use of prenatal sonography for diagnosis of nuchal cords, spontaneous and evoked changes in the fetal heart rate were found to be predictive of the disorder. The probable mechanism is that vigorous fetal movement can lead to concurrent tightening of the nuchal cord, resulting in umbilical cord compression. The potential fetal heart rate consequences of this sequence are variable decelerations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/7,40-42\">",
"     7,40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12602518\">",
"    <span class=\"h3\">",
"     Preterm delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large retrospective studies have not observed differences in gestational age at delivery between infants with and without nuchal cords identified at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/8,34,43\">",
"     8,34,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a retrospective study of 233 pregnancies found that sonographic detection of a nuchal cord in the third trimester was associated with a significantly increased risk of delivery before 37 weeks of gestation (21 versus 11 percent in controls), which was not explained by differences in maternal complications or induction rates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/44\">",
"     44",
"    </a>",
"    ]. There was no difference between groups in mean birthweight, suggesting most of these were late preterm births.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6184444\">",
"    <span class=\"h2\">",
"     Nonreassuring fetal heart rate intrapartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective studies of infant outcomes after antenatal identification of nuchal cords have generally not described increased rates of nonreassuring fetal heart rate patterns or operative delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/24,38,39,45\">",
"     24,38,39,45",
"    </a>",
"    ]. However, each of these studies included fewer than 400 subjects.",
"   </p>",
"   <p>",
"    A large retrospective study of 166,318 deliveries including 24,392 fetuses with nuchal cords at birth did not find an increase in perinatal mortality among infants with nuchal cords (OR 0.7, CI 0.6-0.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/8\">",
"     8",
"    </a>",
"    ]. Nuchal cords were associated with a higher rate of nonreassuring fetal heart rate patterns (OR 1.8; CI 1.6-1.9), labor induction (OR 1.3, CI 1.3-1.4), and Apgar scores &lt;7 at five minutes (OR 0.8, CI, 0.6-0.9), but the cesarean delivery rate was not increased (OR 0.9, CI 0.8-0.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/8\">",
"     8",
"    </a>",
"    ]. Similar results were reported from another large retrospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other small retrospective series have described increased rates of nonreassuring fetal heart rate patterns (eg, variable decelerations, fetal bradycardia), meconium stained amniotic fluid, operative delivery, and lower umbilical artery pH, especially in the presence of multiple nuchal cords [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/9,10,14,27,43,46,47\">",
"     9,10,14,27,43,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study that used fetal near-infrared spectroscopy to assess the intrapartum effect of nuchal cords on cerebral hemodynamics and oxygenation found that nuchal cords were associated with an increase in cerebral blood volume during contractions, without a significant effect on cerebral oxygenation or neonatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/45\">",
"     45",
"    </a>",
"    ]. An increase in variable decelerations was also noted. The authors hypothesized that these findings were due to transient compression of the jugular veins by the cord during contractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6184637\">",
"    <span class=\"h2\">",
"     Long-term risk of neurodevelopmental abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no strong evidence that prolonged presence of a nuchal cord increases the risk of neurodevelopmental impairment. One study compared neurodevelopmental performance at 1 year of age for 66 infants with nuchal cords at birth and 124 infants without a nuchal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/48\">",
"     48",
"    </a>",
"    ]. Although the development scores of both groups were in the normal range and averaged well above the standard means, the nuchal cord group had slightly, but significantly, lower scores, which was attributed to the cases with multiple or tight nuchal cords with intrapartum signs of fetal compromise.",
"   </p>",
"   <p>",
"    There is also no strong evidence that nuchal cords increase the risk of developing cerebral palsy, and the available data are sparse and discordant [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/1,49-51\">",
"     1,49-51",
"    </a>",
"    ]. The collaborative study of cerebral palsy, a large multi-center study including over 12,000 infants, found no increased risk of clinical neurologic impairment at 1 year of age among the over 4200 infants with nuchal cords at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/49\">",
"     49",
"    </a>",
"    ], while a smaller study found an increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study found the presence of tight nuchal cords at delivery significantly increased the odds of developing unexplained spastic quadriplegia, but not diplegia or hemiplegia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/1\">",
"     1",
"    </a>",
"    ]. Other presentations of nuchal cords, such as any or multiple entanglements, were not analyzed. The possible association of a tight nuchal cord with cerebral palsy in this and other retrospective studies may be due to recording bias: documentation of a tight nuchal cord may be more likely when the infant is born in a poor condition. In a study where the presence or absence of nuchal cords was recorded systematically, a significant association between nuchal cords or tight nuchal cords and cerebral palsy was not observed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6184752\">",
"    <span class=\"h1\">",
"     PRENATAL SCREENING AND PREGNANCY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials or prospective studies have compared potential approaches to diagnosis and management of nuchal cords noted prenatally remote from delivery. Data are limited to outcomes observed in retrospective series and reported in case reports.",
"   </p>",
"   <p>",
"    One retrospective study compared the outcomes of 188 pregnancies with nuchal cords detected by sonography during the second and third trimesters of gestation and 115 pregnancies without prenatally detected nuchal cord managed with standard prenatal and intrapartum care [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/44\">",
"     44",
"    </a>",
"    ]. At delivery, 37 percent of pregnancies with prenatally diagnosed nuchal cords had nuchal cords at delivery versus 15 percent of the control group. Both groups had similar perinatal outcomes and few adverse events, suggesting prenatal diagnosis of nuchal cords does not warrant a change in obstetric care. On the other hand, single case reports have described timely intervention because of decreased fetal movement or non-reassuring fetal heart rate patterns in pregnancies prenatally diagnosed with nuchal cords [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25815/abstract/2,6,52,53\">",
"     2,6,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is insufficient evidence to support routine screening for nuchal cords during pregnancy. Such a policy would significantly increase unnecessary sonographic follow-up appointments and possibly antepartum fetal assessment, as sonographic detection of nuchal cords can be expected in one of every three to five patients. In addition, communicating the sonographic finding of a nuchal cord to the mother will inevitably lead to anxiety and may lead to unnecessary intervention. Furthermore, if follow-up of such patients is appropriate, the tests that should be performed and the optimal interval of repeat examination are unknown.",
"   </p>",
"   <p>",
"    Given the lack of high or even moderate quality evidence that prenatal diagnosis of nuchal cords improves pregnancy outcome, we do not screen for the presence of nuchal cords in our institution. Incidental detection of a nuchal cord is not reported, as it can be considered a normal finding. For patients who ask about a nuchal cord, we reassure the patient that a nuchal cord is a common finding that often resolves and that persistent nuchal cords have not been associated with a markedly increased risk of adverse pregnancy outcome. As in all pregnancies, the patient should be instructed to report decreased fetal movement to her provider. Guidelines for, and management of, decreased fetal movement are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15959?source=see_link\">",
"     \"Evaluation of decreased fetal movements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Likewise, we do not recommend ultrasound screening for nuchal cords at admission for delivery, as the presence of nuchal cords should not affect intrapartum management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6184831\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nuchal cords can occur as single or multiple entanglements around the fetal neck. They may be loose or mildly to severely constricting. (See",
"      <a class=\"local\" href=\"#H6183410\">",
"       'ANATOMY'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of nuchal cords at term ranges from 15 to 34 percent of births. They may form at any time and then disentangle and possibly reform or they may persist. (See",
"      <a class=\"local\" href=\"#H6183484\">",
"       'PREVALENCE'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6183631\">",
"       'NATURAL HISTORY'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nuchal cords can be detected by ultrasound. The sensitivity of ultrasound for detecting nuchal cords at term has been reported to be about 70 percent for gray-scale imaging and 83 to 97 percent with color Doppler. (See",
"      <a class=\"local\" href=\"#H6183738\">",
"       'Sensitivity of ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nuchal cords are not associated with a statistically significant increase in any adverse event. Available data are of low quality and suggest that there is no increased risk or no more than a minimal increase in adverse perinatal outcome.",
"     </li>",
"     <li>",
"      Nuchal cords have been associated with fetal demise, impaired fetal growth, meconium stained amniotic fluid, and an increased rate of intrapartum fetal heart rate abnormalities leading to an increased rate of operative delivery, low five-minute and umbilical artery acidemia. They have also been associated with a long-term risk of neurodevelopmental abnormalities. (See",
"      <a class=\"local\" href=\"#H6183967\">",
"       'POTENTIAL EFFECTS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not screening for nuchal cords during pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6184752\">",
"       'PRENATAL SCREENING AND PREGNANCY MANAGEMENT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not report incidental detection of a nuchal cord, as it can be considered a normal finding. For patients who ask about a nuchal cord, we reassure the patient that a nuchal cord is a common finding that often resolves and that persistent nuchal cords have not been associated with a markedly increased risk of adverse pregnancy outcome. As in all pregnancies, the patient should be instructed to report decreased fetal movement to her provider. (See",
"      <a class=\"local\" href=\"#H6184752\">",
"       'PRENATAL SCREENING AND PREGNANCY MANAGEMENT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/1\">",
"      Nelson KB, Grether JK. Potentially asphyxiating conditions and spastic cerebral palsy in infants of normal birth weight. Am J Obstet Gynecol 1998; 179:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/2\">",
"      Verdel MJ, Exalto N. Tight nuchal coiling of the umbilical cord causing fetal death. J Clin Ultrasound 1994; 22:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/3\">",
"      Dhar KK, Ray SN, Dhall GI. Significance of nuchal cord. J Indian Med Assoc 1995; 93:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/4\">",
"      Collins JH. Nuchal cord type A and type B. Am J Obstet Gynecol 1997; 177:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/5\">",
"      Ranzini AC, Walters CA, Vintzileos AM. Ultrasound diagnosis of nuchal cord: the gray-scale divot sign. Obstet Gynecol 1999; 93:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/6\">",
"      Pilu G, Falco P, Guazzarini M, et al. Sonographic demonstration of nuchal cord and abnormal umbilical artery waveform heralding fetal distress. Ultrasound Obstet Gynecol 1998; 12:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/7\">",
"      Sherer DM, Abramowicz JS, Hearn-Stebbins B, Woods JR Jr. Sonographic verification of a nuchal cord following a vibratory acoustic stimulation-induced severe variable fetal heart rate deceleration with expedient abdominal delivery. Am J Perinatol 1991; 8:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/8\">",
"      Sheiner E, Abramowicz JS, Levy A, et al. Nuchal cord is not associated with adverse perinatal outcome. Arch Gynecol Obstet 2006; 274:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/9\">",
"      Sch&auml;ffer L, Burkhardt T, Zimmermann R, Kurmanavicius J. Nuchal cords in term and postterm deliveries--do we need to know? Obstet Gynecol 2005; 106:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/10\">",
"      Larson JD, Rayburn WF, Crosby S, Thurnau GR. Multiple nuchal cord entanglements and intrapartum complications. Am J Obstet Gynecol 1995; 173:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/11\">",
"      Larson JD, Rayburn WF, Harlan VL. Nuchal cord entanglements and gestational age. Am J Perinatol 1997; 14:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/12\">",
"      Tepper R, Kidron D, Aviram R, et al. High incidence of cord entanglement during early pregnancy detected by three-dimensional sonography. Am J Perinatol 2009; 26:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/13\">",
"      S&oslash;rnes T. Umbilical cord encirclements and fetal growth restriction. Obstet Gynecol 1995; 86:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/14\">",
"      Mastrobattista JM, Hollier LM, Yeomans ER, et al. Effects of nuchal cord on birthweight and immediate neonatal outcomes. Am J Perinatol 2005; 22:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/15\">",
"      EASTMAN NJ. Coiling of the umbilical cord around the foetal neck. J Obstet Gynaecol Br Emp 1957; 64:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/16\">",
"      Lal N, Deka D, Mittal S. Does the nuchal cord persist? An ultrasound and color-Doppler-based prospective study. J Obstet Gynaecol Res 2008; 34:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/17\">",
"      Clapp JF 3rd, Stepanchak W, Hashimoto K, et al. The natural history of antenatal nuchal cords. Am J Obstet Gynecol 2003; 189:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/18\">",
"      Sherer DM, Manning FA. Prenatal ultrasonographic diagnosis of nuchal cord(s): disregard, inform, monitor or intervene? Ultrasound Obstet Gynecol 1999; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     AIUM Practice Guideline for the Performance of Obstetric Ultrasound Examinations file://www.aium.org/publications/guidelines/obstetric.pdf (Accessed on July 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/20\">",
"      Qin Y, Wang CC, Lau TK, Rogers MS. Color ultrasonography: a useful technique in the identification of nuchal cord during labor. Ultrasound Obstet Gynecol 2000; 15:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/21\">",
"      Hanaoka U, Yanagihara T, Tanaka H, Hata T. Comparison of three-dimensional, two-dimensional and color Doppler ultrasound in predicting the presence of a nuchal cord at birth. Ultrasound Obstet Gynecol 2002; 19:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/22\">",
"      Jauniaux E, Mawissa C, Peellaerts C, Rodesch F. Nuchal cord in normal third-trimester pregnancy: a color Doppler imaging study. Ultrasound Obstet Gynecol 1992; 2:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/23\">",
"      Funk A, Heyl W, Rother R, et al. [Subpartal diagnosis of umbilical cord encirclement using color-coded Doppler ultrasonography and correlation with cardiotocographic changes during labor]. Geburtshilfe Frauenheilkd 1995; 55:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/24\">",
"      Peregrine E, O'Brien P, Jauniaux E. Ultrasound detection of nuchal cord prior to labor induction and the risk of Cesarean section. Ultrasound Obstet Gynecol 2005; 25:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/25\">",
"      Henry E, Andres RL, Christensen RD. Neonatal outcomes following a tight nuchal cord. J Perinatol 2013; 33:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/26\">",
"      Carey JC, Rayburn WF. Nuchal cord encirclements and risk of stillbirth. Int J Gynaecol Obstet 2000; 69:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/27\">",
"      Jauniaux E, Ramsay B, Peellaerts C, Scholler Y. Perinatal features of pregnancies complicated by nuchal cord. Am J Perinatol 1995; 12:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/28\">",
"      Sherer DM, Manning FA. Prenatal ultrasonographic diagnosis of conditions associated with potential umbilical cord compression. Am J Perinatol 1999; 16:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/29\">",
"      Wang G, Bove KE, Stanek J. Pathological evidence of prolonged umbilical cord encirclement as a cause of fetal death. Am J Perinatol 1998; 15:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/30\">",
"      Parast MM, Crum CP, Boyd TK. Placental histologic criteria for umbilical blood flow restriction in unexplained stillbirth. Hum Pathol 2008; 39:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/31\">",
"      Tantbirojn P, Saleemuddin A, Sirois K, et al. Gross abnormalities of the umbilical cord: related placental histology and clinical significance. Placenta 2009; 30:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/32\">",
"      Ogueh O, Al-Tarkait A, Vallerand D, et al. Obstetrical factors related to nuchal cord. Acta Obstet Gynecol Scand 2006; 85:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/33\">",
"      Osak R, Webster KM, Bocking AD, et al. Nuchal cord evident at birth impacts on fetal size relative to that of the placenta. Early Hum Dev 1997; 49:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/34\">",
"      Lipitz S, Seidman DS, Gale R, et al. Is fetal growth affected by cord entanglement? J Perinatol 1993; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/35\">",
"      Carey JC, Rayburn WF. Nuchal cord encirclements and birth weight. J Reprod Med 2003; 48:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/36\">",
"      Sherer DM, Sokolovski M, Dalloul M, et al. Is fetal cerebral vascular resistance affected by the presence of nuchal cord(s) in the third trimester of pregnancy? Ultrasound Obstet Gynecol 2005; 25:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/37\">",
"      Aksoy U. Prenatal color Doppler sonographic evaluation of nuchal encirclement by the umbilical cord. J Clin Ultrasound 2003; 31:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/38\">",
"      Assimakopoulos E, Zafrakas M, Garmiris P, et al. Nuchal cord detected by ultrasound at term is associated with mode of delivery and perinatal outcome. Eur J Obstet Gynecol Reprod Biol 2005; 123:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/39\">",
"      Ghosh GS, Gudmundsson S. Nuchal cord in post-term pregnancy - relationship to suspected intrapartum fetal distress indicating operative intervention. J Perinat Med 2008; 36:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/40\">",
"      Mendez-Bauer C, Troxell RM, Roberts JE, et al. A clinical test for diagnosing nuchal cords. J Reprod Med 1987; 32:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/41\">",
"      Sherer DM, Menashe M, Sadovsky E. Severe fetal bradycardia caused by external vibratory acoustic stimulation. Am J Obstet Gynecol 1988; 159:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/42\">",
"      Simmons JN, Rufleth P, Lewis PE. Identification of nuchal cords during nonstress testing. J Reprod Med 1985; 30:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/43\">",
"      Miser WF. Outcome of infants born with nuchal cords. J Fam Pract 1992; 34:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/44\">",
"      Gonz&aacute;lez-Quintero VH, Tolaymat L, Muller AC, et al. Outcomes of pregnancies with sonographically detected nuchal cords remote from delivery. J Ultrasound Med 2004; 23:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/45\">",
"      D'Antona D, Aldrich CJ, Spencer JA, et al. Effect of nuchal cord on fetal cerebral haemodynamics and oxygenation measured by near infrared spectroscopy during labour. Eur J Obstet Gynecol Reprod Biol 1995; 59:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/46\">",
"      Rhoades DA, Latza U, Mueller BA. Risk factors and outcomes associated with nuchal cord. A population-based study. J Reprod Med 1999; 44:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/47\">",
"      Hankins GD, Snyder RR, Hauth JC, et al. Nuchal cords and neonatal outcome. Obstet Gynecol 1987; 70:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/48\">",
"      Clapp JF 3rd, Lopez B, Simonean S. Nuchal cord and neurodevelopmental performance at 1 year. J Soc Gynecol Investig 1999; 6:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/49\">",
"      Spellacy WN, Gravem H, Fisch RO. The umbilical cord complications of true knots, nuchal coils, and cords around the body. Report from the collaborative study of cerebral palsy. Am J Obstet Gynecol 1966; 94:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/50\">",
"      Greenwood C, Impey L. The association of nuchal cord with cerebral palsy is influenced by recording bias. Early Hum Dev 2002; 68:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/51\">",
"      Nielsen LF, Schendel D, Grove J, et al. Asphyxia-related risk factors and their timing in spastic cerebral palsy. BJOG 2008; 115:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/52\">",
"      Katz ME, Bass WT, White LE. Dural sinus ectasia after prolonged nuchal cord encirclement. J Ultrasound Med 1992; 11:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25815/abstract/53\">",
"      B&auml;z E, Zikulnig L, Hackel&ouml;er BJ, Hecher K. Abnormal ductus venosus blood flow: a clue to umbilical cord complication. Ultrasound Obstet Gynecol 1999; 13:204.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14181 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-109.230.63.219-AC07DF7577-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25815=[""].join("\n");
var outline_f25_13_25815=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6184831\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6183367\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6183410\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6183459\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6183484\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6183631\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6183676\">",
"      ULTRASOUND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6183738\">",
"      Sensitivity of ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12602594\">",
"      - Multiple versus single nuchal cords",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12602606\">",
"      - Type a versus type b nuchal cords",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12602628\">",
"      - Loose a versus tight nuchal cords",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6183967\">",
"      POTENTIAL EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6183980\">",
"      Antepartum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12602569\">",
"      - Fetal demise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12602460\">",
"      - Impaired intrauterine growth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12602468\">",
"      - Abnormalities in tests for fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12602518\">",
"      - Preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6184444\">",
"      Nonreassuring fetal heart rate intrapartum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6184637\">",
"      Long-term risk of neurodevelopmental abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6184752\">",
"      PRENATAL SCREENING AND PREGNANCY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6184831\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14181\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14181|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/2/7204\" title=\"diagnostic image 1\">",
"      Doppler ultrasound nuchal cord",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/63/22515\" title=\"diagnostic image 2\">",
"      Ultrasound of the nuchal cord",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15959?source=related_link\">",
"      Evaluation of decreased fetal movements",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_13_25816="Atropine: Pediatric drug information";
var content_f25_13_25816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Atropine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"    see \"Atropine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17173?source=see_link\">",
"    see \"Atropine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AtroPen&reg;;",
"     </li>",
"     <li>",
"      Atropine Care&trade;;",
"     </li>",
"     <li>",
"      Isopto&reg; Atropine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dioptic's Atropine Solution;",
"     </li>",
"     <li>",
"      Isopto&reg; Atropine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Organophosphate Poisoning",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Gastrointestinal",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Ophthalmic Agent, Mydriatic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11441969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bradycardia",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Not part of neonatal resuscitation algorithm; some institutions have used the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., I.O.: 0.02 mg/kg/dose; use of a minimum dosage of 0.1 mg will result in dosages &gt;0.02 mg/kg and is not recommended (Barrington, 2011); there is no documented minimum dosage in this age group; may repeat once in 3-5 minutes; reserve use for those patients unresponsive to improved oxygenation and epinephrine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endotracheal: 0.04-0.06 mg/kg/dose; may repeat once if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intubation, nonemergent (preferred vagolytic):",
"     </b>",
"     I.M., I.V.: 0.02 mg/kg/dose (Kumar, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Organophosphate or carbamate insecticide or nerve agent poisoning: Note:",
"     </b>",
"     The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; &ge;2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous I.V. infusion in patients requiring large doses of atropine. Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to pralidoxime for the specific route and dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I .V., I.M.: Initial: 0.05-0.1  mg/kg; repeat every 5-10 minutes as needed, doubling the dose if previous dose did not induce atropinization (Hegenbarth, 2008; Reigart, 1999; Rotenberg, 2003). Maintain atropinization by administering repeat doses as needed for &ge;2-12 hours based on recurrence of symptoms (Reigart, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: Following atropinization (see above), administer 10% to 20% of the total loading dose required to induce atropinization as a continuous I.V. infusion per hour; adjust as needed to maintain adequate atropinization without atropine toxicity (Eddleston, 2004; Roberts, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: AtroPen&reg;: 0.25 mg (yellow pen):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Mild  symptoms (&ge;2 mild symptoms):",
"     </i>",
"     Administer one 0.25 mg (yellow pen) dose as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound  anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld. Mild symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen&reg; product labeling to guide therapy, include: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Severe symptoms (&ge;1 severe symptom):",
"     </i>",
"     Immediately administer",
"     <b>",
"      three",
"     </b>",
"     0.25 mg (yellow pen) doses. Severe symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen&reg; product labeling to guide therapy, include: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary);",
"     <b>",
"      Note:",
"     </b>",
"     Neonates and infants may become drowsy or unconscious with muscle floppiness as opposed to muscle twitching.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endotracheal: Increase the dose by 2-3 times the usual I.V. dose. Mix with 3-5 mL of normal saline and administer. Flush with 3-5 mL of NS and follow with 5 assisted manual ventilations (Rotenberg, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preanesthetic:",
"     </b>",
"     I.M., I.V., SubQ: Patient weight &lt;5 kg: 0.02 mg/kg/dose 30-60 minutes preoperatively then every 4-6 hours as needed; use of a minimum dosage of 0.1 mg will result in dosages &gt;0.02 mg/kg and is not recommended (Barrington, 2011); there is no documented minimum dosage in this age group",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Refraction:",
"     </b>",
"     Ophthalmic: Instill 1 drop of 0.25% solution 3 times/day for 3 days before the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Uveitis:",
"     </b>",
"     Ophthalmic: Instill 1 drop of 0.5% solution 1-3 times daily",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"      see \"Atropine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bradycardia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V., I.O.: 0.02 mg/kg/dose; minimum dose recommended by PALS: 0.1 mg; however, use of a minimum dosage of 0.1 mg in patients &lt;5 kg will result in dosages &gt;0.02 mg/kg and is not recommended (Barrington, 2011); there is no documented minimum dosage in this age group; maximum single dose: 0.5 mg; may repeat once in 3-5 minutes; maximum total dose: 1 mg (PALS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endotracheal: 0.04-0.06 mg/kg/dose; may repeat once if needed (PALS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Organophosphate  or carbamate insecticide or nerve agent poisoning: Note:",
"     </b>",
"     The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; &ge;2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous I.V. infusion in patients requiring large doses of atropine. Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to pralidoxime for the specific route and dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V., I.M.: Initial: 0.05-0.1 mg/kg; repeat every 5-10 minutes as needed, doubling the dose if previous dose does not induce atropinization (Hegenbarth, 2008; Reigart, 1999; Rotenberg, 2003). Maintain atropinization by administering repeat doses as needed for &ge;2-12 hours based on recurrence of symptoms (Reigart, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous I.V. infusion: Following atropinization, administer 10% to 20% of the total loading dose required to induce atropinization as a continuous I.V. infusion per hour; adjust as needed to maintain adequate atropinization without atropine toxicity  (Eddleston, 2004; Roberts, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M. (AtroPen&reg;): Number of doses dependent upon symptom severity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Weight-directed dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &lt;6.8 kg (15 lb): 0.25 mg/dose (yellow pen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     6.8-18 kg (15-40 lb): 0.5 mg/dose (blue pen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     18-41 kg (40-90 lb): 1 mg/dose (dark red pen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;41 kg (&gt;90 lb): 2 mg/dose (green pen)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Mild  symptoms (&ge;2 mild symptoms):",
"     </i>",
"     Administer the weight-based dose listed above as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound  anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld. Mild  symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen&reg; product labeling to guide therapy, include: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     <i>",
"      Severe symptoms (&ge;1 severe symptom):",
"     </i>",
"     Immediately administer",
"     <b>",
"      three",
"     </b>",
"     weight-based doses in rapid succession. Symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen&reg; product labeling to guide therapy, include: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary);",
"     <b>",
"      Note:",
"     </b>",
"     Infants may become drowsy or unconscious with muscle floppiness as opposed to muscle twitching.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endotracheal: Increase the dose by 2-3 times the usual I.V. dose. Mix with 3-5 mL of normal saline and administer. Flush with 3-5 mL of NS and follow with 5 assisted manual ventilations (Rotenberg, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Preanesthetic:",
"     </b>",
"     I.M., I.V., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weight-directed dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants weighing &lt;5 kg: 0.02 mg/kg/dose 30-60 minutes preoperatively then every 4-6 hours as needed; use of a minimum dosage of 0.1 mg will result in dosages &gt;0.02 mg/kg; there is no documented minimum dosage in this age group",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children weighing &ge;5 kg: 0.01-0.02 mg/kg/dose to a maximum 0.4 mg/dose 30-60 minutes preop minimum dose: 0.1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternate dosing; fixed dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     3-7 kg (7-16 lb): 0.1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     8-11 kg (17-24 lb): 0.15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     11-18 kg (24-40 lb): 0.2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     18-29 kg (40-65 lb): 0.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;30 kg (&gt;65 lb): 0.4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Refraction:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants: Instill 1 drop of 0.25% solution 3 times/day for 3 days before the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 1-5 years: Instill 1 drop of 0.5% solution 3 times/day for 3 days before the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children and Adolescents &gt;5 years or Children with dark irides: Instill 1 drop of 1% solution 3 times/day for 3 days before the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Uveitis:",
"     </b>",
"     Ophthalmic: Instill 1 drop of 0.5% solution 1-3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Doses &lt;0.5 mg have been associated with paradoxical bradycardia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bradycardia:",
"     </b>",
"     I.V.: 0.5 mg every 3-5 minutes, not to exceed a total of 3 mg or 0.04 mg/kg (ACLS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Neuromuscular blockade reversal",
"     </b>",
"     : I.V.: 25-30 mcg/kg 30-60 seconds before neostigmine or 7-10 mcg/kg 30-60 seconds before edrophonium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Organophosphate or carbamate insecticide or nerve agent poisoning: Note:",
"     </b>",
"     The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; &ge;2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous I.V. infusion in patients requiring large doses of atropine. Once patient is stable for a period of time, the dose/dosing frequency may be decreased. If atropinization occurs after 1-2 mg of atropine then re-evaluate working diagnosis (Reigart, 1999). Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to Pralidoxime monograph for the specific route and dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M. (AtroPen&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Mild  symptoms (&ge;2 mild symptoms):",
"     </i>",
"     Administer 2 mg as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld. Mild symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen&reg; product labeling to guide therapy, include: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Severe symptoms (&ge;1 severe symptom):",
"     </i>",
"     Immediately administer",
"     <b>",
"      three",
"     </b>",
"     2 mg doses in rapid  succession. Severe symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen&reg; product labeling to guide therapy include: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Inhibit salivation and secretions (preanesthesia):",
"     </b>",
"     I.M., I.V., SubQ: 0.4-0.6 mg 30-60 minutes preop and repeat every 4-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Mydriasis, cycloplegia (preprocedure):",
"     </b>",
"     Ophthalmic: Solution (1%): Instill 1-2 drops 1 hour before the procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Uveitis:",
"     </b>",
"     Ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Solution (1%): Instill 1-2 drops up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Ointment: Apply a small amount in the conjunctival sac up to 3 times/day. Compress the lacrimal sac by digital pressure for 1-3 minutes after instillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F137911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate: 0.05 mg/mL (5 mL); 0.1 mg/mL (5 mL, 10 mL); 0.4 mg/mL (20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AtroPen&reg;: 0.25 mg/0.3 mL (0.3 mL); 0.5 mg/0.7 mL (0.7 mL); 1 mg/0.7 mL (0.7 mL); 2 mg/0.7 mL (0.7 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate [preservative free]: 0.4 mg/0.5 mL (0.5 mL [DSC]); 0.4 mg/mL (1 mL); 1 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic, as sulfate: 1% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sulfate [drops]: 1% (2 mL [DSC], 5 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atropine Care&trade;: 1% (2 mL, 5 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isopto&reg; Atropine: 1% (5 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F137895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11217108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The AtroPen&reg; formulation is available for use primarily by the Department of Defense.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endotracheal: Administer and flush with 1-5 mL NS or SWI based on patient size, followed by 5 manual ventilations. Absorption may be greater with sterile water. Stop compressions (if using for cardiac arrest), spray the drug quickly down the tube. Follow immediately with several quick insufflations and continue chest compressions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Administer undiluted by rapid I.V. injection; slow injection may result in paradoxical bradycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: AtroPen&reg;: Administer to the outer thigh. Firmly grasp the autoinjector with the green tip (0.5 mg, 1 mg, and 2 mg autoinjector) or black tip (0.25 mg autoinjector) pointed down; remove the yellow safety release (0.5 mg, 1 mg, and 2 mg autoinjector) or gray safety release (0.25 autoinjector). Firmly jab the green tip at a 90&deg; angle against the outer thigh; may be administered through clothing as long as pockets at the injection site are empty. In thin patients or patients &lt;6.8 kg (15 lb),  bunch up the thigh prior to injection. Hold the autoinjector in place for 10 seconds following the injection; remove the autoinjector and massage the injection site. After administration, the needle will be visible; if the needle is not visible, repeat the above steps with more pressure. After use, bend the needle against a hard surface (needle does not retract) to avoid accidental injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Preparation of bulk atropine solution for mass chemical terrorism: Add atropine sulfate powder  to 100 mL NS in polyvinyl chloride bags to yield a final concentration of 1 mg/mL (Dix, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Instill solution into conjunctival sac of affected eye(s); compress lacrimal sac with digital pressure for 2-3 minutes after instillation; avoid contact of bottle tip with eye or skin",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F137985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Stable in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amiodarone, argatroban, bivalirudin, doripenem, eptifibatide, etomidate, famotidine, fenoldopam, fentanyl, heparin, hydrocortisone sodium succinate, inamrinone, meropenem, methadone, morphine, nafcillin, pantoprazole, potassium chloride, sufentanil, tirofiban, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Butorphanol, chlorpromazine, cimetidine, dimenhydrinate, diphenhydramine, droperidol, fentanyl, glycopyrrolate, heparin, hydromorphone, hydroxyzine, hydroxyzine with meperidine, meperidine, meperidine with promethazine, metoclopramide, midazolam, milrinone, morphine, nalbuphine, ondansetron, pentazocine, prochlorperazine, promethazine, ranitidine, scopolamine, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Pentobarbital.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); keep tightly closed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Auto-injector (AtroPen&reg;): Store at 25&deg;C (77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F);  do not freeze; protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Preparation of bulk atropine solution for mass chemical terrorism at a concentration of 1 mg/mL is stable for 72 hours at 4&deg;C to 8&deg;C (39&deg;F to 46&deg;F); 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); 32&deg;C to 36&deg;C (90&deg;F to 97&deg;F) (Dix, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Auto-injector: Antidote for anticholinesterase  poisoning (carbamate insecticides, nerve agents, organophosphate insecticides, muscarinic poisoning) (FDA approved in all ages)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Injection: Preoperative medication to inhibit salivation and secretions; treatment of symptomatic sinus bradycardia, AV block (nodal level) adjuvant use with anticholinesterases (eg, edrophonium, neostigmine) to decrease their side effects during reversal of neuromuscular blockade [All indications: FDA approved in pediatric patients (age not specified) and adults];",
"     <b>",
"      Note:",
"     </b>",
"     Use is no longer recommended in the management of asystole or pulseless electrical activity (PEA) (ACLS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic: Produce mydriasis and cycloplegia for examination of the retina and optic disc and accurate measurement of refractive errors; produce papillary dilation in inflammatory conditions (eg, uveitis) (All indications: FDA approved in adults; refer to product-specific information regarding FDA approval in pediatric patients)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13930952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F137984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severity and frequency of adverse reactions are dose related and vary greatly; listed reactions are limited to significant and/or life-threatening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, flushing, hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, coma, delirium, disorientation, dizziness, drowsiness, excitement, fever, hallucinations, headache, insomnia, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Anhidrosis, rash, scarlatiniform rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bloating, constipation, delayed gastric emptying, loss of taste, nausea, paralytic ileus, vomiting, xerostomia, dry throat, nasal dryness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary hesitancy, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Angle-closure glaucoma, blurred vision, cycloplegia, dry eyes, mydriasis, ocular tension increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, laryngospasm, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to atropine sulfate or any component; narrow-angle glaucoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional contraindications:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Injection: Pyloric stenosis, prostatic hypertrophy; asthma  (I.V. use for treatment); pediatric patients who have previously had a severe systemic reaction to atropine;",
"     <b>",
"      Note:",
"     </b>",
"     For the treatment of life-threatening organophosphate or carbamate insecticide or nerve agent poisoning, there are no contraindications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ophthalmic: Predisposition to glaucoma, adhesions between the iris and lens",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic or renal impairment; effects of atropine may be prolonged in severe hepatic or renal impairment. Use with caution in presence of high environmental temperature; heat prostration can occur. Use with caution in children with spastic paralysis or brain damage; children are at increased risk for rapid rise in body temperature due to suppression of sweat gland activity. Paradoxical hyperexcitability may occur in children given large doses. Infants with Down's syndrome have both increased sensitivity to cardiac effects and mydriasis. Use with caution in patients with pyloric stenosis or hiatal hernia associated with reflux esophagitis; avoid use in patients with paralytic ileus, intestinal atony of the elderly or debilitated patient, severe ulcerative colitis, and toxic megacolon complicating ulcerative colitis. Use with caution in cardiovascular disease (myocardial ischemia, heart failure, tachyarrhythmias, and/or hypertension); treatment-related blood pressure increases and tachycardia may lead to ischemia, precipitate an MI, or increase arrhythmogenic potential. In sensitive individuals, psychosis may occur. Use with caution in patients with autonomic neuropathy. Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In heart transplant recipients, atropine will likely be ineffective in treatment of bradycardia due to lack of vagal innervation of the transplanted heart. Cholinergic reinnervation may occur over time (years), so atropine may be used cautiously; however, some may experience paradoxical slowing of the heart rate and high-degree AV block upon administration (ACLS, 2010; Bernheim, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The AtroPen&reg; formulation is available for use primarily by the Department of Defense as an initial treatment of the muscarinic symptoms of insecticide or nerve agent poisoning; its use should be reserved for individuals who have had adequate training in the recognition and treatment of this type of intoxication. Atropine reverses the muscarinic but not the nicotinic effects associated with anticholinesterase toxicity. Clinical symptoms consistent with highly suspected organophosphate or carbamate insecticides or nerve agent poisoning should be treated with antidote immediately; administration should not be delayed for confirmatory laboratory tests. Signs of atropinization include flushing, mydriasis, tachycardia, and dryness of the mouth or nose. Monitor effects closely when administering subsequent injections as necessary. The presence of these effects is not indicative of the success of therapy; inappropriate use of mydriasis as an indicator of successful treatment has resulted in atropine toxicity. Reversal of bronchial secretions is the preferred indicator of success. Adjunct treatment with a cholinesterase reactivator (eg, pralidoxime) may be required in patients with toxicity secondary to organophosphorus insecticides or nerve agents. Treatment should always include proper evacuation and decontamination procedures; medical personnel should protect themselves from inadvertent contamination. Antidotal administration is intended only for initial management; definitive and more extensive medical care is required following administration. Individuals should not rely solely on antidote for treatment, as other supportive measures (eg, artificial respiration) may still be required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Parenteral atropine (I.V.) should not be used to treat asthma; the high doses required to treat asthma may cause excessive drying of bronchiolar mucous plugs. Avoid relying on atropine  for effective treatment of type II second- or third-degree AV block (with or without a new wide QRS complex). Although no evidence exists for significant detrimental effects, routine use of atropine for asystole or bradycardic PEA is unlikely to have a therapeutic benefit and is no longer recommended (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pediatric patients are more susceptible to toxic effects of anticholinergic agents than adults; care should be taken to prevent overexposure. Avoid use if possible in patients with obstructive uropathy or in other conditions resulting in urinary retention; use is contraindicated in patients with prostatic hypertrophy. In patients with myasthenia gravis, use atropine with extreme caution when used to treat side effects of acetylcholinesterase inhibition or avoid; may precipitate a myasthenic crisis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F137904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F137906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B/C (manufacturer specific) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F137921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Atropine has been found to cross the human placenta.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, pulse, mental status; intravenous administration requires a cardiac monitor",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Organophosphate or carbamate insecticide or nerve agent poisoning: Heart rate, blood pressure, respiratory status, oxygenation secretions. Maintain atropinization with repeated dosing as indicated by clinical status. Crackles in lung bases, or continuation of cholinergic signs, may be signs of inadequate dosing. Pulmonary improvement may not parallel other signs of atropinization. Monitor for signs and symptoms of atropine toxicity (eg, fever, muscle fasciculations, delirium); if toxicity occurs, discontinue atropine and monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; increases cardiac output, dries secretions. Atropine reverses the muscarinic effects of cholinergic poisoning due to agents with acetylcholinesterase inhibitor activity by acting as a competitive antagonist of acetylcholine at muscarinic receptors. The primary goal in cholinergic poisonings is reversal of bronchorrhea and bronchoconstriction. Atropine has no effect on the nicotinic receptors responsible for muscle weakness, fasciculations, and paralysis.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhibition of salivation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: I.M.: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum effect: I.M.: 1-1.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: I.M.: Up to 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Increased heart rate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: I.M.: 5-40 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: 20 minutes to 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 2-4 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from all dosage forms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributes throughout the body; crosses the blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 14% to 22%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via enzymatic hydrolysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;2 years: 6.9 &plusmn; 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;2 years: 2.5 &plusmn; 1.2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 3 &plusmn; 0.9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Auto-injector: 3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (30% to 50% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17173?source=see_link\">",
"      see \"Atropine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain adequate hydration, unless instructed to restrict fluid intake. May cause dizziness, blurred vision, sensitivity to light, dry mouth, nausea, vomiting, orthostatic hypotension, constipation, increased sensitivity to heat and decreased perspiration, or decreased milk supply if breast-feeding. Report hot, dry, flushed skin; blurred vision or vision changes; difficulty swallowing; chest pain, palpitations, or rapid heartbeat; painful or difficult urination; increased confusion, depression, or loss of memory; rapid or difficult respirations; muscle weakness or tremors; or eye pain.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Ophthalmic: Wash hands before using. Sit or lie down, open eye, look at ceiling, and instill prescribed amount of solution. Do not blink for 30 seconds. Close eye, roll eye in all directions, and apply gentle pressure to inner corner of eye for 1-2 minutes. Do not let tip of applicator touch eye; do not contaminate tip of applicator (may cause eye infection, eye damage, or vision loss). Temporary stinging or blurred vision may occur.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F11414304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the discontinuance of 0.5% ophthalmic solutions commercially, 0.5% and 0.25% solutions may be prepared under sterile conditions by dilution of 1% atropine ophthalmic solution with artificial tears; 0.5%: An equal part dilution (equal volume of 1% atropine with artificial tears) and 0.25%: Dilute 2.5 mL 1% atropine with 7.5 mL artificial tears",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andriessen P, Janssen BJ, Berendsen RC, et al, \"Cardiovascular Autonomic Regulation in Preterm Infants: The Effect of Atropine,\"",
"      <i>",
"       Pediatr Res",
"      </i>",
"      , 2004, 56(6):939-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/15470200/pubmed\" id=\"15470200\" target=\"_blank\">",
"        15470200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barrington KJ, \"The Myth of a Minimum Dose for Atropine,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 127(4):783-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/21382950/pubmed\" id=\"21382950\" target=\"_blank\">",
"        21382950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bernheim A, Fatio R, Kiowski W, et al, &ldquo;Atropine Often Results in Complete Atrioventricular Block or Sinus Arrest After Cardiac Transplantation: An Unpredictable and Dose-Independent Phenomenon,&rdquo;",
"      <i>",
"       Transplantation",
"      </i>",
"      , 2004, 77(8):1181-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/15114081/pubmed\" id=\"15114081\" target=\"_blank\">",
"        15114081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dempsey EM, Al Hazzani F, Faucher D, et al, \"Facilitation of Neonatal Endotracheal Intubation With Mivacurium and Fentanyl in the Neonatal Intensive Care Unit,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 2006, 91(4):F279-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/16464937/pubmed\" id=\"16464937\" target=\"_blank\">",
"        16464937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dix J, Weber RJ, Frye RF, et al, &ldquo;Stability of Atropine Sulfate Prepared for Mass Chemical Terrorism,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2003, 41(6):771-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/14677786/pubmed\" id=\"14677786\" target=\"_blank\">",
"        14677786",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eddleston M, Dawson A, Karalliedde L, et al, &ldquo;Early Management After Self-Poisoning with an Organophosphorus or Carbamate Pesticide &ndash; A Treatment Protocol for Junior Doctors,&rdquo;",
"      <i>",
"       Crit Care",
"      </i>",
"      , 2004, 8(6):R391-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/15566582/pubmed\" id=\"15566582\" target=\"_blank\">",
"        15566582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, \"Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):S640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, \"Part 14: Pediatric Advanced Life Support (PALS): 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):S876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar P, Denson SE, Mancuso TJ, et al, \"Premedication for Nonemergency Endotracheal Intubation in the Neonate,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 125(3):608-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/20176672/pubmed\" id=\"20176672\" target=\"_blank\">",
"        20176672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, \"Part 8: Adult Advanced Cardiovascular Life Support (ACLS): 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):S729-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/2095622/pubmed\" id=\"2095622\" target=\"_blank\">",
"        2095622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Oei J, Hari R, Butha T, et al, \"Facilitation of Neonatal Nasotracheal Intubation With Premedication: A Randomized Controlled Trial,\"",
"      <i>",
"       J Paediatr Child Health",
"      </i>",
"      , 2002, 38(2):146-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/12030995/pubmed\" id=\"12030995\" target=\"_blank\">",
"        12030995",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reigart JR and Roberts JR, &ldquo;Recognition and Management of Pesticide Poisonings,&rdquo; U.S. Environmental Protection Agency, Washington, DC, 5th ed, 1999: 34-47. Available at",
"      <a href=\"file://www.epa.gov/oppfead1/safety/healthcare/handbook/handbook.htm\" target=\"_blank\">",
"       file://www.epa.gov/oppfead1/safety/healthcare/handbook/handbook.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts DM and Aaron CK, &ldquo;Management of Acute Organophosphorus Pesticide Poisoning,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2007, 334(7594):629-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/17379909/pubmed\" id=\"17379909\" target=\"_blank\">",
"        17379909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roberts KD, Leone TA, Edwards WH, et al, \"Premedication for Nonemergent Neonatal Intubations: A Randomized, Controlled Trial Comparing Atropine and Fentanyl to Atropine, Fentanyl, and Mivacurium,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(4):1583-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/17015550/pubmed\" id=\"17015550\" target=\"_blank\">",
"        17015550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rotenberg JS and Newmark J, \"Nerve Agent Attacks on Children: Diagnosis and Management,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(3 Pt 1):648-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/13/25816/abstract-text/12949297/pubmed\" id=\"12949297\" target=\"_blank\">",
"        12949297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12875 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25816=[""].join("\n");
var outline_f25_13_25816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137934\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137935\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056660\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11441969\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056653\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137911\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137895\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11217108\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056664\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137985\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056656\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056663\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930952\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137984\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056668\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056652\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056651\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298794\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137904\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137906\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137921\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056659\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056650\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056666\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056667\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056658\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11414304\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12875\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12875|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=related_link\">",
"      Atropine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/49/17173?source=related_link\">",
"      Atropine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_13_25817="Digitalis (cardiac glycoside) poisoning";
var content_f25_13_25817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Digitalis (cardiac glycoside) poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/13/25817/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25817/contributors\">",
"     Michael Levine, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25817/contributors\">",
"     Ayrn O'Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/13/25817/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25817/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25817/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/13/25817/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25817/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/13/25817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1785, Sir William Withering described the use of the foxglove plant, Digitalis purpurea, for treatment of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/1\">",
"     1",
"    </a>",
"    ]. More than 200 years later, cardiac glycosides are still prescribed for patients with atrial fibrillation and heart failure or left ventricular dysfunction.",
"   </p>",
"   <p>",
"    While the overall use of digitalis has declined, the number of patients admitted with digitalis toxicity has remained stable and the use of digitalis antibody fragments has increased [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/2\">",
"     2",
"    </a>",
"    ]. In 2007, there were 2565 cases of cardiac glycoside exposures reported to US poison control centers. Of these, 121 patients suffered major toxicity and ten died [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to digitalis, other cardiac glycosides exist and have been associated with toxicity. These include: the xenobiotics ouabain and lanatoside C; various plants, including foxglove, dogbane, red squill, lily of the valley, oleander, and henbane; and bufadienolides, cardioactive steroids found in the skin of toads belonging to the Bufonidae family [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pharmacology, diagnosis, and management of acute and chronic digitalis poisoning will be reviewed here. The dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific antibody (Fab) fragments for the treatment of digoxin toxicity and the therapeutic use of digoxin are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23043?source=see_link\">",
"     \"Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link&amp;anchor=H17#H17\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Digoxin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=see_link\">",
"     \"Treatment with digoxin: initial dosing, monitoring, and dose modification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac glycosides all possess a steroid nucleus with an unsaturated lactone at the C17 position, and at least one glycosidic residue at the C3 position (",
"    <a class=\"graphic graphic_figure graphicRef65821 \" href=\"UTD.htm?5/45/5855\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/5\">",
"     5",
"    </a>",
"    ]. Cardiac glycosides are used primarily to increase inotropy in cardiac myocytes, but also affect cells in the vascular smooth muscle and sympathetic nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal depolarization of the cardiac myocyte begins with the opening of the fast sodium channels. The resulting increase in intracellular sodium, and subsequent change in the resting membrane potential, opens voltage-gated calcium channels. The initial influx of calcium induces further release of calcium from the sarcoplasmic reticulum, which results in muscle contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/8\">",
"     8",
"    </a>",
"    ]. Sodium is then removed from the cell by, among several mechanisms, the sodium-potassium ATPase. Some calcium is removed from the cell by the sodium-calcium antiporter.",
"   </p>",
"   <p>",
"    Cardiac glycosides reversibly inhibit the sodium-potassium-ATPase, causing an increase in intracellular sodium and a decrease in intracellular potassium [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. The increase in intracellular sodium prevents the sodium-calcium antiporter from expelling calcium from the myocyte, which increases intracellular calcium. The net increase in intracellular calcium augments inotropy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Cardiac glycosides also increase vagal tone which results in decreased conduction through the sinoatrial and atrioventricular nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excessive intracellular calcium may cause delayed after-depolarizations, which may in turn lead to premature contractions and trigger arrhythmias. Cardiac glycosides shorten repolarization of the atria and ventricles, decreasing the refractory period of the myocardium, thereby increasing automaticity and the risk for arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of cardiac glycosides on vasoconstriction can vary [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Digitalis has been shown to reduce plasma renin concentrations in patients with advanced decompensated heart failure, causing peripheral vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/12\">",
"     12",
"    </a>",
"    ]. In patients without heart failure, digitalis can increase vasoconstriction. This difference is likely due to enhanced responsiveness of the baroreceptors in patients with chronic heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    and digitoxin are the two cardiac glycosides available for clinical use. Important pharmacokinetic properties of these agents are presented in the attached table (",
"    <a class=\"graphic graphic_table graphicRef60113 \" href=\"UTD.htm?28/6/28779\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    While mechanistically equivalent, these drugs have several different pharmacologic properties. Digitoxin is absorbed more readily and has a smaller volume of distribution, a shorter half-life, and greater protein binding. In addition, digitoxin is hepatically cleared while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is cleared renally.",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and digitoxin have a narrow therapeutic index and toxicity is common [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/15\">",
"     15",
"    </a>",
"    ]. Furthermore, dosing adjustments must be made whenever significant alterations occur in factors affecting absorption, distribution, or elimination. Such factors are numerous and include changes in volume of distribution due to age or increased adipose stores, diminished protein binding from conditions causing hypoalbuminemia, and renal impairment resulting in decreased elimination.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is a substrate of intestinal and renal p-glycoprotein. P-glycoprotein is an efflux pump that excretes many drugs into the intestine or proximal renal tubule, thereby lowering serum concentrations. Drugs that alter p-glycoprotein activity can increase serum digoxin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Examples of such drugs include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef73326 \" href=\"UTD.htm?6/22/6507\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The molecular weight of both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and digitoxin is large, making extracorporeal elimination ineffective for either agent. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Extracorporeal removal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both pharmaceutical formulations and naturally occurring sources of cardiac glycosides can cause toxicity. Critical clinical manifestations of toxicity are usually cardiac, but may include gastrointestinal and neurologic signs. The diagnosis of cardiac glycoside toxicity is based upon clinical and electrocardiographic manifestations rather than isolated elevated serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentrations. Presentation can vary depending upon whether toxicity is acute or chronic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determine the agent, amount taken, time of ingestion, and any coingestants whenever possible. The time is especially important because the serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration ideally should be measured at least six hours after ingestion to ensure accuracy. A level drawn prematurely may be falsely elevated due to incomplete drug distribution. Determine also if the patient normally takes digitalis or if it was someone else's prescription. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Serum digoxin concentration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ask about symptoms suggesting an acute illness, such as gastroenteritis, that may have caused dehydration or acute renal insufficiency and contributed to the development of chronic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/20\">",
"     20",
"    </a>",
"    ]. Inquire carefully about gastrointestinal, cardiac, and neurologic manifestations, including visual disturbances, because these are the most common findings associated with chronic toxicity.",
"   </p>",
"   <p>",
"    Inquire also about symptoms that suggest hypoperfusion, such as confusion and abdominal pain, which may stem from mesenteric ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Obtain a thorough medication history to determine if any recent additions or dosing changes were made. Several medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    , can increase serum digitalis concentrations (",
"    <a class=\"graphic graphic_table graphicRef73326 \" href=\"UTD.htm?6/22/6507\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial evaluation of the patient's airway and breathing, the clinician should assess the patient's vital signs. Bradycardia is frequently encountered in digitalis toxicity.",
"   </p>",
"   <p>",
"    Look for evidence of hypoperfusion and end organ dysfunction. Pay particular attention to mentation and neurologic status, keeping in mind that such effects are often due to direct toxicity but may be secondary to cerebral hypoperfusion. Look for symptoms and signs suggestive of acute mesenteric ischemia, which is a rare complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link\">",
"     \"Acute mesenteric ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In both acute and chronic digitalis toxicity, cardiac effects are of the greatest concern. The cardiac manifestations of digitalis toxicity can include virtually any type of arrhythmia with the exception of rapidly conducted atrial arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/11\">",
"     11",
"    </a>",
"    ]. Digitalis-related arrhythmias are discussed below and separately. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Electrocardiogram'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other symptoms of acute and chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity may overlap, but a few important differences should be noted. With an acute ingestion, the patient may remain asymptomatic for several hours, then develop significant gastrointestinal symptoms such as anorexia, nausea, vomiting, and abdominal pain. Neurologic manifestations such as confusion and weakness, independent of hemodynamic parameters, are common. Electrolyte abnormalities occur with both acute and chronic toxicity and are discussed further below. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Electrolyte abnormalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Chronic toxicity is often more difficult to diagnose, as symptom onset tends to be more insidious and may occur over a period ranging from days to months. Gastrointestinal symptoms, such as anorexia, nausea, and vomiting, can occur, but may be less pronounced. Neurologic manifestations, such as lethargy, fatigue, delirium, confusion, disorientation, and weakness, may be prominent in chronic toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/22\">",
"     22",
"    </a>",
"    ]. Visual changes may include alterations in color vision, the development of scotomas, or blindness. Often patients are brought to medical attention by family members who note a change in mental status since their last visit, which may have been days, weeks, or even months prior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LABORATORY AND ECG EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Approach to testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient with suspected",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity, the following studies should be obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      concentration (obtained six hours following ingestion with acute toxicity and immediately upon presentation with chronic toxicity)",
"     </li>",
"     <li>",
"      Serum potassium concentration",
"     </li>",
"     <li>",
"      Creatinine and BUN to assess renal function",
"     </li>",
"     <li>",
"      Serial electrocardiograms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the setting of an intentional ingestion, the following studies should also be obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestants",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of the sodium-potassium-ATPase, in both heart and skeletal muscle, leads to an increase in extracellular potassium. Thus, hyperkalemia is a major manifestation of acute digitalis toxicity, and an important predictor of mortality. Other electrolyte abnormalities may also occur in the setting of digitalis poisoning. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pharmacology and cellular toxicology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In acute toxicity, the degree of hyperkalemia correlates with mortality. This was first shown in a classic study performed before the advent of antidotal therapy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific antibody (Fab) fragments. In this study of 91 patients primarily with acute digoxin poisoning from intentional overdose, researchers noted that no patient with an initial potassium concentration above 5.5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    (or",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    survived, while no patient with a potassium concentration below 5",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    died [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/23\">",
"     23",
"    </a>",
"    ]. This correlation has also been demonstrated in plant cardiac glycoside ingestions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of chronic toxicity, hypokalemia is of greater concern. Several electrolyte abnormalities, including hypokalemia, hypomagnesemia, and hypercalcemia, increase patient susceptibility to the toxic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/15\">",
"     15",
"    </a>",
"    ]. Loop diuretics to treat heart failure are the most common cause of hypokalemia in these patients, but other causes of hypokalemia (eg, diarrhea or vomiting) do occur.",
"   </p>",
"   <p>",
"    Renal dysfunction is also commonly encountered in the setting of chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity and is often what precipitates the rise in the digoxin level. Assessment of urine output as a measure of renal perfusion is essential. The adjustments needed for digoxin dosing in the setting of renal insufficiency are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment with digoxin: initial dosing, monitoring, and dose modification\", section on 'Dose adjustments'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Serum digoxin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic window of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is narrow, with substantial overlap between &ldquo;therapeutic&rdquo; and &ldquo;toxic&rdquo; serum concentrations (or levels), and the concentration can be affected by many factors (eg, impaired renal function, other medications). Therefore, determining an appropriate therapeutic serum digoxin concentration can be difficult. Issues related to the therapeutic serum concentration of digoxin are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment with digoxin: initial dosing, monitoring, and dose modification\", section on 'Monitoring serum digoxin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A quantitative serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration is readily measured in most hospital laboratories, which use a standard radioimmunoassay. The approximate therapeutic range for patients in heart failure is 0.5 to 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (0.65 to 1",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"    Ideally, blood samples should be collected four hours after an intravenous dose or six hours after an oral dose in order to account for drug distribution and obtain an accurate measurement. The serum digoxin concentration is likely to be falsely elevated if the sample is obtained soon after administration or ingestion because of the time required to equilibrate through the large volume of distribution.",
"   </p>",
"   <p>",
"    The serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration does",
"    <strong>",
"     not",
"    </strong>",
"    necessarily correlate with toxicity. Numerous reports have described asymptomatic patients with a \"toxic\" level, while others described patients with significant toxicity despite a serum digoxin concentration in the therapeutic range [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/22,26-28\">",
"     22,26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although they may not correlate with clinical manifestations of toxicity, serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    levels are used in some cases to determine the dosing of antidotal therapy with Fab fragments. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Antidotal therapy with antibody (Fab) fragments'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    immunoassay is specifically designed to measure digoxin, cross reactivity with other cardiac glycosides does occur. Consequently, patients poisoned with another cardiac glycoside may have an elevated initial digoxin concentration. However, because cross reactivity is incomplete, an elevated digoxin concentration only confirms exposure in such instances and there is",
"    <strong>",
"     NO",
"    </strong>",
"    correlation between the numerical measurement and the degree of toxicity.",
"   </p>",
"   <p>",
"    Following the administration of Fab fragments, serum immunoassays of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    may be unreliable if they measure both bound and unbound drug. Fab treatment frequently causes an elevation in the measured digoxin concentration despite a free digoxin level approaching zero [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. The measurement of \"free\" digoxin concentrations may be helpful in determining when a patient can restart digoxin, if desired. However, the free digoxin level may not be routinely available in some centers.",
"   </p>",
"   <p>",
"    Endogenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -like substances have been identified in pregnant women, newborns, and patients with acromegaly, subarachnoid hemorrhage, liver disease, and renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/31\">",
"     31",
"    </a>",
"    ]. Their clinical significance remains unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digitalis toxicity can produce a range of cardiac arrhythmias, and rhythm disturbances may evolve and change rapidly. Thus, performing continuous cardiac monitoring and obtaining serial electrocardiograms (ECG) is important in the setting of toxicity. An ECG should be obtained upon presentation and repeated with any change in the patient's clinical condition or any significant alteration in the rhythm or waveform on the cardiac monitor.",
"   </p>",
"   <p>",
"    Premature ventricular contractions are the most common rhythm disturbance caused by digitalis toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/9\">",
"     9",
"    </a>",
"    ]. Others include bradycardia, atrial tachyarrhythmias with AV block, ventricular bigeminy, junctional rhythms, various degrees of AV nodal blockade, ventricular tachycardia, and ventricular fibrillation. Bidirectional ventricular tachycardia, while not pathognomonic for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity, is encountered in rare instances; digoxin is one of only a few xenobiotics known to produce this arrhythmia (",
"    <a class=\"graphic graphic_waveform graphicRef71796 \" href=\"UTD.htm?28/24/29063\">",
"     waveform 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Ventricular arrhythmias are reportedly more common in chronic toxicity and in patients with chronic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/26\">",
"     26",
"    </a>",
"    ]. A detailed description of the arrhythmias caused by digitalis is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=see_link\">",
"     \"Basic approach to arrhythmias due to digoxin toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The so-called \"digitalis effect\" on the electrocardiogram consists of T wave changes (flattening or inversion), QT interval shortening, scooped ST segments with ST depression in the lateral leads, and increased amplitude of the U waves. It is often seen with chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    use and does not correlate well with toxicity (",
"    <a class=\"graphic graphic_waveform graphicRef56737 \" href=\"UTD.htm?4/31/4594\">",
"     waveform 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33651379\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poisoning with beta blockers, calcium channel blockers, and alpha agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ) can present in a similar fashion to digitalis toxicity, with bradycardia and hypotension being prominent features. An elevated serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    level distinguishes digitalis poisoning. In addition, significant toxicity from calcium channel blockers generally produces hyperglycemia. Clonidine poisoning leads to greater CNS depression, respiratory depression, and miosis than is seen with digoxin poisoning.",
"   </p>",
"   <p>",
"    Nontoxicologic etiologies may also present with symptoms and signs similar to digitalis poisoning. These may include sick-sinus syndrome, hypothermia, hypothyroidism, myocardial infarction, and hyperkalemia from other causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Basic measures and arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;When digitalis toxicity is suspected, the following measures should be performed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Assess airway, breathing, and circulation; stabilize as necessary",
"     </li>",
"     <li>",
"      Place the patient on continuous cardiac and pulse oximetry monitors",
"     </li>",
"     <li>",
"      Establish intravenous (IV) access",
"     </li>",
"     <li>",
"      Obtain an electrocardiogram (ECG)",
"     </li>",
"     <li>",
"      Obtain a fingerstick glucose measurement if there is any alteration in mental status (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Approach to testing'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment for clinically significant arrhythmia or hypotension due to digitalis toxicity is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific antibody (Fab) fragments. Treatment decisions must be made on an individual basis and are often made in conjunction with a medical toxicologist or a poison control center. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As temporizing measures or if Fab fragments are not immediately available, symptomatic bradycardia or bradyarrhythmia can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    (0.5 mg IV in adults; 0.02",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV in children, minimum dose 0.1 mg) and hypotension with IV boluses of isotonic crystalloid. Life-threatening ventricular arrhythmias are treated according to the algorithms of advanced cardiac life support. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antidotal therapy with antibody (Fab) fragments",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Indications and general approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early recognition of digitalis toxicity and prompt administration of Fab fragments is essential for the successful treatment of severe poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/13,32\">",
"     13,32",
"    </a>",
"    ]. Fab fragments are highly effective and safe and have transformed the management of cardiac glycoside poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dosing of Fab fragments is based upon the clinical setting (eg, agent and amount ingested; serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration) and is discussed in detail separately. Following the acute ingestion of an unknown amount of digitalis, empiric treatment consists of 10 vials of digoxin Fab fragments for adults or 5 vials for children [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/34\">",
"     34",
"    </a>",
"    ]. One vial binds approximately 0.5 mg of digoxin. The indications for treatment are described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23043?source=see_link\">",
"     \"Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fab fragments should be given in all cases of severe digitalis poisoning, as there is no alternative therapy with comparable efficacy and safety. We suggest Fab fragments be given to patients with digitalis toxicity and any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Life-threatening arrhythmia (eg, ventricular tachycardia; ventricular fibrillation; asystole; complete heart block; Mobitz II heart block; symptomatic bradycardia)",
"     </li>",
"     <li>",
"      Evidence of end-organ dysfunction (eg, renal failure, altered mental status)",
"     </li>",
"     <li>",
"      Hyperkalemia (serum potassium &gt;5 to 5.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [&gt;5 to 5.5",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We generally do not treat with Fab fragments solely based upon the serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration or the amount ingested. However, some toxicologists give Fab fragments if the serum digoxin concentration is greater than 10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (13",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    at steady state in acute ingestions, or greater than 4",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (5.1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in chronic ingestions, or when an adult ingests more than 10 mg or a child more than 4 mg acutely.",
"   </p>",
"   <p>",
"    Cross reactivity exists between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    and other cardiac glycosides. Therefore, digoxin-specific antibodies can be used to treat poisoning involving cardiac glycosides from both plants and animals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/24,35,36\">",
"     24,35,36",
"    </a>",
"    ]. However, the dosing of Fab fragments should be done empirically in such cases because the degree of toxicity in naturally occurring cardiac glycosides does not correlate with the serum digoxin concentration. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Serum digoxin concentration'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The advent of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific antibody (Fab) fragments occurred in 1976 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/26,37\">",
"     26,37",
"    </a>",
"    ]. Evidence for the benefit of Fab fragments is found in the many case series that have appeared since that time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/33,38\">",
"     33,38",
"    </a>",
"    ]. Prior to the development of this treatment, the management of digitalis overdose was difficult and often resulted in life-threatening arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Patients with pacemakers",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be impossible to determine the underlying cardiac rhythm and thereby detect early signs of digitalis toxicity in patients with pacemakers. The ECG in such patients may demonstrate a paced rhythm without ventricular ectopy or bradyarrhythmia despite the presence of moderate to severe digitalis toxicity. We suggest treating these patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific antibody fragments if the serum potassium concentration is above 5 to 5.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [&gt;5 to 5.5",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or clinical symptoms are significant (eg, encephalopathy) or progressing. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     GI decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    for gastrointestinal decontamination should be viewed as adjunctive and",
"    <strong>",
"     not",
"    </strong>",
"    primary therapy in patients with digitalis poisoning.",
"   </p>",
"   <p>",
"    Patients suspected of having an acute digitalis intoxication who present to the emergency department within one to two hours of ingestion may benefit from the administration of AC. The standard dose is 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    (maximum 50 g). The decision to administer AC should be made after ensuring that the patient is alert and adequately protecting their airway. We do",
"    <strong>",
"     not",
"    </strong>",
"    advocate insertion of a nasogastric tube in a nonintubated patient solely for the purpose of administering AC. AC is unlikely to benefit patients with chronic digitalis toxicity.",
"   </p>",
"   <p>",
"    Cardiac glycosides undergo some degree of enterohepatic or enteroenteric recirculation and are adsorbed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    . However, there are mixed clinical data regarding the efficacy of AC or multi-dose AC (MDAC) in the setting of yellow oleander poisoning: one randomized trial found a reduction in mortality with AC administration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/39\">",
"     39",
"    </a>",
"    ], while another did not [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When Fab fragments are not readily available, AC or MDAC are reasonable interventions in patients with yellow oleander poisoning, although their efficacy remains unclear. The extrapolation of data from studies of yellow oleander poisoning to poisonings with other glycosides (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) should be made with caution. Most importantly, neither AC nor MDAC should ever be considered an alternative to Fab fragment therapy for any cardiac glycoside poisoning when Fab fragments are available. Fab fragment therapy remains the essential treatment for digitalis poisoning. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Antidotal therapy with antibody (Fab) fragments'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     Cholestyramine",
"    </a>",
"    may interrupt enterohepatic recirculation and its use has been reported in patients with acute digitalis intoxication and renal failure for whom Fab fragments were not available [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. If used, the dose is 4 grams by mouth, given twice daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Electrolyte abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkalemia is common in acute digitalis intoxication and accurately reflects the degree of toxicity and risk of death. However, hyperkalemia itself does not cause death, and treatment with potassium-lowering agents such as insulin and dextrose,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , or ion exchange resins does",
"    <strong>",
"     not",
"    </strong>",
"    reduce mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific antibody (Fab) fragments is instituted, hyperkalemia is rapidly corrected as the regenerated sodium-potassium ATPase pumps potassium back into cells. Thus, aggressive treatment with potassium-lowering agents could cause significant",
"    <strong>",
"     hypo",
"    </strong>",
"    kalemia following antidotal therapy.",
"   </p>",
"   <p>",
"    If a patient with digitalis poisoning is hypokalemic, potassium should be administered since hypokalemia exacerbates digitalis toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/22\">",
"     22",
"    </a>",
"    ]. The need for potassium repletion is particularly important patients who are to be treated with Fab fragments, because this treatment leads to a further reduction in the serum potassium. Many hypokalemic patients are simultaneously hypomagnesemic and should be given magnesium as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been taught that calcium should not be given to patients with digitalis toxicity for the treatment of hyperkalemia. This teaching is based primarily upon five published cases dating back to 1933. Of these five cases, only three patients had a temporal association between calcium administration and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Some studies have shown that hypercalcemic animals given digoxin developed adverse effects with lower doses than normocalcemic animals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. However, the serum calcium levels in these studies exceeded 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    before increased toxicity occurred. Other animal experiments involving lower, more physiologic, serum calcium concentrations did not show increased toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several case reports of patients receiving calcium for treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -induced hyperkalemia without adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In addition, a large retrospective series of patients with digoxin toxicity found no ill effects attributable to the administration of calcium [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, because hyperkalemia is not the cause of death and excessive intracellular calcium is present in digitalis poisoning, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend routine administration of calcium in hyperkalemic patients with recognized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity. In this setting, hyperkalemia is best treated with digoxin-specific antibody fragments. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Antidotal therapy with antibody (Fab) fragments'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     General care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume depletion from diuretics or gastrointestinal losses can cause prerenal disease, contributing to digitalis toxicity. Appropriate fluid resuscitation is necessary in such cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Fab fragment dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    -specific antibody (Fab) fragments does not need to be adjusted in patients with renal failure, but the elimination of both digoxin and Fab fragments is markedly prolonged in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Cases of recurrent digoxin toxicity, including ventricular arrhythmias, have been reported 72 to 90 hours after antidotal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, any patient with significant renal dysfunction who receives Fab fragments should be observed in a closely monitored setting for a minimum of 72 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Extracorporeal removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    's large volume of distribution and molecular weight, extracorporeal removal is not beneficial. Neither hemoperfusion nor hemodialysis have been shown to be helpful in the management of digoxin toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of Fab fragments and plasmapheresis has been used with apparent success in a few patients with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Nevertheless, we do not routinely recommend this approach. Instead, we administer Fab fragments for the usual indications and observe the patient with renal failure in a closely monitored setting over several days. Additional Fab fragments are given if signs of toxicity recur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with signs of digitalis toxicity should be admitted to a ward with continuous cardiac monitoring. Patients who have displayed unstable cardiac rhythms and those with underlying cardiac disease or major comorbidities are admitted to an intensive care setting.",
"   </p>",
"   <p>",
"    Patients with less severe signs of digitalis toxicity who do not receive antidotal therapy with Fab fragments are admitted for monitoring, which should include serial measurements of their serum potassium and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentrations. An electrocardiogram should be obtained at least twice daily, and sooner if any significant changes are noted on the cardiac monitor or in the patient's clinical condition.",
"   </p>",
"   <p>",
"    Patients with suspected digitalis toxicity but without significant manifestations or renal disease are placed on cardiac monitoring and observed for approximately six hours. If they remain asymptomatic and a repeat serum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    concentration is not increasing, they may be discharged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While less common, pediatric ingestions of digitalis are potentially life threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/59\">",
"     59",
"    </a>",
"    ]. Toxicity among children generally presents with signs and symptoms similar to adults, but with a few important exceptions. Children are more likely to present with bradyarrhythmias and heart block, rather than ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, children may be more resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    's cardiotoxic effects than adults at an equivalent serum concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25817/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    toxicity, including the indications for antidotal therapy with digoxin-specific antibody (Fab) fragments, remains unchanged. The dosing of Fab fragments is based upon the clinical setting (eg, agent and amount ingested; serum digoxin concentration) and is discussed in detail separately. The indications for treatment are described above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23043?source=see_link\">",
"     \"Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Antidotal therapy with antibody (Fab) fragments'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmia is the most dangerous manifestation of digitalis (cardiac glycoside) poisoning. Arrhythmias occur through several mechanisms, which are described in the text. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology and cellular toxicology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Kinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardiac manifestations of digitalis toxicity can include virtually any type of arrhythmia with the exception of rapidly conducted atrial arrhythmias. Gastrointestinal (anorexia, nausea, vomiting, and abdominal pain) and neurologic signs (confusion and weakness) may be present. Chronic toxicity is more difficult to diagnose, as symptom onset tends to be more insidious. In addition to gastrointestinal symptoms, visual changes may occur, including alterations in color vision, the development of scotomas, or blindness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for digitalis intoxication includes poisoning with beta blockers, calcium channel blockers, or alpha agonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      ), as well as nontoxicologic etiologies such as sick-sinus syndrome, hypothermia, hypothyroidism, myocardial infarction, and hyperkalemia unrelated to digitalis. (See",
"      <a class=\"local\" href=\"#H33651379\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the patient with suspected",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      toxicity, a serum digoxin concentration, serum potassium concentration, creatinine and BUN, and serial electrocardiograms should be obtained. With acute oral overdose, the serum digoxin concentration is obtained six hours after ingestion to ensure accuracy; with chronic toxicity, it is obtained upon presentation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Laboratory and ECG evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A quantitative serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      concentration is readily determined in most hospital laboratories. The therapeutic range is 0.8 to 2",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (1 to 2.6",
"      <span class=\"nowrap\">",
"       nmol/L).",
"      </span>",
"      The serum digoxin concentration does",
"      <strong>",
"       not",
"      </strong>",
"      necessarily correlate with toxicity. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Serum digoxin concentration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any patient with clinically significant manifestations of digitalis poisoning should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      -specific antibody (Fab) fragments. Significant findings include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Life-threatening arrhythmia (eg, ventricular tachycardia; ventricular fibrillation; asystole; complete heart block; Mobitz II heart block; symptomatic bradycardia)",
"     </li>",
"     <li>",
"      Evidence of end-organ dysfunction (eg, renal failure, altered mental status)",
"     </li>",
"     <li>",
"      Hyperkalemia (serum potassium &gt;5 to 5.5",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      [&gt;5 to 5.5",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Antidotal therapy with antibody (Fab) fragments'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As temporizing measures or if Fab fragments are not immediately available, bradycardia can be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      (0.5 mg IV in adults; 0.02",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV in children, minimum dose 0.1 mg) and hypotension with IV boluses of isotonic crystalloid. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Basic measures and arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperkalemia is common in acute digitalis intoxication and accurately reflects the degree of toxicity and risk of death. However, hyperkalemia itself does not cause death and treatment of hyperkalemia does",
"      <strong>",
"       not",
"      </strong>",
"      reduce mortality but does increase the risk of hypokalemia following treatment with Fab fragments. Therefore, we treat hyperkalemia with Fab fragments as described above; we suggest",
"      <strong>",
"       not",
"      </strong>",
"      treating hyperkalemia in patients with digitalis poisoning with anything other than Fab fragments (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Electrolyte abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients suspected of having acute digitalis intoxication who present to the emergency department within one to two hours of ingestion may benefit from the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      . The standard dose is 1",
"      <span class=\"nowrap\">",
"       g/kg",
"      </span>",
"      (maximum 50 g). The decision to administer activated charcoal should be made after ensuring that the patient is alert and adequately protecting their airway. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'GI decontamination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/1\">",
"      Eichhorn EJ, Gheorghiade M. Digoxin. Prog Cardiovasc Dis 2002; 44:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/2\">",
"      Hussain Z, Swindle J, Hauptman PJ. Digoxin use and digoxin toxicity in the post-DIG trial era. J Card Fail 2006; 12:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/3\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila) 2008; 46:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/4\">",
"      Brubacher JR, Lachmanen D, Ravikumar PR, Hoffman RS. Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. Toxicon 1999; 37:931.",
"     </a>",
"    </li>",
"    <li>",
"     Rocco TP, Fang JC. Pharmacotherapy of congestive heart failure. In: Goodman &amp; Gilman's The Pharmocological Basis of Therapeutics, 11th, Brunton LL, Lazo JS, Parker KL.  (Eds), McGraw-Hill, New York 2006. p.869.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/6\">",
"      Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 1988; 318:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/7\">",
"      Newton GE, Tong JH, Schofield AM, et al. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol 1996; 28:155.",
"     </a>",
"    </li>",
"    <li>",
"     Matthews CG. Cellular Physiology of Nerve and Muscle, 3rd, Blackwell Science, Malden 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/9\">",
"      Li-Saw-Hee FL, Lip GY. Digoxin revisited. QJM 1998; 91:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/10\">",
"      Demiry&uuml;rek AT, Demiry&uuml;rek S. Cardiotoxicity of digitalis glycosides: roles of autonomic pathways, autacoids and ion channels. Auton Autacoid Pharmacol 2005; 25:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/11\">",
"      Ma G, Brady WJ, Pollack M, Chan TC. Electrocardiographic manifestations: digitalis toxicity. J Emerg Med 2001; 20:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/12\">",
"      Ribner HS, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study. Am J Cardiol 1985; 56:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/13\">",
"      Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/14\">",
"      Tisdale JE, Gheorghiade M. Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with congestive heart failure. Am J Cardiol 1992; 69:34G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/15\">",
"      Lip GY, Metcalfe MJ, Dunn FG. Diagnosis and treatment of digoxin toxicity. Postgrad Med J 1993; 69:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/16\">",
"      Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/17\">",
"      Drescher S, Glaeser H, M&uuml;rdter T, et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003; 73:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/18\">",
"      Lin JH, Yamazaki M. Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 2003; 35:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/19\">",
"      Katoh M, Nakajima M, Yamazaki H, Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 2001; 12:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/20\">",
"      Cauffield JS, Gums JG, Grauer K. The serum digoxin concentration: ten questions to ask. Am Fam Physician 1997; 56:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/21\">",
"      Guglielminotti J, Tremey B, Maury E, et al. Fatal non-occlusive mesenteric infarction following digoxin intoxication. Intensive Care Med 2000; 26:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/22\">",
"      Bhatia SJ. Digitalis toxicity--turning over a new leaf? West J Med 1986; 145:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/23\">",
"      Bismuth C, Gaultier M, Conso F, Efthymiou ML. Hyperkalemia in acute digitalis poisoning: prognostic significance and therapeutic implications. Clin Toxicol 1973; 6:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/24\">",
"      Eddleston M, Rajapakse S, Jayalath S, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet 2000; 355:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/25\">",
"      Eddleston M, Ariaratnam CA, Sj&ouml;str&ouml;m L, et al. Acute yellow oleander (Thevetia peruviana) poisoning: cardiac arrhythmias, electrolyte disturbances, and serum cardiac glycoside concentrations on presentation to hospital. Heart 2000; 83:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/26\">",
"      Bayer MJ. Recognition and management of digitalis intoxication: implications for emergency medicine. Am J Emerg Med 1991; 9:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/27\">",
"      Smith TW. New advances in the assessment and treatment of digitalis toxicity. J Clin Pharmacol 1985; 25:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/28\">",
"      Sonnenblick M, Abraham AS, Meshulam Z, Eylath U. Correlation between manifestations of digoxin toxicity and serum digoxin, calcium, potassium, and magnesium concentrations and arterial pH. Br Med J (Clin Res Ed) 1983; 286:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/29\">",
"      Ujhelyi MR, Green PJ, Cummings DM, et al. Determination of free serum digoxin concentrations in digoxin toxic patients after administration of digoxin fab antibodies. Ther Drug Monit 1992; 14:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/30\">",
"      Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. Drug Saf 2004; 27:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/31\">",
"      Dasgupta A. Endogenous and exogenous digoxin-like immunoreactive substances: impact on therapeutic drug monitoring of digoxin. Am J Clin Pathol 2002; 118:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/32\">",
"      Kelly RA, Smith TW. Recognition and management of digitalis toxicity. Am J Cardiol 1992; 69:108G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/33\">",
"      Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 1990; 81:1744.",
"     </a>",
"    </li>",
"    <li>",
"     DigiFab package insert. Savage Laboratories. Melville, NY 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/35\">",
"      Brubacher JR, Ravikumar PR, Bania T, et al. Treatment of toad venom poisoning with digoxin-specific Fab fragments. Chest 1996; 110:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/36\">",
"      Cheung K, Urech R, Taylor L, et al. Plant cardiac glycosides and digoxin Fab antibody. J Paediatr Child Health 1991; 27:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/37\">",
"      Smith TW, Haber E, Yeatman L, Butler VP Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976; 294:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/38\">",
"      Woolf AD, Wenger T, Smith TW, Lovejoy FH Jr. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J Med 1992; 326:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/39\">",
"      de Silva HA, Fonseka MM, Pathmeswaran A, et al. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet 2003; 361:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/40\">",
"      Eddleston M, Juszczak E, Buckley NA, et al. Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. Lancet 2008; 371:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/41\">",
"      Henderson RP, Solomon CP. Use of cholestyramine in the treatment of digoxin intoxication. Arch Intern Med 1988; 148:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/42\">",
"      Rawashdeh NM, al-Hadidi HF, Irshaid YM, Battah AK. Gastrointestinal dialysis of digoxin using cholestyramine. Pharmacol Toxicol 1993; 72:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/43\">",
"      Bower, JO, Mengle, HA. The additive effect of calcium and digitalis: a warning, with a report of two deaths. JAMA 1936; 106:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/44\">",
"      SHRAGER MW. Digitalis intoxication; a review and report of forty cases, with emphasis on etiology. AMA Arch Intern Med 1957; 100:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/45\">",
"      Kne, T, Brokaw, M, Wax, P. Fatality from calcium chloride in a chronic digoxin toxic patient. J Toxicol Clin Toxicol 1997; 5:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/46\">",
"      Gold, H, Edwards, DJ. The effects of aubain on the heart in the presence of hypercalcemia. Am Heart J 1927; 3:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/47\">",
"      Nola GT, Pope S, Harrison DC. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J 1970; 79:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/48\">",
"      Hack JB, Woody JH, Lewis DE, et al. The effect of calcium chloride in treating hyperkalemia due to acute digoxin toxicity in a porcine model. J Toxicol Clin Toxicol 2004; 42:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/49\">",
"      Fenton F, Smally AJ, Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med 1996; 28:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/50\">",
"      Van Deusen SK, Birkhahn RH, Gaeta TJ. Treatment of hyperkalemia in a patient with unrecognized digitalis toxicity. J Toxicol Clin Toxicol 2003; 41:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/51\">",
"      Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med 2011; 40:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/52\">",
"      Renard C, Grene-Lerouge N, Beau N, et al. Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Br J Clin Pharmacol 1997; 44:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/53\">",
"      Ujhelyi MR, Robert S, Cummings DM, et al. Disposition of digoxin immune Fab in patients with kidney failure. Clin Pharmacol Ther 1993; 54:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/54\">",
"      Ujhelyi MR, Robert S, Cummings DM, et al. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med 1993; 119:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/55\">",
"      Warren SE, Fanestil DD. Digoxin overdose. Limitations of hemoperfusion-hemodialysis treatment. JAMA 1979; 242:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/56\">",
"      Slattery JT, Koup JR. Haemoperfusion in the management of digoxin toxicity: is it warranted? Clin Pharmacokinet 1979; 4:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/57\">",
"      Santos-Ara&uacute;jo C, Campos M, Gavina C, et al. Combined use of plasmapheresis and antidigoxin antibodies in a patient with severe digoxin intoxication and acute renal failure. Nephrol Dial Transplant 2007; 22:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/58\">",
"      Rabetoy GM, Price CA, Findlay JW, Sailstad JM. Treatment of digoxin intoxication in a renal failure patient with digoxin-specific antibody fragments and plasmapheresis. Am J Nephrol 1990; 10:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/59\">",
"      Gittelman MA, Stephan M, Perry H. Acute pediatric digoxin ingestion. Pediatr Emerg Care 1999; 15:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25817/abstract/60\">",
"      Thacker D, Sharma J. Digoxin toxicity. Clin Pediatr (Phila) 2007; 46:276.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 319 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-2F8DE301F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25817=[""].join("\n");
var outline_f25_13_25817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LABORATORY AND ECG EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Approach to testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Serum digoxin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33651379\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Basic measures and arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antidotal therapy with antibody (Fab) fragments",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Indications and general approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Patients with pacemakers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      GI decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Electrolyte abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - General care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Fab fragment dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Extracorporeal removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/319\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/319|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/45/5855\" title=\"figure 1\">",
"      Digoxin structure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/319|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/6/28779\" title=\"table 1\">",
"      Digitalis kinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/22/6507\" title=\"table 2\">",
"      P-glycoprotein drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/319|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?28/24/29063\" title=\"waveform 1\">",
"      ECG bidirectional VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?4/31/4594\" title=\"waveform 2\">",
"      Digitalis effect tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/32/23043?source=related_link\">",
"      Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8711?source=related_link\">",
"      Treatment with digoxin: initial dosing, monitoring, and dose modification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_13_25818="Restorative proctocolectomy with ileal pouch-anal anastomosis: Laparoscopic approach";
var content_f25_13_25818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Restorative proctocolectomy with ileal pouch-anal anastomosis: Laparoscopic approach",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/13/25818/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25818/contributors\">",
"     Alessandro Fichera, MD, FACS, FASCRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/13/25818/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25818/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/13/25818/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/13/25818/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/13/25818/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7533267\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A total proctocolectomy (TPC) is the surgical treatment option for patients who have failed medical management for ulcerative colitis, select patients with Crohn&rsquo;s disease (without evidence of anorectal disease), and patients with hereditary nonpolyposis colorectal cancer or synchronous colon cancers. In addition, because of an associated increased risk of colon cancer development, a total proctocolectomy is offered as prophylaxis to patients diagnosed with familial adenomatous polyposis (",
"    <a class=\"graphic graphic_picture graphicRef73267 \" href=\"UTD.htm?30/12/30917\">",
"     picture 1",
"    </a>",
"    ) or inflammatory bowel disease.",
"   </p>",
"   <p>",
"    The development of the continence-preserving procedure, restorative proctocolectomy and ileal pouch-anal anastomosis (RPC-IPAA), has made surgical management a more attractive option than a TPC with a permanent end ileostomy. Both approaches can improve the quality of life and reduce the risk of colonic malignancy, and both can be performed as an open or laparoscopic procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Optimal results depend upon surgical expertise, the clinical setting, and patient selection.",
"   </p>",
"   <p>",
"    This topic will describe technical details of a laparoscopic approach to the restorative proctocolectomy with ileal pouch-anal anastomosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533274\">",
"    <span class=\"h1\">",
"     DESCRIPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A restorative proctocolectomy with ileal pouch-anal anastomosis (RPC-IPAA) removes the entire colon and rectum while preserving the anal sphincter and, hence, normal bowel function and fecal continence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].The pouch serves as an internal pelvic reservoir for intestinal contents.",
"   </p>",
"   <p>",
"    The optimal laparoscopic approach has not been established. A few variations of the procedure have been described that include hand-assisted and laparoscopically assisted techniques, a single-incision laparoscopic technique, and variations in construction of the ileal pouch [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533281\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy of the colon and rectum is shown in the figures and reviewed elsewhere (",
"    <a class=\"graphic graphic_figure graphicRef73756 \" href=\"UTD.htm?40/32/41479\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58219 \" href=\"UTD.htm?38/33/39448\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79743 \" href=\"UTD.htm?38/4/38984\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72874 \" href=\"UTD.htm?12/22/12647\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54523 \" href=\"UTD.htm?20/54/21348\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20744?source=see_link&amp;anchor=H95928447#H95928447\">",
"     \"Left colectomy: Open technique\", section on 'Anatomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/16/34057?source=see_link&amp;anchor=H87588311#H87588311\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Surgical anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533288\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION CRITERIA FOR LAPAROSCOPIC RPC-IPAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have failed medical therapy for ulcerative colitis and Crohn&rsquo;s disease without rectal involvement, and those who are at great risk for colon cancer development, are candidates for a restorative colectomy and ileal pouch-anal anastomosis (RPC-IPAA). Indications for surgical management of inflammatory bowel disease and the role of colectomy in other high-risk clinical settings are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link&amp;anchor=H9#H9\">",
"     \"Surgical management of ulcerative colitis\", section on 'Indications for operative management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=see_link&amp;anchor=H194153889#H194153889\">",
"     \"Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families\", section on 'Colectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link&amp;anchor=H21758709#H21758709\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\", section on 'Colorectal cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a colon or rectal cancer, the surgical oncologic principles must be met, including resection of the mesentery and lymphatics, and resection of an adequate distal margin. Patients with malignancy at the anal transition zone are not candidates for an ileal pouch procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link\">",
"     \"Surgical oncologic principles for the resection of colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/16/34057?source=see_link\">",
"     \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical procedure and approach are based upon clinical setting (elective versus emergent), patient preference (anal sphincter preservation), body habitus, oncologic criteria (prophylactic versus therapeutic), and previous intra-abdominal and pelvic operations.",
"   </p>",
"   <p>",
"    Patient selection criteria for RPC-IPAA include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intact anal sphincter function",
"     </li>",
"     <li>",
"      Desire to preserve physiologic defecatory function",
"     </li>",
"     <li>",
"      Amenable to multiple procedures to construct acceptable ileal pouch-anal anastomosis",
"     </li>",
"     <li>",
"      Body mass index less than morbid obesity. A fatty ileal mesentery may cause the pouch to be rather bulky and ill-fitting in a narrow pelvis; furthermore, the ileal pouch may not reach the upper anal canal despite operative techniques designed to lengthen the ileal mesentery.",
"     </li>",
"     <li>",
"      For patients with colon or rectal cancer, the cancer must be completely resectable with adequate distal margins. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/16/34057?source=see_link&amp;anchor=H87588997#H87588997\">",
"       \"Surgical oncologic principles for resection of primary rectal adenocarcinoma\", section on 'Criteria for operative procedures'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to fecal incontinence, another absolute contraindication to IPAA is a surgical emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/16\">",
"     16",
"    </a>",
"    ]. In the emergency setting, the majority of surgeons would perform a total abdominal colectomy with an end Brooke ileostomy and preservation of the anorectum followed by an IPAA at a later date [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Massive bleeding from the rectal stump identified intraoperatively is seldom an indication for an immediate total proctocolectomy, but more often to a near total proctocolectomy with a very short rectal stump. The issue with such an approach is that retrieving the rectal stump to complete the proctectomy and to construct the anastomosis becomes very difficult at the second operation.",
"   </p>",
"   <p>",
"    In addition to meeting criteria for RPC-IPAA, patients must also fulfill criteria to undergo a laparoscopic approach, including ability to tolerate a pneumoperitoneum and having few previous",
"    <span class=\"nowrap\">",
"     intra-abdominal/pelvic",
"    </span>",
"    operations and few adhesions. As experience with laparoscopic RPC-IPAA increase, previous abdominal operations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    adhesions become a relative contraindication. Laparoscopy can be performed electively as well as in the emergent setting of acute fulminant colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533295\">",
"    <span class=\"h1\">",
"     SURGICAL OPTIONS TO LAPAROSCOPIC RPC-IPAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proctocolectomy procedures are performed using open or laparoscopic approaches. With increasing experience with laparoscopic colorectal surgery, there are no absolute contraindications to laparoscopy and the decision is based upon surgeon judgment, skills, and experience. Minimally invasive techniques are central to fast-track protocols with advantages of a decrease in inflammatory mediators, improved pulmonary function with oncologic outcomes comparable to the open technique, faster return of bowel function, and reduced hospital length of stay (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25656?source=see_link&amp;anchor=H173017457#H173017457\">",
"     \"Fast-track protocols in colorectal surgery\", section on 'Surgical approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who are not candidates for laparoscopy may be candidates for the open approach to the RPC-IPAA procedure. For patients who are not candidates, or who prefer not to undergo RPC-IPAA, a total proctocolectomy (TPC) with an end ileostomy is the alternative surgical option [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/10\">",
"     10",
"    </a>",
"    ]. TPC with a permanent ileostomy can be performed using an open or laparoscopic approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533302\">",
"    <span class=\"h2\">",
"     Open RPC-IPAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are candidates for RPC-IPAA, but not candidates for the laparoscopic approach, an open procedure is the available alternative. Although obesity and previous abdominal operations often make laparoscopic colorectal procedures challenging, they are not considered absolute contraindications to laparoscopy.",
"   </p>",
"   <p>",
"    The principles of an open resection are the same as those for a laparoscopic resection. (See",
"    <a class=\"local\" href=\"#H7533373\">",
"     'Laparoscopic surgical approach RPC-IPAA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533309\">",
"    <span class=\"h2\">",
"     Total abdominal colectomy with temporary ileostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A staged procedure includes a total abdominal colectomy, temporary end ileostomy, and closure of the rectum (Hartmann&rsquo;s pouch) with or without construction of a mucous fistula. This approach is indicated in clinical settings such as pregnancy and acute fulminant colitis requiring emergent operative management, extreme obesity, a narrow pelvis, and uncertainty of diagnosis, such as ulcerative colitis versus Crohn&rsquo;s disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Because of the trend towards more frequent postoperative complications associated with corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/22\">",
"     22",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/23\">",
"     23",
"    </a>",
"    ], we typically perform a staged procedure for such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This strategy avoids the morbidity associated with the rectal dissection, which can be potentially difficult and time consuming in an unstable patient, and maintains the option of an ileal pouch anal anastomosis as a second stage. A delayed proctectomy is typically performed within three to six months after the initial operation. (See",
"    <a class=\"local\" href=\"#H7533422\">",
"     'Staged procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533316\">",
"    <span class=\"h2\">",
"     Total proctocolectomy with permanent end ileostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A total proctocolectomy (TPC) with a permanent end ileostomy removes the entire colon, rectum, and anus, and does not restore gastrointestinal continuity (",
"    <a class=\"graphic graphic_picture graphicRef83909 \" href=\"UTD.htm?6/10/6310\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef84022 \" href=\"UTD.htm?40/28/41408\">",
"     picture 3",
"    </a>",
"    ). TPC is curative for patients with ulcerative colitis. For patients with inflammatory bowel disease complicated by locally advanced cancer involving the distal rectum, TPC is the procedure of choice. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link&amp;anchor=H11#H11\">",
"     \"Surgical management of ulcerative colitis\", section on 'Elective setting procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The indications for a total proctocolectomy (TPC) with a permanent end ileostomy include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/10\">",
"     10",
"    </a>",
"    ] :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients prefer a single operation",
"     </li>",
"     <li>",
"      Medically unable to tolerate an extended operation (eg, comorbidities, advanced age)",
"     </li>",
"     <li>",
"      Very low or ultra-low rectal cancer, not amenable to sphincter-sparing procedures (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=see_link&amp;anchor=H1845484#H1845484\">",
"       \"Overview of surgical procedures for resectable primary rectal cancer\", section on 'Sphincter-sparing procedures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Poor anal sphincter function associated with fecal incontinence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533323\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533331\">",
"    <span class=\"h2\">",
"     Pathology review",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of ulcerative colitis or dysplasia should be confirmed, and Crohn&rsquo;s disease ruled out, by an expert gastrointestinal pathologist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a second opinion review of the biopsy slides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533338\">",
"    <span class=\"h2\">",
"     Mucosectomy versus preservation of ATZ",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have adopted a selective approach to preserve the ATZ based primarily upon the presence of ATZ dysplasia, irrespective of the degree or location [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. We perform a transanal mucosectomy, which removes all rectal mucosa, and a hand-sewn IPAA for patients with biopsy-proven dysplasia. A stapled IPAA, which preserves the AZT in the rectal cuff [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/28\">",
"     28",
"    </a>",
"    ], is performed only for patients with no evidence of AZT dysplasia of any grade. The stapled approach requires a small amount of rectal tissue to be spared for the anastomosis. Patients with a malignancy at the AZT are not candidates for RPC-IPAA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533345\">",
"    <span class=\"h2\">",
"     Ostomy site selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an ileostomy, either temporary or permanent, is planned, a stoma therapist should mark the abdominal site for the ileostomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=see_link&amp;anchor=H21062994#H21062994\">",
"     \"Surgical principles of ostomy construction\", section on 'Preoperative preparations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533352\">",
"    <span class=\"h2\">",
"     Mechanical bowel preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the evidence suggests that a mechanical bowel preparation is not required to safely perform a laparoscopic colectomy, many surgeons have not adopted this approach. Mechanical bowel preparation is utilized in our practice, with the exception of the presence of acute fulminant colitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=see_link&amp;anchor=H125365129#H125365129\">",
"     \"Surgical oncologic principles for the resection of colon cancer\", section on 'Mechanical bowel preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533359\">",
"    <span class=\"h2\">",
"     Antimicrobial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    , or ciprofloxan plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    are routinely administered (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ). We do not use oral antibiotics or continue prophylaxis postoperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=see_link\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antimicrobial prophylaxis for prevention of surgical site infection is administered 0 to 2 hours prior to making the incision to begin the colectomy (",
"    <a class=\"graphic graphic_table graphicRef79097 \" href=\"UTD.htm?22/46/23275\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533366\">",
"    <span class=\"h2\">",
"     Venous thromboembolism prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing intra-abdominal surgery are at a moderate to high risk for developing a deep venous thrombosis (DVT) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/29\">",
"     29",
"    </a>",
"    ]. All patients scheduled for colonic resection should receive primary prophylaxis. Prevention of DVT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533373\">",
"    <span class=\"h1\">",
"     LAPAROSCOPIC SURGICAL APPROACH RPC-IPAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic restorative proctocolectomy with ileal pouch-anal anastomosis (RPC-IPAA) can be performed in a single setting or as a staged procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533380\">",
"    <span class=\"h2\">",
"     Single stage procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single stage procedure includes the proctocolectomy and immediate construction of the IPAA, without a temporary ileostomy to protect the anastomosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533387\">",
"    <span class=\"h3\">",
"     Resection of colon and rectum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles for performing a laparoscopic assisted RPC-IPAA include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Ports and extraction sites",
"      </strong>",
"      &mdash; For our single-stage laparoscopic IPAA operations, we use 5.5 mm trocars, placed as shown in the figure (",
"      <a class=\"graphic graphic_figure graphicRef83861 \" href=\"UTD.htm?20/11/20657\">",
"       figure 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef83873 \" href=\"UTD.htm?12/47/13043\">",
"       picture 4",
"      </a>",
"      ), and a 5 mm 30&ordm; laparoscope. The general approach for peritoneal access and placement of ports is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"       \"Abdominal access techniques used in laparoscopic surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Exploration",
"      </strong>",
"      &mdash; Each operation is started by completely evaluating the small intestine from the ligament of Treitz to the ileocecal valve to rule out concomitant pathologies. For example, despite preoperative radiologic imaging and histologic evaluations to confirm the diagnosis of ulcerative colitis, patients have subsequently developed signs and symptoms of Crohn&rsquo;s disease following IPAA [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Mobilization",
"      </strong>",
"      <strong>",
"       and dissection",
"      </strong>",
"      &mdash; The colon is mobilized from the right to the left. The monitors are placed at the head of the table to facilitate the intra-abdominal portion of the procedure (",
"      <a class=\"graphic graphic_figure graphicRef83867 \" href=\"UTD.htm?12/3/12342\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The ileocolic vascular pedicle is identified, ligated, and divided (",
"      <a class=\"graphic graphic_picture graphicRef83863 \" href=\"UTD.htm?33/15/34032\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The mesentery is divided using the laparoscopic 5 mm vessel sealing devices to control hemorrhage.",
"     </li>",
"     <li>",
"      The ascending colon is mobilized in the submesenteric avascular plane, using a medial-to-lateral technique and avoiding injury to the underlying structures (",
"      <a class=\"graphic graphic_picture graphicRef83864 \" href=\"UTD.htm?16/42/17057\">",
"       picture 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef54457 \" href=\"UTD.htm?1/18/1318\">",
"       figure 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The transverse colon is mobilized by dividing the greater omentum to provide an unobstructed view of the transverse mesocolon leading to the splenic flexure (",
"      <a class=\"graphic graphic_picture graphicRef83865 \" href=\"UTD.htm?37/22/38245\">",
"       picture 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53153 \" href=\"UTD.htm?17/33/17938\">",
"       figure 9",
"      </a>",
"      ). It is possible to achieve a high ligation of the middle colic vessels if indicated (",
"      <a class=\"graphic graphic_figure graphicRef73756 \" href=\"UTD.htm?40/32/41479\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The splenic flexure is mobilized using a combination medial-to-lateral and lateral-to-medial technique (",
"      <a class=\"graphic graphic_figure graphicRef81638 \" href=\"UTD.htm?38/22/39265\">",
"       figure 10",
"      </a>",
"      ). The visualization with the 30&ordm; laparoscope makes this step easier and more controlled than in open surgery.",
"     </li>",
"     <li>",
"      The descending colon is mobilized using a medial-to-lateral technique, down to the level of the pelvic brim. The laparoscopic monitors are moved to the foot of the bed to facilitate identification of the superior hemorrhoidal artery and pelvic structures (",
"      <a class=\"graphic graphic_picture graphicRef83866 \" href=\"UTD.htm?38/18/39215\">",
"       picture 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef83868 \" href=\"UTD.htm?7/12/7366\">",
"       figure 11",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The peritoneum overlying the sacral promontory on the right side is incised, and through the submesenteric window, the left ureter and gonadal vessels are visualized (",
"      <a class=\"graphic graphic_picture graphicRef83869 \" href=\"UTD.htm?21/42/22181\">",
"       picture 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef77687 \" href=\"UTD.htm?40/12/41156\">",
"       figure 12",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef56743 \" href=\"UTD.htm?6/44/6853\">",
"       figure 13",
"      </a>",
"      ). The superior hemorrhoidal artery (",
"      <a class=\"graphic graphic_picture graphicRef83872 \" href=\"UTD.htm?10/42/10917\">",
"       picture 10",
"      </a>",
"      ) and the inferior mesentery vein are now divided.",
"     </li>",
"     <li>",
"      The rectum is sharply dissected in the avascular plane, posterior to the mesorectum (",
"      <a class=\"graphic graphic_figure graphicRef83874 \" href=\"UTD.htm?29/41/30355\">",
"       figure 14",
"      </a>",
"      ). The avascular plane is readily identified and limits blood loss. While some surgeons may preserve the mesorectum when performing a total proctocolectomy for a benign diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/17\">",
"       17",
"      </a>",
"      ], we advocate including it with the resection for the following reasons: the plane between the rectum and mesorectum is vascular and the risk of retrograde ejaculation is negligible with the improved optics of the high-definition cameras available. The rectal dissection proceeds laterally dividing the lateral ligaments, then anteriorly (",
"      <a class=\"graphic graphic_figure graphicRef83874 \" href=\"UTD.htm?29/41/30355\">",
"       figure 14",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bowel transection and specimen extraction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A classic Pfannenstiel incision is made suprapubically (",
"      <a class=\"graphic graphic_figure graphicRef83861 \" href=\"UTD.htm?20/11/20657\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The specimen is exteriorized through this incision (",
"      <a class=\"graphic graphic_picture graphicRef86182 \" href=\"UTD.htm?30/54/31587\">",
"       picture 11",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The terminal ileum is divided extracorporeally with a stapling device in preparation for construction of the ileal pouch. [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7533394\">",
"       'Construction of ileal pouch'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The rectum is transected at the level of the dentate line using an open stapling device rather than an endoscopic stapler to avoid overlapping staple lines that can result from multiple applications of the endoscopic device.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533394\">",
"    <span class=\"h3\">",
"     Construction of ileal pouch",
"    </span>",
"    &nbsp;&mdash;&nbsp;The J-pouch is the preferred ileal reservoir because of the efficiency of construction and optimal functional results. Alternatives to the J-pouch configuration for the ileal reservoir include three- and four-limbed pouches, such as an S or W pouch. These alternative configurations are rarely performed due to the complexity of construction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/6\">",
"     6",
"    </a>",
"    ]. A randomized trial that included 94 patients found no long-term benefits for patients managed with a W-pouch compared with those managed with a J-pouch [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/32\">",
"     32",
"    </a>",
"    ]. At one year, patients undergoing a J-pouch had a higher daily bowel movement frequency compared with patients with a W-pouch (7 versus 5). In addition, patients with a J-pouch also had a higher daytime bowel movement frequency (6 versus 4), but no difference in nocturnal frequency. After nine years of observation, bowel function for patients undergoing the W-pouch had a similar 24-hour bowel movement frequency compared with patients undergoing the J-pouch (6 versus 6.5). In addition, there was no difference in daytime frequency, nocturnal function, incontinence, and quality of life. However, time for construction of the W-pouch was significantly longer (215 versus 195 minutes).",
"   </p>",
"   <p>",
"    We perform the construction of the J-pouch through the Pfannenstiel incision [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/33\">",
"     33",
"    </a>",
"    ]. The general principles for construction of a J-pouch include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The terminal ileum is mobilized laparoscopically to the root of the mesentery at the level of the duodenum.",
"     </li>",
"     <li>",
"      The length of ileum required for construction of the pouch is approximately 30 to 40 cm in length. The pouch is constructed as follows [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Identify the most dependent loop of the terminal ileum.",
"     </li>",
"     <li>",
"      Lengthen the mesentery if foreshortened or mobilize the third portion of the duodenum so that the most dependent portion of the pouch will reach the pubic symphysis.",
"     </li>",
"     <li>",
"      Place a 30 inch long marking suture at the apex of this loop (",
"      <a class=\"graphic graphic_picture graphicRef83913 \" href=\"UTD.htm?20/1/20502\">",
"       picture 12",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Fold the loop back on itself and secure with silk sutures (",
"      <a class=\"graphic graphic_picture graphicRef83914 \" href=\"UTD.htm?27/45/28374\">",
"       picture 13",
"      </a>",
"      ). &nbsp;",
"     </li>",
"     <li>",
"      Create an enterotomy on the antimesenteric surface of the proximal loop and the distal loop. Insert a linear stapler to construct the pouch (",
"      <a class=\"graphic graphic_picture graphicRef83915 \" href=\"UTD.htm?21/63/22516\">",
"       picture 14",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pouch is everted with the mucosal layer as the outer surface as we proceed with stapling the ileal limbs to create a pouch (",
"      <a class=\"graphic graphic_picture graphicRef83916 \" href=\"UTD.htm?2/48/2822\">",
"       picture 15",
"      </a>",
"      ). This technique allows us to precisely place the next stapler and to achieve hemostasis on the staple line. When we reach the apex of the pouch and complete the side-to-side anastomosis, the pouch is inverted with the serosal layer as the outer surface (",
"      <a class=\"graphic graphic_picture graphicRef83917 \" href=\"UTD.htm?37/24/38276\">",
"       picture 16",
"      </a>",
"      ). We prefer this technique, as it minimizes the trauma to the apex, which will serve as the site for the ileal-anal anastomosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533401\">",
"    <span class=\"h3\">",
"     Ileal pouch - anal anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles for construction of the ileal pouch anal anastomosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ileal anal anastomosis is performed using the stapled or hand-sewn technique, depending upon the preference of the surgeon. We perform a hand-sewn IPAA for patients with biopsy-proven dysplasia or cancer, and a stapled IPAA when there is no evidence of AZT dysplasia. (See",
"      <a class=\"local\" href=\"#H7533338\">",
"       'Mucosectomy versus preservation of ATZ'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Using the stapled technique, the center rod and anvil of the circular stapler is advanced to the apex of the pouch, delivered through the apex, and secured in place with a purse string suture. The shaft of the circular stapler is inserted transanally and the anastomosis constructed.",
"     </li>",
"     <li>",
"      In case of a hand-sewn anastomosis, after the transanal mucosectomy is completed, the pouch is marked with three stay sutures that are delivered through the anus (",
"      <a class=\"graphic graphic_picture graphicRef83918 \" href=\"UTD.htm?38/4/38979\">",
"       picture 17",
"      </a>",
"      ). The hand-sewn anastomosis between the pouch apex and the anal canal at the level of the dentate line is constructed in two layers with absorbable sutures through the anus (",
"      <a class=\"graphic graphic_picture graphicRef83919 \" href=\"UTD.htm?42/17/43282\">",
"       picture 18",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ileal enterotomies are approximated in two layers with an inner layer of absorbable sutures and an outer of non-absorbable suture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533408\">",
"    <span class=\"h3\">",
"     Pelvic drains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic drains are used in the clinical setting of fecal spillage. Since in our practice the dissection is performed in the presacral avascular space, the use of pelvic drains is rarely indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533415\">",
"    <span class=\"h3\">",
"     Temporary loop ileostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of using a diverting loop ileostomy to reduce the risk of an anastomotic leak or dehiscence has not been clearly established [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/35\">",
"     35",
"    </a>",
"    ]; however, we selectively use this approach to minimize the risk of a leak, dehiscence, or pelvic sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/6,36,37\">",
"     6,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to construct a temporary diverting loop ileostomy in our practice does not follow any strict guidelines. We typically reserve this procedure for clinical settings where there is moderate or greater tension on the ileal-anal anastomosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    preoperative usage of corticosteroids or anti-TNF therapy, malnutrition, serious intraoperative blood loss or other such risks for a leak or dehiscence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4186?source=see_link&amp;anchor=H800363#H800363\">",
"     \"Management of anastomotic complications of colorectal surgery\", section on 'Dehiscence and leaks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The construction of a loop ileostomy is described elsewhere (",
"    <a class=\"graphic graphic_figure graphicRef56828 \" href=\"UTD.htm?35/23/36223\">",
"     figure 15",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=see_link&amp;anchor=H14009881#H14009881\">",
"     \"Surgical principles of ostomy construction\", section on 'Loop ostomy with a defunctionalized distal limb'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533422\">",
"    <span class=\"h2\">",
"     Staged procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The staged procedure includes a total abdominal colectomy, preservation of the rectum, and a temporary end ileostomy at the initial operation, followed by a period of recovery and a delayed construction of the IPAA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533429\">",
"    <span class=\"h3\">",
"     First stage",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533437\">",
"    <span class=\"h4\">",
"     Total colectomy and end ileostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first stage includes a laparoscopic total abdominal colectomy with an end ileostomy, performing the colectomy similar to that described for the single stage approach. A proctectomy is not performed in this setting. (See",
"    <a class=\"local\" href=\"#H7533387\">",
"     'Resection of colon and rectum'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If performing the total colectomy as an emergent procedure, we often use a hand-assisted approach, which can facilitate the procedure and requires less operating time. Hand-assisted laparoscopic approaches include using the nondominant hand through a hand port device, typically inserted through a small incision in the suprapubic location (",
"    <a class=\"graphic graphic_figure graphicRef84019 \" href=\"UTD.htm?0/24/385\">",
"     figure 16",
"    </a>",
"    ). The ileostomy site, the primary access point to the abdomen, and two additional 5 mm trocars are inserted via incisions in the umbilicus and the left lower quadrant (",
"    <a class=\"graphic graphic_picture graphicRef84020 \" href=\"UTD.htm?41/13/42194\">",
"     picture 19",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533444\">",
"    <span class=\"h4\">",
"     Preservation of the rectum and pelvic vasculature",
"    </span>",
"    &nbsp;&mdash;&nbsp;The descending colon is dissected to the level of the sacral promontory and divided, preserving the superior hemorrhoidal pedicle to lower the risk of rectal stump ischemia and dehiscence. The rectal stump can be managed as a mucous fistula (rectum sutures to the abdominal wall) or a Hartmann&rsquo;s operation (oversewing of the rectal stump), depending upon the surgeon's preference and the severity of the inflammatory disease in the rectosigmoid colon. The risk of massive postoperative hemorrhage from the preserved rectum is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer a Hartmann&rsquo;s operation since the mucous fistula drains blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucous, and complicates postoperative management for the patients. We also insert a large rectal tube into the rectal stump for decompression and drainage for a minimum of five days to limit the risk of &ldquo;blowout&rdquo; complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533451\">",
"    <span class=\"h3\">",
"     Second stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;At this stage of the procedure, the rectum will be resected and the ileal-pouch anal anastomosis (IPAA) constructed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533458\">",
"    <span class=\"h4\">",
"     Timing of second procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of the second stage of the procedure depends upon the patient&rsquo;s general condition and rationale for a staged procedure, but is typically performed between three and six months after the first stage [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/23,38-40\">",
"     23,38-40",
"    </a>",
"    ]. The decision to proceed with the second, and most important, stage should be individualized and based upon clinical judgment, rather than a fixed guideline. Specifically these patients should be weaned off all preoperative medication and have normalization of nutritional parameters. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533465\">",
"    <span class=\"h4\">",
"     Abdominal access",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ileostomy is taken down and the peritoneal cavity is accessed through this ostomy site via a 12 mm trocar. The remainder of the trocars are inserted as previously described (",
"    <a class=\"graphic graphic_figure graphicRef83861 \" href=\"UTD.htm?20/11/20657\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83873 \" href=\"UTD.htm?12/47/13043\">",
"     picture 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7533387\">",
"     'Resection of colon and rectum'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533472\">",
"    <span class=\"h4\">",
"     Delayed construction of ileal pouch",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same criteria to construct either a stapled or a hand-sewn anastomosis apply to a staged operation. A Pfannenstiel incision is utilized for rectal transection, pouch construction, and anastomosis as previously described. (See",
"    <a class=\"local\" href=\"#H7533394\">",
"     'Construction of ileal pouch'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7533401\">",
"     'Ileal pouch - anal anastomosis'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533479\">",
"    <span class=\"h4\">",
"     Temporary diversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The same criteria for constructing a diverting loop ileostomy apply to a staged operation. (See",
"    <a class=\"local\" href=\"#H7533415\">",
"     'Temporary loop ileostomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533486\">",
"    <span class=\"h4\">",
"     Rectal tube insertion",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the clinical settings where there is a large amount of tension on the anastomosis, we perform a diverting loop ileostomy",
"    <strong>",
"     and",
"    </strong>",
"    insert a small caliber rectal tube into the rectum. The rectal tube is secured to the perianal skin and remains in place often past discharge from the hospital, to prevent anastomotic stricture. (See",
"    <a class=\"local\" href=\"#H7533542\">",
"     'Closure of temporary ileostomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533493\">",
"    <span class=\"h1\">",
"     INTRAOPERATIVE CHALLENGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle intraoperative challenges that a surgeon may encounter include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Failure of the ileal pouch to reach the pelvic floor",
"      </strong>",
"      &ndash; The most common reasons for an ileal pouch to fail to reach the pelvic floor include a foreshortened mesentery from acute inflammation and suboptimal body habitus (eg, obese, narrow pelvis).",
"     </li>",
"     <li>",
"      <strong>",
"       Failure of the anastomotic devices",
"      </strong>",
"      &ndash; An incomplete anastomotic doughnut (incomplete stapled ring) or demonstrated air leak must be immediately addressed and corrected with a hand-sewn repair. If the repair cannot be performed through the Pfannenstiel incision, a transanal approach is performed. A diverting loop ileostomy should also be performed in this clinical setting.",
"     </li>",
"     <li>",
"      <strong>",
"       Patent anal stump in a staged procedure",
"      </strong>",
"      &ndash; Technical failure of the linear stapler used to divide the rectum can result in an incomplete stapled suture line. The failed staple line should be repaired with hand-placed sutures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533500\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative management of colectomy patients has evolved, with contemporary emphasis on early postoperative feeding, early ambulation, reduction of perioperative fluid volume, pain management, and avoidance of intra-abdominal drains [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/41-48\">",
"     41-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533507\">",
"    <span class=\"h2\">",
"     Fast-track programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The components and results of fast-track protocols are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25656?source=see_link\">",
"     \"Fast-track protocols in colorectal surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28024?source=see_link&amp;anchor=H186830109#H186830109\">",
"     \"Right and extended right colectomy: Open technique\", section on '\"Fast track\" Postoperative management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533514\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous thromboprophylaxis is continued postoperatively until discharge. For high-risk patients (eg, cancer), we continue prophylaxis for 30 days with low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . The prevention of venous thromboembolism is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H9#H9\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Prevention of VTE'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Pharmacologic agents for VTE prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533521\">",
"    <span class=\"h2\">",
"     Unanticipated splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an inadvertent splenectomy is necessary and performed without prophylaxis, immunizations to avoid sepsis should be administered no sooner than 14 days after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/49\">",
"     49",
"    </a>",
"    ]. Immunization and prevention of sepsis in the asplenic patient is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533528\">",
"    <span class=\"h2\">",
"     Management of pelvic drains",
"    </span>",
"    &nbsp;&mdash;&nbsp;If pelvic drains were used, they are removed within 48 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533535\">",
"    <span class=\"h2\">",
"     Management of rectal tubes",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a rectal tube is placed to avoid an anastomotic stricture secondary to tension on the anastomosis, the tube remains in place post hospital discharge as long as tolerated by the patient, or removed when there is no indication of an anastomotic complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533542\">",
"    <span class=\"h2\">",
"     Closure of temporary ileostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The temporary diverting loop ileostomy is closed after 8 to 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/6\">",
"     6",
"    </a>",
"    ]. Typically, a dynamic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    contrast study is performed before closure of the ileostomy to confirm anastomotic",
"    <span class=\"nowrap\">",
"     healing/patency.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533549\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR POUCH FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty-one preoperative risk factors were evaluated as potential indicators for pouch failure using a novel random forest methodology. In a review of 3754 patients undergoing an ileoanal pouch, a forest of 3000 random survival trees was grown to estimate pouch failure for each patient and to identify important risk factors that maximize survival prediction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following factors increased the risk of pouch failure using a multivariable regression analysis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Completion proctectomy versus total proctocolectomy (hazard ratio [HR] 1.44, 95% CI 1.08-1.93)",
"     </li>",
"     <li>",
"      Hand-sewn versus stapled anastomosis (HR 1.72, 1.23-2.42)",
"     </li>",
"     <li>",
"      Crohn&rsquo;s disease diagnosis versus mucosal ulcerative colitis, indeterminate colitis, and familial adenomatous polyposis (FAP) (HR 2.37, 1.48-3.79)",
"     </li>",
"     <li>",
"      Diagnosis of diabetes versus no diabetes (HR 2.67, 1.46-4.89)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When patients with FAP (n = 233) were excluded from the analysis, the following variables were associated with an increased risk of pouch failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hand-sewn versus stapled anastomosis (HR 1.71, 1.21-2.43)",
"     </li>",
"     <li>",
"      Crohn&rsquo;s disease diagnosis versus mucosal ulcerative colitis, indeterminate colitis (HR 2.28, 1.42-3.65)",
"     </li>",
"     <li>",
"      Diagnosis of diabetes versus no diabetes (HR 2.46, 1.27-4.76)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Crohn's disease involving the ileal pouch is generally associated with a high failure rate and pouch-related fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/51\">",
"     51",
"    </a>",
"    ]. The complications associated with failure are extensive and the options for reconstructive surgery in patients with Crohn's disease should be questioned [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/52\">",
"     52",
"    </a>",
"    ]. On the other hand, in a series of 204 patients with Crohn's disease who underwent primary IPAA, overall 10-year pouch retention was 71 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/53\">",
"     53",
"    </a>",
"    ]. Pouch retention rates were higher and functional results were most favorable when the diagnosis of Crohn's disease was established preoperatively or immediately following surgery (85 to 87 percent 10-year pouch retention). Outcomes in patients with delayed diagnosis were worse, but half still retain their pouch at 10 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533556\">",
"    <span class=\"h1\">",
"     MORTALITY AND MORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The techniques for performing a laparoscopic RPC-IPAA have been refined and simplified since the procedure was first described. The in-hospital and 30-day mortality rates are low (&lt;1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/31\">",
"     31",
"    </a>",
"    ]; however, the overall morbidity rates approach 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/6,31,54-59\">",
"     6,31,54-59",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Adverse sequelae of mechanical, inflammatory, functional, neoplastic, and metabolic conditions related to the pouch can occur postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/60\">",
"     60",
"    </a>",
"    ]. Early and late postoperative complications include bowel obstruction, anastomotic dehiscence, pelvic abscess, wound infection, urinary tract infection, anastomotic stenosis requiring mechanical dilatation, tract infection, large enteric losses from ileostomy, impotence, retrograde ejaculation, and dyspareunia (",
"    <a class=\"graphic graphic_table graphicRef70706 \" href=\"UTD.htm?4/2/4140\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/31,57,60-63\">",
"     31,57,60-63",
"    </a>",
"    ]. Hemorrhage from the rectal stump in staged procedures is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute and chronic complications can necessitate removal of the ileal reservoir and construction of a permanent ileostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/58,64-68\">",
"     58,64-68",
"    </a>",
"    ]. For example, a retrospective review of 1005 patients total undergoing an IPAA found that the pouch was removed in 15 of 858 patients (1.7 percent) with ulcerative colitis, and 19 of 147 patients (12.9 percent) with a diagnosis other than ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533563\">",
"    <span class=\"h2\">",
"     Pelvic sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic sepsis is a common early complication of IPAA and occurs in 6 to 16 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/31,54-56,58,62\">",
"     31,54-56,58,62",
"    </a>",
"    ]. Postoperative anastomotic leak with pelvic sepsis is associated with poor pouch function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Portal vein thrombosis can occur in patients with intra-abdominal septic complications. In a retrospective review of 702 patients undergoing a RPC-IPAA, 94 patients had a computerized scan (CT scan) to assess abdominal pain, fever, leukocytosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    delayed bowel function [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/69\">",
"     69",
"    </a>",
"    ]. Septic complications were responsible for these symptoms in 45 patients (48 percent), and 20 patients (21 percent of those scanned, 3 percent of total) were found to have a portal vein thrombosis.",
"   </p>",
"   <p>",
"    The long-term impact of pelvic abscess was illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transabdominal salvage surgery was required in 55 percent and local surgery in 8 percent.",
"     </li>",
"     <li>",
"      Pouch failure occurred in 26 percent, usually within two years.",
"     </li>",
"     <li>",
"      Daytime incontinence was significantly more common in the patients who kept their reservoir. These patients also had significantly more restricted ability to perform work, domestic, and recreational activities compared with patients in whom an abscess had not developed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A controlled septic condition does not preclude salvage surgery. Furthermore, excision of the pouch is associated with a high risk of complications, particularly delayed perineal wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533570\">",
"    <span class=\"h2\">",
"     Pouchitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pouchitis is the inflammation of the ileal reservoir, and is the most common late postoperative complication. It typically involves the ileal mucosa but it may also extend transmurally, and affects from approximately 25 to 40 percent of patients undergoing an IPAA [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/58,72,73\">",
"     58,72,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pouchitis represents an acute and chronic condition and is associated with poorer long-term bowel function results. Even in the absence of clinically active pouchitis, patients who have suffered at least one episode of pouchitis have a poorer long-term functional result after IPAA [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. The following studies illustrate the frequency and complications associated with pouchitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 120 patients with ulcerative colitis keeping a bowel habit diary when free from symptoms of acute pouchitis, patients with at least one episode of pouchitis (n = 50) were significantly more likely to experience major incontinence compared with those without an episode (37 versus 17 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/72\">",
"       72",
"      </a>",
"      ]. Patients with a history of pouchitis were also significantly more likely to report minor incontinence (75 versus 45 percent), less formed stools (31 versus 24 percent), and more likely to wear a protective pad at night (40 versus 13 percent) or during the day (21 versus 7 percent). Two-thirds of patients had multiple episodes of pouchitis, chronic pouchitis developed in six, and the pouch was removed in two patients.",
"     </li>",
"     <li>",
"      In another series, the cumulative probability of suffering at least one episode of clinical pouchitis was 18 and 48 percent at 1 and 10 years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other pouch disorders have been recognized, such as irritable pouch syndrome and anismus (anorectal dysfunction) (",
"    <a class=\"graphic graphic_algorithm graphicRef57382 \" href=\"UTD.htm?8/51/9008\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/60\">",
"     60",
"    </a>",
"    ]. The pathogenesis, clinical manifestations, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32759?source=see_link\">",
"     \"Pouchitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533577\">",
"    <span class=\"h2\">",
"     Anal transition zone inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute and chronic inflammation is common following an IPAA for patients with ulcerative colitis. In a retrospective review of 225 patients with a stapled IPAA, acute inflammation at the ATZ was identified in 4.6 percent of patients, chronic inflammation in 84.9 percent, and normal mucosa in 10.5 percent; no patient had evidence of dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of inflammation at ATZ, however, does not negatively affect functional outcomes or quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/25,75\">",
"     25,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link&amp;anchor=H13#H13\">",
"     \"Surgical management of ulcerative colitis\", section on 'Long-term functional results'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533584\">",
"    <span class=\"h2\">",
"     Anal transitional zone dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;ATZ dysplasia after stapled IPAA is infrequent and is usually self-limiting. ATZ preservation did not lead to the development of cancer with a minimum of 10 years of follow-up. Long-term surveillance is recommended to monitor dysplasia. If repeat biopsy confirms persistent dysplasia, we perform a mucosectomy with perineal pouch advancement and neo-ileal pouch-anal anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533591\">",
"    <span class=\"h2\">",
"     Diverting ostomy complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closure of the diverting loop ileostomy is also associated with frequent postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/77\">",
"     77",
"    </a>",
"    ]. Ileostomy closure is associated with significant complications; one large series of 1504 patients reported a morbidity rate of 11.4 percent and a mortality rate of 0.06 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/78\">",
"     78",
"    </a>",
"    ]. Small bowel obstruction accounted for more than half of the complications. A number of factors have been implicated in morbidity after ileostomy closure, including the interval between primary surgery and closure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/79\">",
"     79",
"    </a>",
"    ], method of closure (stapled versus",
"    <em>",
"    </em>",
"    sutured) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/80\">",
"     80",
"    </a>",
"    ], and impaired function of the distal defunctioned limb [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533598\">",
"    <span class=\"h2\">",
"     Unusual complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of unusual late complications have been described, including [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Superior mesenteric artery syndrome",
"     </li>",
"     <li>",
"      Solitary ileal ulcer",
"     </li>",
"     <li>",
"      Traumatic ileal ulcer perforation",
"     </li>",
"     <li>",
"      Fibroid polyps",
"     </li>",
"     <li>",
"      Mucosal prolapse with outlet obstruction",
"     </li>",
"     <li>",
"      Puborectal spasm",
"     </li>",
"     <li>",
"      Sacral osteomyelitis",
"     </li>",
"     <li>",
"      Volvulus",
"     </li>",
"     <li>",
"      Pharmacobezoar",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7549156\">",
"    <span class=\"h2\">",
"     Laparoscopic versus open approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon observational studies, the complication rates and functional outcomes of the laparoscopic total proctocolectomy are similar to that of the open approach, however, patient acceptance, body image, cosmesis, and quality of life are better with the laparoscopic approach [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. A prospective study of 73 patients undergoing a laparoscopic restorative proctocolectomy had significantly less blood loss (231.5 versus 305.0 mL), a faster return of bowel function (flatus) (2.6 versus 3.6 days), and a lower incidence of incisional hernias (0 versus 8.8 percent) compared with 106 patients undergoing the open approach [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/85\">",
"     85",
"    </a>",
"    ]. Patients undergoing a laparoscopic approach had no statistical difference in hospital mortality (1.4 versus 0 percent), prolonged ileus (4.1 versus 2.9 percent), anastomotic septic complications (19.2 versus 11.8 percent), or strictures requiring mechanical dilation (19.2 versus 25.5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533605\">",
"    <span class=\"h1\">",
"     FUNCTIONAL RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term functional results and quality of life with a pelvic ileal reservoir are typically superior to that of patients with a Brooke ileostomy, continent Kock ileostomy, or medically treated colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/6,26,87-89\">",
"     6,26,87-89",
"    </a>",
"    ]. Even patients with chronic inflammation of the ATZ reported better functional parameters and improved quality of life after an IPAA when compared with patients with no retained rectal tissue in the IPAA (mucosectomy, hand-sewn anastomosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/26\">",
"     26",
"    </a>",
"    ]. For example, in a retrospective review of 294 patients with ulcerative colitis undergoing a RPC-IPAA, patients with retained rectal mucosa (stapled IPAA, n = 66) and chronic inflammation at the ATZ were significantly more likely to report complete continence compared with patients undergoing a mucosectomy (no retained rectal mucosa, hand-sewn IPAA) (90.3 versus 66.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/13/25818/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term functional results and quality of life following a RPC-IPAA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link&amp;anchor=H13#H13\">",
"     \"Surgical management of ulcerative colitis\", section on 'Long-term functional results'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7533612\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A restorative proctocolectomy with ileal pouch-anal anastomosis (RPC-IPAA) is a major surgical procedure that removes the entire colon and rectum while preserving the anal sphincter. The ileal pouch serves as an internal pelvic reservoir for intestinal contents. (See",
"      <a class=\"local\" href=\"#H7533274\">",
"       'Description'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with no dysplasia or malignancy at the ATZ, we perform an ATZ sparing IPAA by constructing a stapled ileal pouch. (See",
"      <a class=\"local\" href=\"#H7533338\">",
"       'Mucosectomy versus preservation of ATZ'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with dysplasia or cancer, we perform a mucosectomy (resection of all rectal mucosa and ATZ) and construct a hand-sewn IPAA pouch (see",
"      <a class=\"local\" href=\"#H7533338\">",
"       'Mucosectomy versus preservation of ATZ'",
"      </a>",
"      above). Patients with locally advanced low rectal cancer are not candidates for a RPC-IPAA.",
"     </li>",
"     <li>",
"      For most patients, we recommend the J-pouch for the construction of the ileal reservoir (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The advantages of the J-pouch include greater technical efficiency and similar long-term results (eg, 24-hour bowel movement frequency, nocturnal frequency) compared with the more complex W-pouch approach. However, at one year, patients undergoing a W-pouch had fewer 24-hour bowel movement frequencies. (See",
"      <a class=\"local\" href=\"#H7533394\">",
"       'Construction of ileal pouch'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of using a diverting loop ileostomy to reduce the risk of an anastomotic leak or dehiscence has not been clearly established. The decision to construct a temporary diverting loop ileostomy in our practice does not follow any strict guidelines. We typically reserve this procedure for clinical settings where there is moderate or greater tension on the ileal-anal anastomosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      preoperative usage of corticosteroids or other such factors that may increase the risk of an anastomotic leak or dehiscence. (See",
"      <a class=\"local\" href=\"#H7533415\">",
"       'Temporary loop ileostomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/1\">",
"      Hult&eacute;n L. Proctocolectomy and ileostomy to pouch surgery for ulcerative colitis. World J Surg 1998; 22:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/2\">",
"      McLeod, RS. Quality of life after surgery for ulcerative colitis. Problems in General Surgery 1999; 16:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/3\">",
"      Ravitch MM. The reception of new operations. Ann Surg 1984; 200:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/4\">",
"      Parks AG, Nicholls RJ, Belliveau P. Proctocolectomy with ileal reservoir and anal anastomosis. Br J Surg 1980; 67:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/5\">",
"      Utsunomiya J, Iwama T, Imajo M, et al. Total colectomy, mucosal proctectomy, and ileoanal anastomosis. Dis Colon Rectum 1980; 23:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/6\">",
"      Sagar PM, Pemberton JH. Intraoperative, postoperative and reoperative problems with ileoanal pouches. Br J Surg 2012; 99:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/7\">",
"      Larson DW, Dozois EJ, Piotrowicz K, et al. Laparoscopic-assisted vs. open ileal pouch-anal anastomosis: functional outcome in a case-matched series. Dis Colon Rectum 2005; 48:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/8\">",
"      Larson DW, Cima RR, Dozois EJ, et al. Safety, feasibility, and short-term outcomes of laparoscopic ileal-pouch-anal anastomosis: a single institutional case-matched experience. Ann Surg 2006; 243:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/9\">",
"      Geisler DP, Condon ET, Remzi FH. Single incision laparoscopic total proctocolectomy with ileopouch anal anastomosis. Colorectal Dis 2010; 12:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/10\">",
"      Wexner SD, Rosen L, Lowry A, et al. Practice parameters for the treatment of mucosal ulcerative colitis--supporting documentation. The Standards Practice Task Force. The American Society of Colon and Rectal Surgeons. Dis Colon Rectum 1997; 40:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/11\">",
"      Martel P, Majery N, Savigny B, et al. Mesenteric lengthening in ileoanal pouch anastomosis for ulcerative colitis: Is high division of the superior mesenteric pedicle a safe procedure? Dis Colon Rectum 1998; 41:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/12\">",
"      Radice E, Nelson H, Devine RM, et al. Ileal pouch-anal anastomosis in patients with colorectal cancer: long-term functional and oncologic outcomes. Dis Colon Rectum 1998; 41:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/13\">",
"      Ziv Y, Fazio VW, Strong SA, et al. Ulcerative colitis and coexisting colorectal cancer: recurrence rate after restorative proctocolectomy. Ann Surg Oncol 1994; 1:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/14\">",
"      Thompson-Fawcett MW, Richard CS, O'Connor BI, et al. Quality of life is excellent after a pelvic pouch for colitis-associated neoplasia. Dis Colon Rectum 2000; 43:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/15\">",
"      Wiltz O, Hashmi HF, Schoetz DJ Jr, et al. Carcinoma and the ileal pouch-anal anastomosis. Dis Colon Rectum 1991; 34:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/16\">",
"      Harms BA, Myers GA, Rosenfeld DJ, Starling JR. Management of fulminant ulcerative colitis by primary restorative proctocolectomy. Dis Colon Rectum 1994; 37:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/17\">",
"      Bell RL, Seymour NE. Laparoscopic treatment of fulminant ulcerative colitis. Surg Endosc 2002; 16:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/18\">",
"      Holubar SD, Larson DW, Dozois EJ, et al. Minimally invasive subtotal colectomy and ileal pouch-anal anastomosis for fulminant ulcerative colitis: a reasonable approach? Dis Colon Rectum 2009; 52:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/19\">",
"      Robert JR, Sachar DB, Greenstein AJ. Severe gastrointestinal hemorrhage in Crohn's disease. Ann Surg 1991; 213:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/20\">",
"      Hurst RD, Finco C, Rubin M, Michelassi F. Prospective analysis of perioperative morbidity in one hundred consecutive colectomies for ulcerative colitis. Surgery 1995; 118:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/21\">",
"      Greenstein AJ, Sachar DB, Gibas A, et al. Outcome of toxic dilatation in ulcerative and Crohn's colitis. J Clin Gastroenterol 1985; 7:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/22\">",
"      Ferrante M, D'Hoore A, Vermeire S, et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 2009; 15:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/23\">",
"      Yang Z, Wu Q, Wu K, Fan D. Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis. Aliment Pharmacol Ther 2010; 31:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/24\">",
"      Pandey S, Luther G, Umanskiy K, et al. Minimally invasive pouch surgery for ulcerative colitis: is there a benefit in staging? Dis Colon Rectum 2011; 54:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/25\">",
"      Fichera A, Ragauskaite L, Silvestri MT, et al. Preservation of the anal transition zone in ulcerative colitis. Long-term effects on defecatory function. J Gastrointest Surg 2007; 11:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/26\">",
"      Silvestri MT, Hurst RD, Rubin MA, et al. Chronic inflammatory changes in the anal transition zone after stapled ileal pouch-anal anastomosis: is mucosectomy a superior alternative? Surgery 2008; 144:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/27\">",
"      Holder-Murray J, Fichera A. Anal transition zone in the surgical management of ulcerative colitis. World J Gastroenterol 2009; 15:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/28\">",
"      Litzendorf ME, Stucchi AF, Wishnia S, et al. Completion mucosectomy for retained rectal mucosa following restorative proctocolectomy with double-stapled ileal pouch-anal anastomosis. J Gastrointest Surg 2010; 14:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/29\">",
"      Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:381S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/30\">",
"      Yu CS, Pemberton JH, Larson D. Ileal pouch-anal anastomosis in patients with indeterminate colitis: long-term results. Dis Colon Rectum 2000; 43:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/31\">",
"      Michelassi F, Lee J, Rubin M, et al. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study. Ann Surg 2003; 238:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/32\">",
"      McCormick PH, Guest GD, Clark AJ, et al. The ideal ileal-pouch design: a long-term randomized control trial of J- vs W-pouch construction. Dis Colon Rectum 2012; 55:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/33\">",
"      Michelassi F, Block GE. A simplified technique for ileal J-pouch construction. Surg Gynecol Obstet 1993; 176:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/34\">",
"      Johnston D, Williamson ME, Lewis WG, et al. Prospective controlled trial of duplicated (J) versus quadruplicated (W) pelvic ileal reservoirs in restorative proctocolectomy for ulcerative colitis. Gut 1996; 39:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/35\">",
"      Gorfine SR, Gelernt IM, Bauer JJ, et al. Restorative proctocolectomy without diverting ileostomy. Dis Colon Rectum 1995; 38:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/36\">",
"      Sagar PM, Lewis W, Holdsworth PJ, Johnston D. One-stage restorative proctocolectomy without temporary defunctioning ileostomy. Dis Colon Rectum 1992; 35:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/37\">",
"      Lovegrove RE, Constantinides VA, Heriot AG, et al. A comparison of hand-sewn versus stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy: a meta-analysis of 4183 patients. Ann Surg 2006; 244:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/38\">",
"      Bordeianou L. In flux on infliximab: conflicting studies on surgical outcomes. Inflamm Bowel Dis 2009; 15:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/39\">",
"      Bordeianou L, Kunitake H, Shellito P, Hodin R. Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. Int J Colorectal Dis 2010; 25:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/40\">",
"      Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008; 12:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/41\">",
"      Delaney CP, Fazio VW, Senagore AJ, et al. 'Fast track' postoperative management protocol for patients with high co-morbidity undergoing complex abdominal and pelvic colorectal surgery. Br J Surg 2001; 88:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/42\">",
"      Basse L, Hjort Jakobsen D, Billesb&oslash;lle P, et al. A clinical pathway to accelerate recovery after colonic resection. Ann Surg 2000; 232:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/43\">",
"      Basse L, Thorb&oslash;l JE, L&oslash;ssl K, Kehlet H. Colonic surgery with accelerated rehabilitation or conventional care. Dis Colon Rectum 2004; 47:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/44\">",
"      Behrns KE, Kircher AP, Galanko JA, et al. Prospective randomized trial of early initiation and hospital discharge on a liquid diet following elective intestinal surgery. J Gastrointest Surg 2000; 4:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/45\">",
"      Di Fronzo LA, Cymerman J, O'Connell TX. Factors affecting early postoperative feeding following elective open colon resection. Arch Surg 1999; 134:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/46\">",
"      DiFronzo LA, Yamin N, Patel K, O'Connell TX. Benefits of early feeding and early hospital discharge in elderly patients undergoing open colon resection. J Am Coll Surg 2003; 197:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/47\">",
"      Delaney CP, Zutshi M, Senagore AJ, et al. Prospective, randomized, controlled trial between a pathway of controlled rehabilitation with early ambulation and diet and traditional postoperative care after laparotomy and intestinal resection. Dis Colon Rectum 2003; 46:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/48\">",
"      Khoo CK, Vickery CJ, Forsyth N, et al. A prospective randomized controlled trial of multimodal perioperative management protocol in patients undergoing elective colorectal resection for cancer. Ann Surg 2007; 245:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/49\">",
"      Harji DP, Jaunoo SS, Mistry P, Nesargikar PN. Immunoprophylaxis in asplenic patients. Int J Surg 2009; 7:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/50\">",
"      Manilich E, Remzi FH, Fazio VW, et al. Prognostic modeling of preoperative risk factors of pouch failure. Dis Colon Rectum 2012; 55:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/51\">",
"      Reese GE, Lovegrove RE, Tilney HS, et al. The effect of Crohn's disease on outcomes after restorative proctocolectomy. Dis Colon Rectum 2007; 50:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/52\">",
"      Tekkis PP, Heriot AG, Smith O, et al. Long-term outcomes of restorative proctocolectomy for Crohn's disease and indeterminate colitis. Colorectal Dis 2005; 7:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/53\">",
"      Melton GB, Fazio VW, Kiran RP, et al. Long-term outcomes with ileal pouch-anal anastomosis and Crohn's disease: pouch retention and implications of delayed diagnosis. Ann Surg 2008; 248:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/54\">",
"      Gorfine SR, Fichera A, Harris MT, Bauer JJ. Long-term results of salvage surgery for septic complications after restorative proctocolectomy: does fecal diversion improve outcome? Dis Colon Rectum 2003; 46:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/55\">",
"      McIntyre PB, Pemberton JH, Wolff BG, et al. Comparing functional results one year and ten years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Dis Colon Rectum 1994; 37:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/56\">",
"      Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. Br Med J 1978; 2:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/57\">",
"      Meagher AP, Farouk R, Dozois RR, et al. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998; 85:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/58\">",
"      Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995; 222:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/59\">",
"      Le Q, Melmed G, Dubinsky M, et al. Surgical outcome of ileal pouch-anal anastomosis when used intentionally for well-defined Crohn's disease. Inflamm Bowel Dis 2013; 19:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/60\">",
"      Shen B, Remzi FH, Lavery IC, et al. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol 2008; 6:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/61\">",
"      Farouk R, Pemberton JH, Wolff BG, et al. Functional outcomes after ileal pouch-anal anastomosis for chronic ulcerative colitis. Ann Surg 2000; 231:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/62\">",
"      Farouk R, Dozois RR, Pemberton JH, Larson D. Incidence and subsequent impact of pelvic abscess after ileal pouch-anal anastomosis for chronic ulcerative colitis. Dis Colon Rectum 1998; 41:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/63\">",
"      Tulchinsky H, Hawley PR, Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 2003; 238:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/64\">",
"      Galandiuk S, Scott NA, Dozois RR, et al. Ileal pouch-anal anastomosis. Reoperation for pouch-related complications. Ann Surg 1990; 212:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/65\">",
"      Foley EF, Schoetz DJ Jr, Roberts PL, et al. Rediversion after ileal pouch-anal anastomosis. Causes of failures and predictors of subsequent pouch salvage. Dis Colon Rectum 1995; 38:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/66\">",
"      Cohen Z, Smith D, McLeod R. Reconstructive surgery for pelvic pouches. World J Surg 1998; 22:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/67\">",
"      Burke D, van Laarhoven CJ, Herbst F, Nicholls RJ. Transvaginal repair of pouch-vaginal fistula. Br J Surg 2001; 88:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/68\">",
"      Johnson PM, O'Connor BI, Cohen Z, McLeod RS. Pouch-vaginal fistula after ileal pouch-anal anastomosis: treatment and outcomes. Dis Colon Rectum 2005; 48:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/69\">",
"      Remzi FH, Fazio VW, Oncel M, et al. Portal vein thrombi after restorative proctocolectomy. Surgery 2002; 132:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/70\">",
"      Karoui M, Cohen R, Nicholls J. Results of surgical removal of the pouch after failed restorative proctocolectomy. Dis Colon Rectum 2004; 47:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/71\">",
"      Prudhomme M, Dehni N, Dozois RR, et al. Causes and outcomes of pouch excision after restorative proctocolectomy. Br J Surg 2006; 93:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/72\">",
"      Hurst RD, Chung TP, Rubin M, Michelassi F. The implications of acute pouchitis on the long-term functional results after restorative proctocolectomy. Inflamm Bowel Dis 1998; 4:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/73\">",
"      Hurst RD, Molinari M, Chung TP, et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996; 131:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/74\">",
"      Hahnloser D, Pemberton JH, Wolff BG, et al. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg 2007; 94:333.",
"     </a>",
"    </li>",
"    <li>",
"     Silvestri, M.T., et al., Chronic inflammatory changes in the anal transition zone after stapled ileal pouch-anal anastomosis: is mucosectomy a superior alternative? Surgery, 2008. 144(4): p. 533-7; discussion 537-9.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/76\">",
"      Remzi FH, Fazio VW, Delaney CP, et al. Dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of prospective evaluation after a minimum of ten years. Dis Colon Rectum 2003; 46:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/77\">",
"      Saha AK, Tapping CR, Foley GT, et al. Morbidity and mortality after closure of loop ileostomy. Colorectal Dis 2009; 11:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/78\">",
"      Wong KS, Remzi FH, Gorgun E, et al. Loop ileostomy closure after restorative proctocolectomy: outcome in 1,504 patients. Dis Colon Rectum 2005; 48:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/79\">",
"      Perez RO, Habr-Gama A, Seid VE, et al. Loop ileostomy morbidity: timing of closure matters. Dis Colon Rectum 2006; 49:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/80\">",
"      Pokorny H, Herkner H, Jakesz R, Herbst F. Predictors for complications after loop stoma closure in patients with rectal cancer. World J Surg 2006; 30:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/81\">",
"      Williams L, Armstrong MJ, Armstrong M, et al. The effect of faecal diversion on human ileum. Gut 2007; 56:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/82\">",
"      Taylor WE, Wolff BG, Pemberton JH, Yaszemski MJ. Sacral osteomyelitis after ileal pouch-anal anastomosis: report of four cases. Dis Colon Rectum 2006; 49:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/83\">",
"      Jain A, Abbas MA, Sekhon HK, Rayhanabad JA. Volvulus of an ileal J-pouch. Inflamm Bowel Dis 2010; 16:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/84\">",
"      Mmeje C, Bouchard A, Heppell J. Image of the month. Pharmacobezoar: a rare complication after ileal pouch-anal anastomosis for ulcerative colitis. Clin Gastroenterol Hepatol 2010; 8:A28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/85\">",
"      Fichera A, Silvestri MT, Hurst RD, et al. Laparoscopic restorative proctocolectomy with ileal pouch anal anastomosis: a comparative observational study on long-term functional results. J Gastrointest Surg 2009; 13:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/86\">",
"      Dunker MS, Bemelman WA, Slors JF, et al. Functional outcome, quality of life, body image, and cosmesis in patients after laparoscopic-assisted and conventional restorative proctocolectomy: a comparative study. Dis Colon Rectum 2001; 44:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/87\">",
"      Pemberton JH, Phillips SF, Ready RR, et al. Quality of life after Brooke ileostomy and ileal pouch-anal anastomosis. Comparison of performance status. Ann Surg 1989; 209:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/88\">",
"      Sagar PM, Lewis W, Holdsworth PJ, et al. Quality of life after restorative proctocolectomy with a pelvic ileal reservoir compares favorably with that of patients with medically treated colitis. Dis Colon Rectum 1993; 36:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/13/25818/abstract/89\">",
"      Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg 2013; 257:679.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15017 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-79.122.249.114-3C057D9C1B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25818=[""].join("\n");
var outline_f25_13_25818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7533612\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533267\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533274\">",
"      DESCRIPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533281\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533288\">",
"      PATIENT SELECTION CRITERIA FOR LAPAROSCOPIC RPC-IPAA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533295\">",
"      SURGICAL OPTIONS TO LAPAROSCOPIC RPC-IPAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533302\">",
"      Open RPC-IPAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533309\">",
"      Total abdominal colectomy with temporary ileostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533316\">",
"      Total proctocolectomy with permanent end ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533323\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533331\">",
"      Pathology review",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533338\">",
"      Mucosectomy versus preservation of ATZ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533345\">",
"      Ostomy site selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533352\">",
"      Mechanical bowel preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533359\">",
"      Antimicrobial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533366\">",
"      Venous thromboembolism prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533373\">",
"      LAPAROSCOPIC SURGICAL APPROACH RPC-IPAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533380\">",
"      Single stage procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7533387\">",
"      - Resection of colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7533394\">",
"      - Construction of ileal pouch",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7533401\">",
"      - Ileal pouch - anal anastomosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7533408\">",
"      - Pelvic drains",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7533415\">",
"      - Temporary loop ileostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533422\">",
"      Staged procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7533429\">",
"      - First stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7533437\">",
"      Total colectomy and end ileostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7533444\">",
"      Preservation of the rectum and pelvic vasculature",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7533451\">",
"      - Second stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7533458\">",
"      Timing of second procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7533465\">",
"      Abdominal access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7533472\">",
"      Delayed construction of ileal pouch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7533479\">",
"      Temporary diversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7533486\">",
"      Rectal tube insertion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533493\">",
"      INTRAOPERATIVE CHALLENGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533500\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533507\">",
"      Fast-track programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533514\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533521\">",
"      Unanticipated splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533528\">",
"      Management of pelvic drains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533535\">",
"      Management of rectal tubes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533542\">",
"      Closure of temporary ileostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533549\">",
"      RISK FACTORS FOR POUCH FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533556\">",
"      MORTALITY AND MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533563\">",
"      Pelvic sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533570\">",
"      Pouchitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533577\">",
"      Anal transition zone inflammation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533584\">",
"      Anal transitional zone dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533591\">",
"      Diverting ostomy complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7533598\">",
"      Unusual complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7549156\">",
"      Laparoscopic versus open approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533605\">",
"      FUNCTIONAL RESULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7533612\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15017\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15017|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/51/9008\" title=\"algorithm 1\">",
"      Dx ileal pouch disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15017|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/32/41479\" title=\"figure 1\">",
"      Blood supply to the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/33/39448\" title=\"figure 2\">",
"      Lymphatic drainage of the colon and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/4/38984\" title=\"figure 3\">",
"      Blood supply venous and lymphatic drainage of the rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/22/12647\" title=\"figure 4\">",
"      Anatomy of the anal canal and rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/54/21348\" title=\"figure 5\">",
"      Anal rectal anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/11/20657\" title=\"figure 6\">",
"      Port placement for laparoscopic proctocolectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/3/12342\" title=\"figure 7\">",
"      Placement of laparoscopic monitors at head of table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/18/1318\" title=\"figure 8\">",
"      Relationship between ascending colon and posterior structures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/33/17938\" title=\"figure 9\">",
"      Dissection of greater omentum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/22/39265\" title=\"figure 10\">",
"      Mobilization of the splenic flexure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/12/7366\" title=\"figure 11\">",
"      Placement of laparoscopic monitors at foot of table",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/12/41156\" title=\"figure 12\">",
"      Anatomy of the ureters - female pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/44/6853\" title=\"figure 13\">",
"      Anatomy of ureters - male pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/41/30355\" title=\"figure 14\">",
"      Laparoscopic mobilization of rectum in avascular space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/23/36223\" title=\"figure 15\">",
"      Construction of a loop ileostomy - defunctionalized distal limb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/24/385\" title=\"figure 16\">",
"      Hand-assisted laparoscopic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15017|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/12/30917\" title=\"picture 1\">",
"      Familial polyposis Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/10/6310\" title=\"picture 2\">",
"      Proctocolectomy extraction via perineum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/28/41408\" title=\"picture 3\">",
"      Matured Brooke end ileostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/47/13043\" title=\"picture 4\">",
"      Placement of laparoscopic instruments for total colectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/15/34032\" title=\"picture 5\">",
"      Ileocolic pedicle laparoscopic view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/42/17057\" title=\"picture 6\">",
"      Laparoscopic mobilization of the ascending colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/22/38245\" title=\"picture 7\">",
"      Laparoscopic mobilization of the transverse colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/18/39215\" title=\"picture 8\">",
"      Laparoscopic mobilization of the superior hemorrhoidal artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/42/22181\" title=\"picture 9\">",
"      Laparoscopic visualization of the left ureter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/42/10917\" title=\"picture 10\">",
"      Laparoscopic ligation of the superior hemorrhoidal artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/54/31587\" title=\"picture 11\">",
"      Proctocolectomy specimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/1/20502\" title=\"picture 12\">",
"      Ileal J pouch construction and identification of the apex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/45/28374\" title=\"picture 13\">",
"      Ileal J pouch construction by securing loop of ileum to ileum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/63/22516\" title=\"picture 14\">",
"      Ileal pouch construction with enterotomies and linear stapling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/48/2822\" title=\"picture 15\">",
"      Ileal J pouch eversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/24/38276\" title=\"picture 16\">",
"      Ileal J pouch construction with inversion of the pouch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/4/38979\" title=\"picture 17\">",
"      Ileal pouch anal anastomosis visualized through the anus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/17/43282\" title=\"picture 18\">",
"      Ileoanal hand-sewn pouch anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/13/42194\" title=\"picture 19\">",
"      Port placement for hand-assisted laparoscopic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15017|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 1\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/46/23275\" title=\"table 2\">",
"      Timing of surgical prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/2/4140\" title=\"table 3\">",
"      Classification ileal pouch",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=related_link\">",
"      Abdominal access techniques used in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16618?source=related_link\">",
"      Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/3/25656?source=related_link\">",
"      Fast-track protocols in colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20744?source=related_link\">",
"      Left colectomy: Open technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4186?source=related_link\">",
"      Management of anastomotic complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=related_link\">",
"      Overview of surgical procedures for resectable primary rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32759?source=related_link\">",
"      Pouchitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28024?source=related_link\">",
"      Right and extended right colectomy: Open technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/16/34057?source=related_link\">",
"      Surgical oncologic principles for resection of primary rectal adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/23/16762?source=related_link\">",
"      Surgical oncologic principles for the resection of colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/12/28873?source=related_link\">",
"      Surgical principles of ostomy construction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_13_25819="Probability of paternity by CPI and RMNE";
var content_f25_13_25819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of the probability of paternity, the combined paternity index, and the random man not excluded statistics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Probability of paternity, (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average combined paternity index, CPI",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average number of individuals with the same genetic pattern, (random man not excluded) RMNE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1 out of 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        1 out of 35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        1 out of 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        1 out of 100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99.9",
"       </td>",
"       <td>",
"        1,000",
"       </td>",
"       <td>",
"        1 out of 1,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99.99",
"       </td>",
"       <td>",
"        10,000",
"       </td>",
"       <td>",
"        1 out of 10,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        99.999",
"       </td>",
"       <td>",
"        100,000",
"       </td>",
"       <td>",
"        1 out of 100,000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25819=[""].join("\n");
var outline_f25_13_25819=null;
var title_f25_13_25820="Rx pregnant dialysis patient";
var content_f25_13_25820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Management of the pregnant dialysis patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intensification of dialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood urea nitrogen should be maintained below 50 mg/dL (17 mmol/L) to avoid polyhydramnios.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If hemodialysis is used, intensification of the regimen should be considered, 5 to 7 sessions per week is likely to provide more optimal control of uremia, and better fecal outcomes. The&nbsp;prescription should include bicarbonate buffer, minimal heparinization and slow-rate ultrafiltration, in order to avoid dialysis hypotension and volume contraction.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If peritoneal dialysis is used, the exchange volumes should be decreased (eg, to 1.5 liters) and the frequency should be increased.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adequate supply of calories and protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Protein intake should be 1 g/kg per day plus an additional 20 g/day for fetal growth.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diet should be supplemented with water soluble vitamins and zinc.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antihypertensive regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diuretics, ACE inhibitors,&nbsp;angiotensin receptor blockers (ARBs) are avoided. Acceptable antihypertensives&nbsp;include labetalol, Nifedipine XL, methyldopa, and metoprolol.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The diastolic blood pressure should range between 80 and 90 mmHg.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Correction of anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythropoietin should be given to maintain a hemoglobin level of at least 10 to 11 g/dL.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron and folic acid should be supplemented.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Avoidance of metabolic acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prevention of hypocalcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral calcium carbonate should be administered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypercalcemia should be avoided at the end of hemodialysis treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment of premature labor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The use of beta agonists as first-line drug treatment is preferred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonsteroidal antiinflammatory drugs are used with great caution and only for a limited duration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reinforced fetal monitoring as soon as viability is reached",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Jungers, P, Chauveau, D. Kidney Int 1997; 52:871.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25820=[""].join("\n");
var outline_f25_13_25820=null;
var title_f25_13_25821="Carvedilol and LVEF";
var content_f25_13_25821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65184&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Carvedilol improves left ventricular ejection fraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After six months of therapy in patients with heart failure, carvedilol produced a dose-related increase in left ventricular ejection fraction (LVEF) which is significant with all doses used when compared to placebo.",
"    <div class=\"footnotes\">",
"     * p &lt;0.005 versus placebo.",
"     <br>",
"      &bull; p &lt;0.0001 versus placebo.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bristow MR, Gilbert EM, Abraham WT, et al. Circulation 1996; 94:2807.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25821=[""].join("\n");
var outline_f25_13_25821=null;
var title_f25_13_25822="Dietary sources of iron";
var content_f25_13_25822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary sources of iron",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\">",
"        Approximate measure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Iron (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        High iron sources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cream of Wheat (quick or instant)*",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kidney, beef",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver, beef",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver, calf",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        9.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver, chicken",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liverwurst",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prune juice",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spinach",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Moderate iron sources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All-Bran cereal",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Almonds, dried unblanched",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Dried beans and peas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Baked beans, no pork",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Blackeye peas, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chick peas, dry",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Great northern beans, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Green peas, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lentils, dry",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lima beans, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Navy beans, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Red beans, dry",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Soybeans, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        White beans, dry",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beef, cooked",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        2-3&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ham, cooked",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lamb, cooked",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peaches, dried",
"       </td>",
"       <td>",
"        1/4 cup",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peanuts, roasted without skins",
"       </td>",
"       <td>",
"        3 1/2 oz (100 g)",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pork, cooked",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        2-3&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prunes, dried",
"       </td>",
"       <td>",
"        2 large",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scallops",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Turkey, cooked",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Approximate iron content of children's favorite foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Hamburger, small",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        1",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Large",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        5.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Big Mac",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        4.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Quarter Pounder",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        5.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spaghetti with meatballs",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frankfurter and beans",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pork and beans",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raisins",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        5/8 cup",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cereals, fortified",
"       </td>",
"       <td>",
"        1 serving",
"       </td>",
"       <td>",
"        4.5-17.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nuts",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        5.0-7.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seeds, sunflower",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        3 1/2 oz (100 g)",
"       </td>",
"       <td>",
"        7.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chile con carne",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beef burrito or tostado",
"       </td>",
"       <td>",
"        1 medium",
"       </td>",
"       <td>",
"        3.4-4.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cheese pizza",
"       </td>",
"       <td>",
"        2 slices",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cheese pizza with beef",
"       </td>",
"       <td>",
"        2 slices",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White bread",
"       </td>",
"       <td>",
"        1 piece",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Or other fortified cereals which contain 10 mg of iron per ounce or 100 percent RDA per serving.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      As organ meats are generally high in cholesterol, these iron-rich foods should be eaten in moderation.",
"      <br>",
"       &Delta; Depending on cut, the greatest amounts of iron are generally found in the chuck, flank, and bottom round cuts of beef.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Depending on cut, the greatest amounts of iron are generally found in the loin, sirloin, tenderloin, and picnic shoulder cuts of pork.",
"        <br>",
"         &sect; Raisins, nuts, and seeds are not generally recommended for children under age three because of risk of choking.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Walker WA, Watkins JB (Eds), Nutrition in Pediatrics, 2nd ed, BC Decker, Inc, London 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25822=[""].join("\n");
var outline_f25_13_25822=null;
var title_f25_13_25823="Crohns disease stomach UGI";
var content_f25_13_25823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Crohn's disease of the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This upper gastrointestinal series, performed in a young man with known Crohn's disease of the terminal ileum shows numerous rounded filling defects in the stomach produced by edematous mucosa. In some of these areas, small central collections of barium are demonstrated (arrow) resulting from superficial erosions. These features are suggestive of Crohn's disease, but may also be seen in patients with peptic ulcer disease, and in viral gastritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_13_25823=[""].join("\n");
var outline_f25_13_25823=null;
